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FOREWORD 
Six years ago I came to Sweden on an adventure to learn tumor immunology under 
the tutelage of Prof. Rolf Kiessling. When I started, I came to the lab knowing nearly 
next to nothing of the rudiments of immunology. After a couple of years I felt my 
grasp on this field was tightening, but only recently have I come to the understanding 
that knowing tumor immunology is not enough. The work I have done, as is partially 
represented in this thesis, requires the foundations that have been laid by ingenious 
immunologists, transplantation and tumor biologists. For example, Macfarlane 
Burnet and his seminal “The clonal selection theory of acquired immunity”. But 
beyond building on “correct” work, we are building on the rubble of many 
unsuccessful but required endeavors. The course of any PhD students’ tribulation is 
littered with the rubble of many failed experiments. And yet, it is these failed 
experiments that are the guide toward success. Ask Rolf how many times we had to 
sit down and discuss why his favorite 51Cr cytotoxicity assay did not work in my 
hands. One must also not forget that rubble plays an important role in the 
construction of magnificent buildings as well. The history of tumor immunology and 
immunotherapy is rife with failure and tons of rubble. Nonetheless, tumor 
immunologists have not lost faith in our collective work, and many have built fantastic 
foundations for future work. I have recently come to the realization of the importance 
of these historical works, both those that are foundational as well as rubble. In this 
thesis I hope to shed some light on the researchers that laid the solid foundations 
that we build on.  
One thing that my colleagues will be happy to share with you has been my 
enthusiasm for asking questions. To be honest, it may very well be that I am too 
insistent with my enduring inquires (my apologies dear colleagues), nonetheless I 
believe that this is an essential part of being who I hope to become, a competent 
researcher. Often it has been the case that someone has given a fantastic 
presentation that does not spawn any discussion or questions. This is painful to see, 
particularly when a group of researchers are present, even more so when it is a 
group of PhD students, but also when laypeople are present. Our research is one 
that has direct application for the lives of many people. I wonder if it is 
embarrassment of lacking knowledge that precipitates a lack of participation. To this 
end, I have added to this thesis an extended layman’s introduction that I hope will 
allow for the participation of a greater audience in the discussion of cancer and 
cancer therapy.  
  
  
  
ABSTRACT 
The treatment of disease in cancer patients by harnessing the potent mechanisms that exist 
within the immune system is not a novel approach, and has been first attempted more than a 
century ago. During the major part of this century cancer immunotherapy has been relegated 
to the periphery of standard care for patients. Within the last few years a dramatic shift has 
occurred in the treatment of cancer, and patients are now the recipients of drugs and 
therapies that aim to modulate and modify their immunity towards cancer. These treatments 
fall into one of two categories; either the therapy is passive immunotherapy or active 
immunotherapy. The first is based on the premise of introducing specific immunity in the 
form of cytokines, monoclonal antibodies or tumor specific T cells into the tumor-bearing 
patient. Active immunotherapy aims at inducing an in vivo tumor specific response, typically 
through various means of vaccination to activate specific immunity. We have directed our 
efforts at strengthening the pillar of passive immunotherapy through harnessing our 
understanding of the tumor microenvironment. Tumors generate large amounts of reactive 
oxygen species which adversely effect anti-tumor effector T cells. One approach to mitigate 
the effects of reactive oxygen intermediates is by co-expressing high levels of catalase in 
tumor-redirected T cells that express chimeric antigen receptors. Increased levels of 
catalase neutralize the negative effects of oxidative stress on T cells and allows them to 
survive, proliferative and perform their cytolytic functions whereas typically they would 
become anergic. In addition, these cells are able to protect bystander T and NK cells from 
oxidative stress mediated dysfunction. This strategy of attenuating the negative effects 
derived from the tumor microenvironment can potentially increase the efficacy of chimeric 
antigen receptor based passive immunotherapy. To strengthen the pillar of active 
immunotherapy we attempted to identify, enhance and broaden the potential targets of DNA 
based vaccine delivery. Vaccines, that activate immunity against tumor antigens, have the 
potential to revolutionize the field of cancer treatment. DNA vaccines in particular remain an 
interesting platform for activating tumor specific immunity. The delivery of DNA vaccines into 
the skin, where professional antigen presenting cells that can be readily primed are present, 
can induce recruitment of tumor specific T cells as well as antibody producing B cells. We 
found that dermal DNA vaccination relies heavily on NF-κB activation but surprisingly not on 
the IRF. IRF induces the production of type I interferon which are strong activators of 
antiviral activity in immune cells.  This is particularly relevant for inducing anti-tumor 
responses, which are mediated in large part by cytotoxic T lymphocytes. To harness this 
mechanism we delivered a genetically encoded intracellular DNA sensing molecule, DAI, 
which increased type I interferon molecule production as well as matured skin resident 
dendritic cells. This led to increased anti-tumor T cell activity as well as provided long-term 
protection from tumor re-challenge by generating more abundant tumor specific memory T 
cells. Generation of vaccine responses against cancer requires targeting antigens expressed 
by the tumor. To increase the potential targets available to cancer immunotherapists we 
explored the capacity of eliciting an immunological response against oncofetal tumor antigen 
Cripto-1. Delivery of DNA vaccine encoding full length Cripto-1 into the dermis of mice 
generated a cellular as well as humoral response that was able to inhibit the growth of 
transplanted tumors as well as decreased metastatic burden.  
The pillars of cancer immunotherapy rest upon foundations laid by a myriad of 
immunologists and cancer biologists. By protecting adoptively transferred tumor specific 
lymphocytes and furthering the understanding, as well as boosting the immunogenicity of 
classical and novel tumor antigen encoding DNA vaccines, we hope to improve the 
outcomes of cancer immunotherapy.  
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A GUIDE TO “STRENGTHENING THE PILLARS OF 
CANCER IMMUNOTHERAPY” 
 
I would like to take you on a short trip through time to a fictional Roman border town 
around the year 200 AD. Romans are of course famous for building prosperous 
towns with many buildings requiring strong pillars; this is a town similar to many 
other Roman towns. There is a central governing body made up of wealthy 
aristocrats, whom are busy administering and planning the future of the town. It also 
has many important local craftsmen: the farmer providing the food and energy for the 
townsfolk; the carpenter and stonemasons building the strong structures that keep 
the buildings standing; the bankers storing wealth around the town for later use; the 
merchants transporting goods from one part of the town to the other. Each is 
specialized at his skill and each being essential to the functioning of the town; all 
typically working together with the goal of ensuring the well being of the town.  
And as with any prospering town in the 2nd century, barbarians and raiders are 
watching like wolves from the edge of the forest salivating at the idea of pillaging the 
town. The town of course is not helpless. As with any interesting story, the 
barbarians add a bit of conflict making this a juicy tale. The Romans have, after 
centuries of dealing with barbarians, developed many interesting methods of keeping 
them at bay. The first line of defense is the wooden palisade. This wooden wall is 
able to deter most barbarians and raiders from entering the town. But all is not lost if 
or when they are able to break in; the Romans still have a couple of natural barriers 
to help. Throughout the town and at the town walls there are complex spike traps 
laid out ready to snap shut on specific types of barbarians. When the barbarians 
break through the walls the citizens of the town scream out for help, alerting the 
soldiers that the walls have been breached. Standing watch on the walls are the 
Roman guards and sentinels, the guards rush to the aid of the citizens and directly 
confront the barbarians that break through the wall. The sentinels from the walls 
come to join in the brawl but during the fight they pick up armor and weapons from 
the dead barbarians and run to the camps where the Roman legionaries are waiting. 
These sentinels play a crucial role in waking up and helping to train the legionaries 
identify the barbarians they need to destroy. There are three main types of 
legionaries; the Velites: soldiers that would cast long javelins at the enemy; the 
Equites: soldiers that formed the cavalry that would strike directly at the enemy; and 
finally the Legionary: heavy infantry soldiers that would support both the Velites and 
Equites. Some barbarians would be more susceptible to the javelins of the Velites 
and others to the swords of the Equites. The Legionary infantry always aided both 
responses against the barbarians. The response of the legionaries would always 
take a while as a training process would be required, and until they could act, the 
guards, traps and the walls had to keep the barbarians at bay. Once the battle was 
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won, a great deal of the legionaries would retire, but some would remain in service 
and wait in the camps telling tales of their victory against the enemy and if they were 
required for their experience in tackling a specific barbarian again, they would be 
roused and would retrain a new army to return to the battle field.  
Unfortunately, our story does not end there. During this age of Roman wealth and 
prosperity it would sometimes occur that one of the obedient citizens, the 
stonemasons, the aristocrats, the merchants, and sometimes even the legionaries 
themselves would become greedy and corrupt. While their neighbors would protest 
against the corrupt Romans telling them to stop stealing and that there are already 
enough of them in the town, the offenders would ignore these signals and take it 
upon themselves to attempt to take as much of the prosperity for themselves as they 
could. There are of course guards patrolling the town, checking in on the citizens, 
sometimes even arresting and killing unruly ones. Sometimes the legionaries dealt 
directly as vigilantes with these offensive citizens. But as often is the case, the 
corrupt and greedy would have a couple of tricks up their sleeves to keep the guards 
off their back. These include: directly killing of the guards with a stealthy knife to the 
gut or by making the environment hostile by intentionally throwing their foul waste in 
front of their houses making patrolling impossible, or even by recruiting and 
corrupting the guards to aid and abet their crime. Eventually, the corrupt citizens 
spread around the town using up all the resources, resulting in the Romans failing in 
their function to carry out their assigned tasks. Eventually this corruption would lead 
to the demise of our Roman border-town.  
To illuminate what we have achieved in this thesis, I ask you to return to our 
imaginary Roman border-town prior to its demise due to the greedy corrupt citizens. 
There are two methods that are being used to help our Roman towns: the first by 
giving the town guards and legionnaires directly the tools to handle the problem; the 
second is by educating the town legionnaires to identify the offending citizens. 
The first method that has been used effectively to cull offending citizens in other 
towns has been by endowing legionnaires with laser vision goggles, allowing them to 
easily identify their targets. This has worked very well against corrupted Velites  
(legionaries with the javelins), but citizens that live in one location, such as corrupted 
milkmaids, have been unsuccessfully treated. In the first part of this thesis we 
attempt to solve the problem that the legionnaires encounter when they visit the 
hostile surroundings of offending citizens, namely, all that foul waste they throw on 
the street. We train the legionnaires to brave this environment and put them in a boot 
camp and give them gas masks to make them resistant to the noxious stench that 
surrounds the corrupt citizens. In addition, we have given them laser vision goggles 
so that they can better see which are the disobedient citizens to cull. We show that 
even in the presence of foul waste, our re-trained legionnaires are able to survive 
and kill the corrupt citizens. These newly trained legionnaires were even able to 
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share their own gas masks with other fellow guards, allowing them to also spring into 
action (Paper I). 
The second method, while exceedingly effective against barbarians, has been more 
difficult to realize against roman citizens, even those that are corrupt and offensive. 
For more than a century immunologists have been educating the towns defenses by 
showing the weapons/armor of the barbarians to the sentinels on the walls of the 
town. This allows the sentinels to train the legionnaires as to the appearance of the 
barbarians, and offers profound protection. In the second part of this thesis we 
describe a method to retrain the sentinels to recognize the identifying features of the 
enemy from within- i.e. the offending corrupt citizens and their wicked ways they use 
to overcome the sentinels. The sentinels are able to teach and train the legionnaires 
in their new skills at identifying corrupt citizens. We attempted to understand how the 
sentinels recognize the plans that were introduced and which of their perceptions 
were important in getting them to present the tools and cloths in a manner that elicits 
the legionnaires to become educated to kill the corrupt Romans. We found that they 
use only a particular set of senses to recognize assistance (Paper II). Using this 
knowledge we introduced a method for the sentinels to improve their recognition that 
would facilitate eradicating the offending citizens. The improved recognition 
consequently led to an improved legionary response that was able to eliminate the 
corrupt Romans and keep the town from its demise (Paper III). Finally, we were also 
able to show that we could arouse the legionaries to the weapons of the corrupt 
Romans which they used to spread throughout the town. We were able to identify 
which part of the weapons the Equites recognized as well as showing that the 
Velites produced javelins specific for this weapon. This training was able to protect a 
couple of different Roman towns from two types of corrupt citizen (Paper IV).  
The findings contained within this thesis will join the scaffolding that allows for the 
strengthening of the pillars of cancer immunotherapy.  
Cancer and the therapy of cancer is a shockingly commonplace occurrence that 
many of my own family and friends have had to confront. The diagnosis of cancer 
can be overwhelming and confusing. I believe that a great part of the overwhelming 
nature is derived from the common understanding that cancer is a complex and not 
wholly understood and treatable disease. This extended layman’s abstract, I hope, 
will allow for a broader understanding of cancer and the basis of cancer 
immunotherapy. Of course the description given above also highlights the work we 
have been doing, but I believe that within the context of this metaphor many 
therapies and diseases can be understandably described.  
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1 FOUNDATIONS OF IMMUNOLOGY AND CANCER 
IMMUNOLOGY 
All organisms known to exist on our planet survive in an environment in which they 
are confronted by constant competition. Their competitors come in the form of similar 
species competing for identical niches for survival, but they also come in the form of 
opportunistic parasitic organisms that invade their hosts. These parasitic organisms 
vary from large multicellular helminthes, single cellular bacteria to viruses. When 
these organisms cause dysfunction and are able to disseminate to new hosts they 
can be classified as pathogens. Both types of competition at a macro and at a micro 
scale are drivers of Darwinism. Over millennia this has led to the development of 
very complex anti-pathogen mechanisms, termed immunity. Previously, it was 
thought that immunity was only the domain of large complex multicellular animals, 
but now it can be argued that mechanisms of immunity can be found in all forms of 
life. Immunity can be categorized into two general terms, namely innate and adaptive 
immunity though there is much flexibility and flux between both categories. The 
innate immunity consists of, but is not limited to, peptidoglycan or cell walls in 
bacteria, cross-linked cellulose fibers in plants or outer epithelial layers in mammals. 
These are natural boundaries and mechanisms to prevent invasion of the organisms 
by potential pathogens. Adaptive immunity is a response generated within the 
organism that is able to specifically neutralize a single type of pathogen; in bacteria 
the CRISPR/Cas complexes neutralizes foreign DNA, in plants RISC/ago complexes 
neutralize foreign RNA, in mammals the TCR/MHC complexes neutralize foreign 
protein. The more complex the organism is, the greater the requirement and 
availability of the immune arsenal to eliminate disease.  
While in general immunology of organisms is of great interest, human immunology is 
of primary concern for us. The first section of the introductory part of this thesis will 
lay the foundations of immunology and how the immune system interacts with 
cancer. The second section will focus on the current pillars of cancer immunotherapy 
and how researchers are harnessing the immune system to treat cancer. Finally, in 
the third section, I will describe how our work has strengthened these pillars as well 
as provide speculation on the form of cancer immunotherapy in the future. 
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1.1 IMMUNOLOGY 
The study of the human immune system is a complex and constantly developing 
field. When pathogens invade the human host, the anti-pathogen response is 
mounted immediately; this response is broad in scope and potent enough to 
eliminate a variety of pathogens. Protection is mediated by direct as well as indirect 
cellular responses. These important players in immunity are leukocytes. 
Hematological cells have the highest turnover of all human cells. This requires the 
replenishment of these populations on a constant basis. To fulfill this requirement we 
have pluripotent hematopoietic stem cells (HSC), that in addition to maintaining their 
own self-renewal give rise to common lymphoid progenitors (CLP) and common 
myeloid progenitors (CMP). The CLP cells differentiate into natural killer (NK), 
plasmacytoid DC (pDC), B and T cells. The CMP cells can differentiate into either 
megakaryocyte/erythroid progenitors, which are responsible for red blood cell and 
platelet production, or granulocyte/macrophage progenitor that lead to the 
generation of mast, eosinophil and neutrophil cells as well monocytes. Monocytes 
differentiate further into macrophages and monocytic dendritic cells (mDC) (Figure 
1). These cells provide the basis of immunity that will be discussed in the following 
pages(1). 
1.1.1 Innate Immunity 
Innate immunity is characterized by nature of its presence prior to challenge by 
pathogens. The first barrier to entry is mechanical, namely the epithelial surfaces, 
 12 
which through tight junctions simply do not allow entry to pathogens. Epithelial 
surfaces are also covered with commensal bacteria that are competitors to 
pathogenic bacteria. Additionally, internal epithelial layers secrete glycoprotein 
mucins in mucus that prevent bacterial adhesion. The epithelial cells also have the 
capacity to produce antimicrobial enzymes, such as lysozyme, and peptides, 
including defensins, histatins and cathelicidins; these are highly evolutionarily 
conserved and are able to cause bacterial membrane dysfunction and death. Direct 
lysis of pathogens is also mediated by the complement system that includes 
molecules that recognize mannose, antibodies or complement proteins that 
accumulate on the pathogen cell surface. This initiates protein cleavage cascades 
that release complement peptides that activate inflammation and recruit phagocytic 
cells. The cleaved complement signals opsonization and also recruitment of the 
membrane attack complex proteins that are able to directly lyse pathogens(2,3). 
While these soluble factors are a potent protection, they often require components of 
cellular immunity to successfully clear the disease. 
Innate Cellular Compartment 
The innate immune cells are directly responsible for initiating immediate action 
against pathogens that have colonized the host, mainly through phagocytosis as well 
as activation and recruitment of additional immune cells. CMP innate immune 
derived cells include the granulocytes, macrophages and DCs. The largest 
proportion of circulating leukocytes is comprised of granulocytes, such as 
neutrophils, eosinophils and basophils and mast cells.  These cells are named after 
their highly granular nature, and are filled with antimicrobial peptides and enzymes. 
Neutrophils are highly abundant and short lived. Upon activation neutrophils become 
highly phagocytic, releasing their granules and even generating neutrophil 
extracellular traps from their own genomic DNA (4). Eosinophils and basophils have 
been recognized as essential for parasitic protection, but it is fast becoming clear 
that their role extends beyond this. They express Fc receptors that allow for binding 
of Ig coated pathogens leading to the release of cytotoxic basic proteins and 
inflammatory cytokines and to further recruitment of cells (5). Mast cells are 
infamous for their role in allergic responses, typically through the release of 
histamine, but also through release of proteases that damage nearby cells. Mast 
cells reside at the host-environment interface and respond within seconds to 
pathogens. They induce the activation of nearby DCs and orchestrate increased 
cellular migration into infected tissues (6). An other essential class of innate immune 
cell is the macrophage; these are professional phagocytes responsible for clearage 
of cellular debris. Macrophages are able to present antigens to the adaptive immune 
system and support their activation through the production of IL-12 and IFN-γ.  
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These cellular responses that are 
of myeloid origin are effective at 
eliminating extracellular pathogens 
and recruiting further inflammatory 
responses. The innate immune 
system also includes NK cells that 
eliminate host cells that display 
signs of “stress”. These stresses, 
due to either pathogen infection or 
malignant transformation, modulate 
cell surface receptors which results 
in destruction by NK cells that are 
able to recognize these altered 
surface characteristics. NK cells 
are typically identified by their 
expression of CD56, CD16 and lack of CD3. In mice identification of NK cells can be 
done through their NKp46 or NK1.1 cell surface markers. The levels of CD56 
delineate their function - CD56high NK cells are responsible for cytokine production 
while CD56dim are highly cytotoxic. Activation of NK cells occurs through the balance 
of activating receptors, such as NKG2D, CD16, DNAM-1 and a host of natural 
cytotoxic receptor, while inhibitory receptors, such as KIR, NKG2A and CD96 down 
regulate NK activity. The activating receptors bind to stress induced ligands on the 
target cell and the inhibitory receptors bind to MHC molecules. When there is an 
abundance of activation relative to inhibitory signals the NK cell releases its cytolytic 
perforin and granzyme loaded granules or ligate death receptors through expression 
of TRAIL and FasL (8,9).  
Cytokines 
Cells of the immune system do not function independently. Rather they are in 
constant communication with each other and their surroundings. The soluble 
mediators that facilitate this communication are termed cytokines and chemokines. 
Cytokines and chemokines are produced by a wide variety of cells including 
leukocytes, endothelial and epithelial cells. They bind to their cognate receptors on 
immune cells that induce a biological response such as activation, expansion, 
maturation, migration or suppression. These molecules can typically be categorized 
as interleukins, interferons and colony stimulating factors. These soluble factors can 
have effects in an autocrine, paracrine as well as endocrine fashion, making them 
amenable for use in immunotherapy. Interleukin 2 (IL-2) was the first described 
cytokine and is a key regulator of T cell proliferation. Its name describes its essential 
role in the interaction between leukocytes. Type I interferon α (IFN-α) binds to IFN-α 
receptor and leads to the upregulation of antiviral proteins and activation of DCs to 
prime T cells for function (10). Recruitment of appropriate cellular responses is 
Rolf Kiessling is responsible for laying the 
foundations of a whole field within immunology. 
Particularly here at the Karolinska Institutet there 
are many who are directly indebted to the high 
background in his assays. About this background 
reactivity he has said: “High background reactivity 
in a laboratory assay was the bane of my existence! 
Much to my dismay, the background lysis of YAC-1 
cells in the presence of mouse splenocytes 
remained high and persisted despite my best 
efforts, even with cells from non-immunized, control 
mice. By hindsight, it was through sheer serendipity 
that we chose YAC-1 cells but the choice was 
fortuitous indeed since even today, I cannot think of 
any cell that is more exquisitely sensitive to natural 
killer cell activity.” (7) 
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mediated by chemokine and their cognate G-protein-coupled receptors. 
Inflammatory responses typically include the production of CXCL8, which leads to 
the recruitment of neutrophils to combat inflammation-inducing pathogens. The 
stimulation of different populations of immune cells is also mediated through 
cytokines such as GM-CSF. This colony-stimulating factor drives the production of 
new granulocytes and monocytes from the bone marrow (1,11). 
1.1.2 Bridging Immunity 
Innate immunity is able to clear the majority of pathogens infecting the human host, 
but some pathogens manage to evade elimination and require a more specific 
response to be raised against it. DCs mediate the transition from a general response 
to a specific one. They can be subdivided into classical DC (cDC), mDC, pDC and 
Langerhans cells. Within these subsets DCs can be further categorized based on the 
expression of cell surface markers as well as tissue location. These subsets are 
specialized in particular functions and bridge the innate immune response to the 
adaptive immunity (12,13). 
Antigen Processing and Presentation 
The central role that DCs play is that of professional antigen presenting cells (APC). 
DCs phagocytose pathogens as well as other antibody or complement labeled cells 
and in doing so take them up in lysosomes where they are broken down into 
constituent proteins. These proteins are then presented to T cells on MHC class II 
molecules, while intracellular pathogen proteins are degraded in the cytosol and 
presented on MHC class I to T cells. MHC class I molecules are recognized by CD8+ 
T cells, while MHC class II molecules are recognized by CD4+ T cells. The peptides 
that are loaded into MHC class I are typically from the cytosol of the APC. Cytosolic 
proteins are cleaved by the proteasome into peptide fragments that range from 8-10 
amino acids in length that are subsequently transported and processed through 
transporter associated with antigen processing (TAP) into the endoplasmic reticulum 
(ER). MHC class I molecules are bound to calnexin in the ER till they bind to the β2-
microglobulin. This allows for peptide-loading complex to associate. One of the 
proteins in this complex is tapasin that forms a bridge with TAP and facilitates the 
loading of the short peptide into the cleft on the face of the MHC molecule. This is 
then exported via the golgi to the cell surface when loaded. MHC class II molecules 
are loaded in a different manner, relying instead on extra-cellular proteins as a 
source of peptides. CD4+ T cells bind to MHC class II and recognize MHC class II 
loaded peptide. Due to the nature of proteins being loaded are involved in the 
regulation or responses against extracellular targets. MHC class II molecules are 
produced in the ER and are loaded with the invariant chain to block binding of 
endogenous peptides. The invariant chain is cleaved in the endosome, leaving an 
invariant peptide in the MHC class II cleft. Upon fusion of the lysosome with MHC 
class II endosomes the invariant peptide is discarded and peptides produced in the 
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lysosome of lengths varying from 14-20 amino acids are loaded into the cleft. MHC 
class II is then brought to the cell surface allowing for interaction with CD4+ T cells 
(1,12). While this describes the classical loading of epitopes, APCs are notorious for 
finding ways around these theoretical boundaries. Cross-presentation is a 
phenomena whereby APCs phagocytose antigens and instead of being loaded onto 
MHC II antigens are leaked to the cytosol and processed by the proteasome, passed 
through TAP into the cleft of MHC class I (14,15). Cross-dressing is another 
mechanism that APCs use to present MHC class I complexes loaded by other cells. 
Here DCs trogocytose MHC class I complexes from adjacent cells and are able to 
prime CD8+ T cells (16). Additionally, the field of antigen presentation seems to 
become more complex as it is now clear that alternative pathways of loading 
epitopes onto MHC are also available to non-APCs including tumors (17). 
Activation of Dendritic Cells 
Presentation of antigens on MHC complexes is far from adequate to elicit a cellular 
immune response in itself. All cells are constantly loading peptides into MHC to allow 
for screening of potential intracellular pathogenesis. What is required is the activation 
of the antigen-presenting cell. This is achieved through the recognition of pathogen 
associated molecular patterns (PAMPs) (18) or danger associated molecular 
patterns (DAMPs) (19). PAMPs are naturally occurring molecules present in most 
pathogens such as LPS or CpG motifs in bacterial DNA. These are not specific 
enough typically for inducing anti-pathogen elimination by innate immunity, but will 
trigger a cascade within DCs leading to maturation and activation. In addition to 
PAMPs, DAMPs are also able to strongly activate DCs. The distinction between the 
two is that DAMPs are host derived. DAMPs characteristically are normal cellular 
molecules that are expressed ectopically in a cell under stress. A good example of 
this is genomic extracellular DNA, which is normally sequestered in the nucleus (20).  
APCs, as well as many other cells, express pattern recognition receptors (PRRs) 
that bind these PAMPs and DAMPs. PRRs are both transmembrane as well as 
cytoplasmic receptors that lead to the activation of transcriptional signaling pathways 
such as NF-κB, activator protein 1 (AP-1) and interferon regulatory factors (IRF). 
PRRs can also trigger the formation of inflammasomes that lead to the generation of 
IL-1β and IL-18. These are highly conserved proteins and have been found in all 
multicellular organisms. The classic family of PRRs are the Toll-like receptors 
(TLRs), which are similar in structure to drosophila Toll protein, of which there are 
nine in humans. These bind PAMPs such as flagellin, lipoprotein, peptidoglycans, 
LPS, dsRNA, ssRNA as well as CpG-rich bacterial DNA which trigger the cytosolic 
Toll-interleukin receptor domains that signal to adaptor proteins such as MyD88 
further propagating a cascade of inflammation. Recognition of these agonists occur 
both at the plasma membrane as well as intracellularly (21). TLRs do not function 
individually; co-receptors, such as HMGB1, LL-37 or CD14, may be expressed by 
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APCs or other activated innate immune cells that increase the affinity of PAMPs for 
their receptors leading to stronger activation (22).  
A relatively recently described class of PRRs are those that sense nucleic acids in 
the cytosol. This has proven to be an essential mechanism of protection from 
cytomegalovirus (CMV), herpes simplex virus (HSV) among others (23-25). As well 
as detecting and activating response against pathogen derived DNA; natural 
occurring nucleic acids are location restricted, allowing cytosolic sensors for self 
nucleic acids to be a potent recognition mechanism of cellular dysfunction. DNA 
binding cytosolic sensors includes: DAI, LRRFIP, AIM2, IFI16, cGAS and many 
more. There is extensive redundancy within that hints at the essential nature of 
these molecules. Due to the wide variety of sensors the localization is still under 
investigation. As with the classical PRRs these cytosolic DNA sensors lead to the 
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activation of transcription factors AP-1, NF-κB as well as IRFs. AP-1 and NF-κB are 
responsible for the up-regulation of survival, migration, maturation and pro-
inflammatory genes. While there is such a broad panel of molecules directly binding 
to DNA, the activation of IRFs seem to converge on the stimulator of interferon 
genes (STING) adaptor protein (Figure. 2) (26-28). Cytosolic DNA through these 
sensors is capable of strong activation of DC leading to signaling through all three 
essential signals for T cell activation.  
The Three Signals for T cell Activation 
When the processed peptides are presented and the DCs have become activated 
through PRR activation by DAMPs or PAMPs then the scene is set for inducing 
resting naive T cells to a state of activation and clonal proliferation. DCs, that are 
activated, migrate to the secondary lymphoid tissues and increase their capacity to 
present antigens. This is the first signal. The second signal is the upregulation of co-
stimulatory molecules. These are proteins of such as CD80, CD86, ICOSL and 
CD40 on DCs that bind to the CD28 family member proteins on T cells. Finally, the 
third signal comes in the form of cytokines produced either directly by the engaging 
DC or from peripheral signaling. Specific cocktails of interleukins sensed by T cells 
will shape the response generated. IL-12 and type I IFNs provide a means for the 
encountering CD8+ T cell to sense ‘danger’ (29,30). Together, these three signals 
are required for activating cellular responses. When one is missing, this can lead to 
T cell anergy or even skewing T cells towards a regulatory phenotype. 
1.1.3 Adaptive Immunity 
Although the components of adaptive immunity have been mentioned above, 
adaptive immunity, as the name implies, describes the ability of the arm of immunity 
to adapt a specific response towards pathogens evading innate immune elimination. 
The incredible capacity for the adaptive immunity to respond to pathogens with an 
individualized approach lies in their ability to rearrange genes that encode for 
different parts of either their T cell receptor (TCR) or B cell receptor (BCR) (1). T 
cells derive their name from their trafficking to the thymus prior to entering 
circulation. T cells come in two flavors, namely CD4 and CD8, which can further be 
segregated. The first has classically been termed helper T cells and are essential in 
the production of cytokines and other factors to regulate and establish immunity. 
They bind epitopes presented in MHC class II and are essential to B cell maturation 
into antibody producing plasma cells as well as being essential to produce cytokines 
to give the “third” signal to activate other T cells. The CD8 proteins on T cells allow 
them to bind to MHC class I, recognizing the epitope presented triggers a cascade 
that typically leads to lysis of target cells. B cells derive their name from their origin of 
discovery, namely the bursa of Fabricius in birds that coincidently is also appropriate 
in humans where they originate from the bone marrow. They enter circulation and 
with their BCR bind their cognate antigen. The B cells then process and present this 
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antigen to be recognized by T helper cells who then initiate the differentiation of the 
B cells into plasma cells that produce antigen specific clonal antibodies (1). 
1.1.4 Restraining Immunity 
The near infinite rearrangements 
available to adaptive immunity 
endow it with the ability to react to a 
nearly endless repertoire of 
antigens on pathogens. This 
boundless potential also has a 
great weakness, i.e. randomization 
of specificity will also generate 
responses that have the ability to 
react to self-antigens. It has been 
proposed that self-reactive T and B 
cells are eliminated by central 
tolerance. Both T and B cells, in 
their common lymphoid progenitor 
cell (CLP) state have their full 
genomes prior to recombination. 
Pre-T cells migrate to the thymus 
where, after recombination of their 
TCR, they undergo positive and negative selection. The first requirement is that the 
randomly recombined TCR binds MHC. If this is the case, the fate of CD4+CD8+ pre-
T cells is determined to either CD4 or CD8 lineage. In the next phase, negative 
selection deletes T cells that bind with high affinity to MHC presented “self” antigens 
by medullary thymic epithelial cells. Pre-B cells expressing surface IgM that bind 
strongly to cell surface expressed antigens are eliminated in a process termed clonal 
deletion. In the case that B cell IgM binds to soluble self-antigens they are not 
deleted but become anergic. If there is no binding they go into circulation, awaiting 
CD4+ helper T cell activation (31). When in circulation after central tolerance, T cells 
and B cells encounter peripheral tolerance. In the periphery they may encounter DCs 
that present their cognate antigen on MHC but lack second or third signals, thus 
inducing anergy in the cells. Additionally, regulatory T (Treg) cells mediate 
suppression via the production of inhibitory cytokines, suppression of DC maturation 
and function. Thus preventing T or B cells from activating (32) and providing the 
basis for the “self-non-self” theory.  
While central and peripheral tolerance are well-established mechanisms they do not 
determine the entirety of immunological regulation. An alternate theory of tolerance 
has been proposed, and discussed a bit above in the form of DAMPs, namely the 
“danger theory” suggests that “self-non-self” T cells are not restricted but await DC 
Peter Medawar and Macfarlane Burnet were 
instrumental (and won a Nobel Prize) for developing 
the theory of immunological tolerance. Peter spent a 
large amount of time during the Second World War 
with the problem of rejected skin transplants in burn 
patients. One burn patient “Mrs. McK” was treated 
with both her own transplanted skin and that of her 
bother. Medawar observed that her brothers skin was 
rejected, and rejected more rapidly the second time 
around while her own was not. This started Medawar 
on the road to understanding transplantation and 
acquired tolerance. Medawar was responsible for 
executing the experiments that Macfarlane suggested 
would be the proofs for establishing the theory of 
immunological tolerance. He suggested about 
acquired tolerance: “If in embryonic life expendable 
cells from a genetically distinct race are implanted and 
established, no antibody response should develop 
against the foreign cell antigen when the animal takes 
on independent existence”. (33) 
  19 
activation through DAMPs to stimulate responses (19,34). Additionally, tolerance 
could be mediated differently in each tissue-based location (35). It seems to be more 
of an amalgamation of these theories as recently Yu et al. has been able to 
experimentally substantiate theories that central tolerance deletes self-reacting T 
cells but only to a limited degree. They found that in the periphery of non-infected 
donors the circulation of both foreign epitope specific T cells as well as a large 
amount of endogenous epitope specific T cells, related to keratin, preproinsulin and 
aldolase, were present. When evaluating a Y chromosome encoded antigen and 
comparing female to male healthy donors, only a reduction of 33% was observed 
(36) indicating that self-reactive T cells were indeed present and could be potentially 
primed.  
1.2 CANCER IMMUNOLOGY 
Cancer is a disease of unrestricted proliferation of cells. The uncontrolled nature of 
cell growth by cancer can be caused by many factors, such as mutations in 
oncogenes and tumor suppressor genes as well as virally encoded proteins causing 
deregulation of the cell cycle. Typically two to eight driver mutations are required to 
initiate tumorigenesis, a varying fraction of which eventually develop into metastatic 
cancer. Classic mutations occur in KRAS, SMAD4 and TP53, and have been very 
well documented in colorectal carcinoma (CRC). These driver mutations fall into 
three categories that regulate cellular processes, namely: genome maintenance, cell 
fate and cell survival. The accumulation of these mutations that lead to 
tumorigenesis can take decades (37,38). The single cell that acquires the mutations 
to initiate tumorigenesis does so due to exposure from endogenous as well as 
exogenous factors. These factors include oxidative stress induced by cellular 
metabolism, radiation, carcinogens and cellular machinery errors resulting in DNA 
strand breaks (39). These errors can be detected and directly repaired by inherent 
DNA repair mechanisms or indirectly through the activation of apoptosis. The 
accumulation of mutations in oncogenes or tumor suppressor genes, such as those 
mentioned above, lead to tumorigenesis which endows the mutation-rich cell with the 
hallmarks typically present in cancer. These include, sustained proliferation, 
resistance to cell death, angiogenesis, evasion of growth suppressors, replicative 
immortality, genomic instability, escape from immune destruction, tumor-promoting 
inflammation, deregulated cellular energetics as well as invasive characteristics (40). 
This is quite an extensive list, and for the tumor to become an aggressive cancer it is 
required to fulfill these hallmarks. This may explain why the frequency of cancer is 
not overwhelming in the human population.  
1.2.1 Spontaneous Anti-Tumor Immunity 
In the previous sections we have been referring to pathogens and their interaction 
with the immune system. I would like to draw your attention to the fact that in most 
aspects the hallmarks of cancer are exceedingly similar to those we would use to 
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describe a successful pathogen. The major distinction of course is that most cancers 
are not directly transmittable (with the exception of intentionally transplantable tumor 
models, certain canine malignancies and Tasmanian devils facial tumors (41)). The 
importance of immune mediated tumor surveillance is now well established after 
struggling for years with the concepts of “self-non-self” tolerance and inadequate 
tools to study this interaction.  
The first clear indications of the importance and involvement of immune rejection of 
tumors was found when the technology became available to transplant organs from 
donors into recipients. This is one of the greatest kindnesses possible for us to 
bestow upon our fellow human, the irony is immense when this blessing turns into a 
life-threatening curse. For example, a kidney transplant was done on a patient with 
polycystic disease that after engraftment functioned well. After discovery of a nodule 
in the breast a biopsy was performed and was diagnosed as a secondary 
melanoma, no primary melanoma could be found. The patient had been on 
immunosuppressants, which were stopped immediately, but to no avail, she died of 
metastatic melanoma. The recipient of the other donor kidney was found to also 
have metastatic melanoma. Fortunately, this was restricted to the donated organ. 
After halting immunosuppression and treatment with interferon the kidney was 
rejected along with the tumor. The donor had a melanoma removed 16 years prior to 
donating the organs and being tumor free for 15 years (42). Multiple follow-up 
studies on renal transplants have shown significantly increased incidence of cancer 
in these patients compared to the predicted frequency in the general population 
(43,44). Cardiac transplants have similar side effects with patients receiving 
immunosuppressives to retain the graft, but allowing for escape of the tumor in the 
donor tissue from immunosurveillance. In cardiac and lung transplant patients, lung 
cancer derived from the transplant led to extremely poor prognosis (45,46). 
Additionally, these studies indicate that there are two categories of tumorigenesis: 
those driven by virus and those driven by mutational burden. Virally induced cancers 
are much more likely to occur in immunosuppressed patients (47). This was also the 
case when immunosuppression was caused by HIV/AIDS (48).  
The second proof arose from the development of monoclonal antibodies reactive to 
a wide variety of immune related antigens. Once this was available, and paraffin 
embedded patient tumor samples were accessible initially for immunohistochemistry, 
and presently augmented by flow cytometry, the race was on to search for and 
identify prognostic markers that were immune related. Many research groups were 
able to identify that CD8+ cells were prognostic in melanoma, head and neck cancer, 
breast cancer, renal cell carcinoma, colorectal carcinoma and non-small cell lung 
cancer among many others (49). It was the evaluation of CRC and the 
immunoinfiltrate that conclusively showed that T cell infiltration was key to improved 
prognosis. This was done by Galon et al. where they were able to show that 
CD45RO and CD3 in the invasive margin as well as in the central tumor predicted 
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disease-free survival. Establishing an immune contexture and immunoscore they 
were able to break down the classic UICC TNM staging system into new categories 
that showed that patients typically found in TNM III could have a 80% disease free 
survival if they had CD3hiCD45ROhi infiltration of both the invasive margin as well as 
the center of the tumor (50). Other infiltrating immune cells, such as B (51), NK (52-
54) and DCs were prognostic for delayed tumor progression (52). 
Other immune cells correlate with a negative prognosis for patients. For example; 
CD68+ tumor associated macrophage (TAM) infiltration is a negative prognostic 
marker in classic Hodgkin’s lymphoma (55). TAMs are recruited to the tumor by 
CCL2 and result in the progression of colorectal cancer (56). Infiltration of 
macrophages into invasive breast carcinoma correlated with increased vascular 
grade and reduced relapse-free survival (57). MDSC predict the survival of 
metastatic melanoma patients (58). Tregs predict negatively the outcome of 
colorectal cancer that has spread to the liver (59), but they have also been shown to 
be a positive prognostic marker (60) potentially due to their recruitment when anti-
tumor immune responses generate IL-2 and IFN-γ. The immune landscape of 
cancer is complex, but a clear fingerprint is being elucidated that will provide robust 
prognostic and predictive benefit for patients (61). 
The final group of evidence is based upon the carcinogen-induced tumors in various 
mouse models. Early on, it was described that carcinogens, such as 
methylcholanthrene (MCA), could induce sarcomas, particularly in inbred strains of 
mice (62). These MCA induced tumors were shown to induce immunity against 
specific tumors but not others. 
Furthermore, mice that had a primary 
tumor regress were immune to tumor 
growth when rechallenged with the 
same tumor but not others (63).This 
was followed up by vaccination 
studies that clearly demonstrated the 
immunogenicity of carcinogen-
induced tumors (64). Later is was 
confirmed that CD8+ T cells were 
responsible for recognizing MCA 
sarcoma antigens (65). Using the 
MCA sarcoma model, which was 
know to generate immunogenic 
tumors, and nude mice Engel et al. 
was able to show that mice deficient 
in thymus, and there for T cell 
development, were more susceptible 
to MCA induced tumors (66). Similar 
Paul Ehrlich’s contributions to the field of 
immunology were fundamental in nature. He 
postulated that cells were responsible for the 
production of chemical structures, “side-chains”, 
that would bind toxins. The side chain would then 
break off the cell and enter circulation; seeking out 
and neutralizing toxins as “magic bullets”. His 
depictions of these “side-chains” are remarkable 
similar to how antibodies are represented to date. In 
addition to this Paul speculated that these antitoxin 
responses could play a role in immune surveillance. 
He said: “I am convinced that during development 
and growth malignant cells arise extremely 
frequently, but in the majority of people they remain 
latent due to the protective action of the host. I am 
also convinced that this natural immunity is not due 
to the presence of antimicrobial bodies but is 
determined purely by cellular factors. These may be 
weakened in older age groups where cancer is 
more prevalent.” (68) 
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results were found in Rag2 knock out (KO) mice, a more restricted mouse model of 
T cell deficiency (67). One of the main mechanisms of T and NK cell lytic capacity is 
dependent on perforin. MCA induced sarcomas, virus induced tumors and 
spontaneous lymphomas were studied in perforin KO mice. In both instances the 
tumors grew rapidly in KO mice but not in wild type (WT) mice (69-71). Further 
investigation into immunosurveillance was done using IFN-γ receptor KO mice, 
which were more susceptible to MCA induced sarcomas than their WT litter mates 
(72). Not only were NK and T cells implicated in immunosurveillance, but also γδ T 
cells are responsible for surveillance via NKG2D (73). Type I interferon were also 
designated a role in immunosurveillance (74). Finally, on the other side of the 
spectrum, depleting T regulatory cells allowed for enhanced immunosurveillance 
(75). 
All three aspects come together to form definitive proof that immunoediting is 
ongoing during tumorigenesis. This model consists of three potential states, whereby 
initially the tumor is eliminated. This elimination is mediated by any of the above-
described cytolytic mechanisms. If the tumor manages to evade direct elimination it 
may enter a stage of equilibrium where there is a constant tug of war between anti-
tumor immunity and tumor growth. This was definitely the case for the unfortunate 
patients who received the metastatic melanoma infested kidneys whose donor had 
no signs of disease for 16 years. Finally, the tumor enters a state of escape. Escape 
leads to the dissemination of the disease throughout the host, and is typically when 
the patient enters the care of the medical system (Figure 3) (76). The mechanisms of 
escape are described below.  
1.2.2 Tumor Immune Escape Mechanisms 
Experiments proving the importance of immune-mediated tumor elimination and 
equilibrium have established that the tumor must escape the cytolytic anti-tumor 
responses of various populations of lymphocytes for clinical disease to occur. The 
method with which this happens is not merely through the selection of 
immunoevading tumor clones. While the majority of tumor variants are eliminated, 
few clones with the ability to avoid immune detection and/or possessing mechanisms 
to actively suppress the immune system manage to establish themselves and 
proliferate into clinically obvious disease. Tumors of substantial volume gain 
additional immunoevading features as well as recruiting immunosuppressive cells 
into their milieu. An example of the immunosuppression induced by tumors that has 
been described in a wide variety of tumors, including but not limited to RCC (77), 
CRC (78), oral carcinoma (79), is where T cells lose CD3-ζ chain and thus their 
ability to function.  
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1.2.2.1 Tumor derived immune evasion 
Reducing detection of tumors by T cells is one of the mechanisms that tumors 
employ to evade elimination. Expression of MHC class I was found to be 
downregulated or deregulated in several tumor types. Alterations in MHC class I are 
often observed to be due to direct structural alterations or transcriptional or post-
transcriptional dysregulation. Mutations in the HLA class I β2 side chain is mutated in 
21% of CRC and 15% of melanomas. Haplotype loss was found in 36% of head and 
neck squamous cell carcinomas. These modifications allow for evasion for immune 
surveillance (80). In addition to loss of MHC, tumor antigens can be lost, shielding 
tumors from TAA specific T or B cell responses. Additionally, tumors equip 
themselves with increased levels of antiapoptotic proteins such as survivin and 
cFLIP that are able to render the tumors resistant to death receptor-mediated 
apoptosis. While impervious to death receptor-mediated killing themselves, tumors 
exploit these mechanisms and express FasL which induces death in Fas+ immune 
cells. FasL expression has been described in melanoma, colon carcinoma and lung 
carcinoma (81). Tumors also present PD-1 ligands (PD-L1 and PD-L2) that induce 
anergy in T cells directly after contact. In addition to direct cell interaction molecules, 
tumors upregulate immune suppressive and tumor promoting cytokines such as 
VEGF, IL-10, TGF-β, PGE2, soluble Fas and FasL (82). Finally, solid tumors are 
notorious for creating oxidative stress (83) that directly impact the survival of anti-
tumor immunity (84) but are able to enrich suppressive Tregs due to their increased 
TRX1 levels (85) .  
1.2.2.2 Tumor recruited immune suppressive cells 
 
The chronic inflammation that the tumors induce leads to the recruitment of diverse 
cells types whose principle function is to dampen inflammation. In a natural 
pathogenic event, the immune system responds and induces inflammation to allow 
for the recruitment of a wide variety of cells to clear the pathogen. Once this has 
been achieved and inflammation is no longer required Tregs and Myeloid-derived 
suppressor cells (MDSC) are recruited to subside the immune response. This 
mechanism is hijacked by the tumor to facilitate its immune escape.  
 
Tregs have an essential role in peripheral tolerance, and when recruited to the tumor 
microenvironment are able to significantly inhibit anti-tumor immune responses. 
Tregs are CD4+ T cells typically characterized with the high expression of CD25 and 
FoxP3. They have a myriad of different methods by which they exert their 
suppressive nature. Tregs, when activated, secrete IL-10, TGF-β and IL-35 that bind 
to their cognate receptors on conventional T cells that suppress cytokine production 
and cytolytic as well proliferative functions. IL-2 is required for T cell activation and 
proliferation; the high expression of CD25 facilitates the ability of Tregs to remove all 
local IL-2. This effectively blocks second signals from reaching anti-tumor immune 
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cells. In addition to mopping up IL-2 from the immediate milieu, Tregs are able to 
quench the local environment of ATP, generating adenosine that in addition to 
inhibiting T cells is able to tolerize DCs. Tolerizing DCs is the other main mechanism 
that Tregs utilize to prevent further T cell activation. It has been proposed that Tregs 
express LAG3 to bind MHC class II molecules and activate ITAMs within the DCs 
(32). 
 
 MDSC are recruited to the tumor microenvironment by chemokines as well as other 
tumor-secreted factors such as IL-1β, CSF and PGE2. The population of cells 
termed MDSCs are very well defined in mice, namely they express CD11b and Gr1 
cell surface proteins and are suppressive in nature. In humans the term MDSC 
refers to a highly heterogeneous population that has a variety of cell surface markers 
associated with them, but the key factor is their ability to be immune suppressive. 
Their suppressive potential is derived from multiple mechanisms. The secretion of 
suppressive cytokines, similar to those produced by Tregs, IL-10 and TGF-β. In 
addition to cytokines MDSC are able to produce ARG1 that catabolizes L-arginine to 
urea and ornithine, limiting the access of this essential amino acid to proliferating T 
cells. MDSC also deplete L-arginine from the microenvironment by producing iNOS 
that converts L-arginine to citrullin and nitric oxide. NO is typically converted into 
radical peroxynitrite, which can lead to the nitrosylation of TCRs, impairing their 
function. Reactive oxygen species are another potent mediator of immune 
dysfunction. NADPH oxidase subunits generate super oxide upon MDSC activation 
and mediate suppression in a cell-cell contact dependent manner (86). In addition to 
these mechanisms prostaglandins function directly as suppressive signals to effector 
T cells as well as supporting further recruitment and generation of MDSC (87). 
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1.2.3 Tumor Antigens 
Anti-tumor immunity can be mediated through various pathways, as described 
above. Some of the most potent are those mediated by adaptive immune cells. The 
ability of adaptive immune cells to mediate tumor killing requires the recognition of 
tumor antigens. There are two classes of tumor antigens, those that are unique to 
the tumor and those that are shared with healthy tissue. 
Antigens that are unique to the tumor are prime targets for anti-tumor immunity due 
to the fact that there can be no central tolerance to these antigens and TCR as well 
as BCR affinities to those epitopes can be high.  Tumors that are driven by 
mutations have a unique immunopeptidome, and these mutations can generate 
novel epitopes by altering a specific amino acid, shifting the reading frame or by 
extending the protein beyond the stop codon. The T cell response against melanoma 
is dominated by neo-antigen specificity (88). The anti-tumor immune response, and 
the prognosis for the patient, is determined by the immunogenicity of the mutations. 
If more than one immunogenic mutation is present the survival probability of the 
patient is improved (89). Tumors that are driven by viral infection, such as: head and 
neck, cervical, adult T cell leukemia, hairy-cell leukemia and Kaposi’s sarcoma all 
have the possibility to present highly immunogenic viral antigens. These antigens 
are unique to the virus and prophylactic vaccination against HPV, the driver virus 
behind head and neck as well as cervical cancer, has already proven effective. 
Gardasil and Cervarix, vaccines specific for HPV-16 and 18, induce high levels of 
antibody that neutralize HPV. HPV specific T cell epitopes have also been identified 
and are being used as targets for therapeutic vaccination (90). Tumors of the 
hematological B cell variety also express a unique antigen. These malignancies 
have, if their BCR is fully rearranged, a unique variable region in their BCR that 
defines is specificity, the idiotype (Id). There is a natural anti-Id antibody response 
that occurs upon high levels of immunoglobulin production, revealing the lack of 
tolerance to these antigens. Unique tumor antigens represent an interesting class of 
targetable antigens, particularly the viral antigens. The neo-antigen and Id-antigens 
retain the requirement of a per-patient identification of the epitopes and equally 
unique immunotherapeutic approaches (91,92).  
The other class of tumor antigens are those shared by the tumor and normal healthy 
tissue. But within this class there is a type of tumor antigen that is relatively specific; 
these are the cancer germline antigens (also known as cancer testis antigens). 
These are antigens that are expressed in relatively exclusively to testicular and 
ovarian germ cells. The MAGE family of cancer germline antigens have been found 
to be expressed in many different cancer types, including breast cancer, CRC and 
melanoma (93). NY-ESO-1 is a cancer testis antigen that was identified through 
screening of serum for cancer patients on bacteria transformed with tumor cDNA. 
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NY-ESO-1 is expressed by a wide variety of tumor types and represents an 
interesting tumor antigen due in part to its cell surface expression, allowing for 
antibody therapy, as well having described T cell epitopes, allowing for T cell therapy 
(94). Differentiation antigens represent a group of TAA that are antigens shared with 
a specific differentiated cell type. The most common examples are MART1, 
tyrosinase and gp100 that are all antigens expressed on melanocytes as well as 
melanomas. Targeting these antigens has shown to be effective, but has led to on-
target off-tumor side effects such as vitiligo. MART1 is an interesting antigen due to 
its relatively high frequency of specific T cells, 1 per 103, in healthy donor PBMC. 
Finally, the least specific TAA are those that are overexpressed on tumors, but are 
also expressed on healthy tissue. HER2, for example, is a member of the human 
epidermal growth factor receptor family and can be over expressed on breast 
cancer. Current antibody therapies target this molecule, but HER2 is also expressed 
on the cardiomyocytes epithelial cells and other tissues (95,96). Other tumor 
antigens overexpressed in tumors are carcinoembryonic antigen, Wilms’ tumor 
protein (WT1), which is expressed 10 to 1,000 fold higher in leukemic cells, and 
mucin 1 (MUC1), which is often overexpressed on adenocarcinomas and has both T 
as well as B cell epitopes (91,92,97).  
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2 PILLARS OF IMMUNOTHERAPY 
The pillars of cancer immunotherapy can be divided into two types, namely those 
therapies that can be either classified as passive or active immunotherapy. 
2.1 PASSIVE IMMUNOTHERAPY 
Passive immunotherapy includes 
those pillars of immunotherapy that 
are built around introducing 
immune system components, such 
as cytokines, monoclonal 
antibodies or adoptively transferred 
cells, into the patient that provides 
immunity against the tumor. 
2.1.1 Cytokine Therapy 
Cytokine-mediated signaling 
between cells cumulatively results 
in a diverse and pathogen-specific 
response. Cytokines, the small 
molecules responsible for 
intracellular communication, were 
one of the first immunotherapeutics 
available for the therapy of cancer patients. It is exactly for their role in activating and 
stimulating particular immune cell compartments that they make for interesting 
molecules to deliver. Two type I interferon molecules have been approved by the 
FDA. These are IFN-α2a, used in patients with hairy cell leukemia and Philadelphia 
chromosome-positive CML, and IFN-α2b which is applied to diseases such as AIDS-
related Kaposi’s sarcoma, follicular lymphoma, melanoma and cervical cancer. The 
FDA has also approved IL-2 for the treatment of metastatic melanoma and renal cell 
carcinoma. Many other cytokines are used in combination with varying 
immunotherapeutic modalities (98). 
2.1.2 Antibody Therapy 
Antibody therapy became a reality once the technique for the generation of 
monoclonal antibodies had been properly harnessed. In 1975 the first monoclonals 
were generated using hybridoma techniques with the first licensed monoclonal being 
OKT3, the antibody binding to CD3, for treatment in preventing kidney transplant 
rejection (100). Monoclonal antibodies are able to mediate an anti-tumor effect by 
binding directly to tumor antigens, or by engaging antigens found in the tumor 
microenvironment that indirectly lead to an anti-tumor effect. Antibody therapies 
have a couple of functional modalities, which include: Fc-region activation of 
William B. Coley is the grandfather of cancer 
immunotherapy. Serendipitously, he noticed that 
patients with sarcomas could have regression of their 
disease after severe infection post surgery (at this 
time, sterile technique was a novel concept). He 
decided to intentionally infect sarcoma patients with 
Streptococcus pyogenes; this immediately led to 
difficulties in dosage, infection rate and sepsis related 
fatality. To make patient responses more uniform to 
treatment he switched to an inoculation with killed S. 
pyogenes and Serratia marcescens. His first patient 
treated with this inoculation had a strong response 
that led to total disease regression; the patient died 26 
years later of a heart attack. “Coley’s toxins” were 
used many different malignant diseases with some 
success, but few studies were poorly documented, 
and with the advent of chemo and radiation therapy 
“Coley’s toxins” fell into obscurity. (99) 
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cytotoxicity through ADCC, ADCP and CDC, the inhibition of target protein signaling, 
the activation of TRAILR2 or other apoptosis inducing receptors, the delivery of 
toxins or radionuclides, the binding of factors produced by the tumor to enable 
growth and metastasis (101). Unconjugated antibodies used for therapy include 
Rituximab, which binds to CD20 expressed by non-Hodgkin lymphoma and chronic 
lymphocytic leukemia (102), Trastuzumab, which binds to HER2 on breast cancer 
(103,104), Cetuximab, which binds to EGFR on colorectal cancer (105) which have 
human IgG1 Fc regions allowing for functional Fc based cytotoxicity. These 
monoclonal antibodies target the tumor directly, though there are also a plethora of 
antibodies targeting the vast array of tumor associated pathways (106).  
Recently, antibody based therapy has once more come into the spotlight through the 
effective targeting of immune related targets, of which inhibitory checkpoint receptors 
PD-1 and CTLA4 targeted antibodies are having a phenomenal impact on cancer 
therapy. These antibodies block the inhibition of activated T cells. Ipilimumab and 
Tremelimumab, both target CTLA4 expressed on activated T cells and interfere with 
engagement of the ligands CD80 and CD86 on APC. Pembrolizumab and 
Nivolumab, both bind PD-1 and block its interaction with its cognate ligands PD-L1 
and PD-L2 expressed on a wide variety of cells including tumors (107,108).  
CTLA-4 blockade in stage III or IV melanoma increased overall survival to 10 months 
compared to 6.4 months for patients receiving gp100 peptide vaccines. This was a 
surprising finding as the group with gp100 plus Ipilimumab had similar overall 
survival to those only treated with Ipilimumab (109). PD-1 blockade using Nivolumab 
was able to induce objective responses in one of four patients burdened with either 
non-small-cell lung cancer, melanoma or renal-cell carcinoma but not in castration 
resistant prostate cancer or colorectal cancer (108,110,111).  
Monotherapy with checkpoint inhibitors has yielded promising results, pushing 
researchers to dream of combination therapies. Of course, as with all combination 
therapies, there are nearly unlimited combinations possible, but there are a couple I 
would like to highlight. Checkpoint blockade therapies could be combined together. 
Combination of Nivolumab together with Ipilimumab resulted in objective-response 
rates of 40%, with 65% of patients having immune-related clinical activity (112). This 
may not be surprising as both pathways provide T cell checkpoint blockades at 
different stages. The synergy between these antibodies and vaccination strategies is 
also very apparent. One example is the combination of αPD-1 treated mice together 
with multi-peptide based vaccine in a breast cancer mouse model (113). 
Combinations with checkpoint blockade antibodies also extend to classical 
therapies, where fractionated radiotherapy delivered in combination with either αPD-
1 or αPD-L1 increased tumor control in a IFN-γ T cell dependent manner (114). This 
was also the case of radiotherapy combined with anti-CTLA-4 antibody (115,116). 
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Additionally, the exploration of chemotherapies together with checkpoint inhibitors 
may prove fruitful (117,118). 
Patients who benefited from CTLA-4 blockade treatment were demonstrated to have 
high mutational load in their primary tumors. Further evaluation established that a 
neo-epitope signature could be predictive towards response to CTLA-4 treatment 
(119). This observation potentially extends towards other checkpoint inhibitors as 
well as immunostimulatory antibody therapies. Patients with colorectal carcinoma 
whose tumors lack the ability to correct mismatch defects have been reported to 
have greater benefit with anti-PD-1 therapy with significantly increased overall 
survival, a response pattern akin to that noted with neo-antigens and CTLA-4 
blockade (120). The above observations highlight the importance of T cell specific 
responses to unique tumor antigens.   
2.1.3 Adoptive Cell Therapy 
Originally, cancer therapy using cell transfer was done to restore the immune 
compartment in patients receiving high-dose myeloablative treatment. Myeloablative 
therapy could effectively cure some patients, but would result in hematopoietic 
failure. This led to attempts to rescue with hematopoietic stem cell transplant (HSCT) 
after treatment. HSCT in turn came with graft versus host disease (GVHD), the 
immunological rejection of host cells by grafted immune cells, which in some cases 
had a beneficial effect associated with lower relapse rates due to graft versus tumor 
effects. This graft versus tumor effect leading to potential cures in some patients was 
the first indication that immunotherapy using adoptive cell therapy (ACT) could be a 
potent actor in cancer therapy (121,122). 
2.1.3.1 Tumor infiltrating lymphocytes 
The transplant of HSC into patients after chemotherapies always had, and still 
struggles with severe GVHD. This undesirable off-target effect can be ameliorated 
by harnessing the antigen specificity of T cells. The difficulty however is that T cells 
specific for the tumor must be found in the patient. T cell infiltration into tumors is in 
most instances, a good prognostic factor for many tumor types. Tumor infiltrating 
lymphocytes (TIL) represent a source of tumor reactive T cells without the required 
exploration for patient-specific tumor antigens. Tumor samples are excised from the 
patient, cut into pieces and cultured with high dose IL-2. This leads to lymphocytes 
overgrowing the tumor tissue and allowing for testing of tumor reactivity. Tumor 
infiltrating lymphocytes are then expanded to approximately 1010 cells and re-infused 
into patients. Originally tumor-reactive TIL were generated from MC-38 colon 
adenocarcinomas in mice. Syngeneic mice treated with TIL in combination with IL-2 
and cyclophosphamide had dramatic increase in survival (123). Within two years this 
therapy, without the cyclophosphamide, was applied in human patients bearing 
resectable metastatic melanoma lesions, with regression in observable tumors in 
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60% of patients (124). When cyclophosphamide was added to the treatment 
regimen no difference in response rate was found between the arm without or with 
cyclophosphamide, while objective response rate was around 30% (125). This was 
followed up by using a total body irradiation, either chemotherapy alone, two or 12 
Gy irradiation, to lymphodeplete the patients prior to ACT. In the arm receiving the 
highest irradiation 72% of patients had objective response compared to 49% in the 
no total body irradiation group (126). These reports of TIL therapy of melanoma, 
driven in large part by the Rosenberg group at the NIH, has now spread to many 
other research institutions, including the Karolinska Institutet.  
TIL therapy requires the generation of tumor reactive lymphocytes derived from the 
patients tumor, this is frequently not possible due to surgical specimens not being 
available or limited infiltration of lesions by lymphocytes. Oved K et. al. has been 
able to establish that within non-reactive TIL there are populations of tumor reactive 
T cells. They generated an algorithm-based approach for enriching for tumor 
reactive TIL by screening patients that produced reactive TIL and compared their 
immunological signature with patients that had non-reactive TIL. To test their 
approach new patients were recruited, and from the 12 non-reactive TIL it was 
possible to recover 9 that would qualify for inclusion in TIL ACT (127). Removing 
non-essential, potentially suppressive cells from non-reactive TIL can be combined 
with positive selection for PD-1 positive TIL. T cells from TIL that were positive for 
inhibitory molecules, PD-1, LAG3 and TIM3 positive, were identified to be 
responsible for the autologous tumor reactive repertoire found in TIL (128). Though 
these strategies do increase the potential patient pool for TIL therapy, there will be 
many diseases for which this strategy will remain unfeasible (129,130).  
2.1.3.2 Transduced T cells 
The T cell receptor, and random recombination of its genes, enables T cells to 
specifically target antigens. TIL can be reactive towards tumor specific antigens, 
particularly those that have generated de novo mutations termed neo-antigens 
(131). In those patients where TIL and tumor specific T cells cannot be generated it 
is possible to engineer T cells with TCRs specific for tumor specific antigens. TCRs 
specific for MART-1, a melanoma differentiation antigen that has been a model 
melanoma tumor associated antigen, had been cloned out of human lymphocytes 
and transduced into patient PBL. MART-1-TCR-T were able to specifically react to 
MART-1 positive tumors in a HLA-A2 dependent manner. Two patients out of 15 had 
objective responses (132). An antigen that may prove interesting for tumor specific 
TCR redirected T cells is NY-ESO1. This is a cancer testis antigen that is well 
characterized, being expressed on 80% synovial cell sarcoma as well as 25% of 
melanomas. Treatment of patients with NY-ESO1-TCR-T led to four out of six 
objective responses in synovial cell sarcoma and five out of 11 objective responses 
in melanoma (133). To circumvent the pruning of high affinity TCRs by central 
  31 
tolerance mouse TCRs have been isolated in HLA-A2 transgenic mice specific for an 
epitope shared between MAGE family antigens. When MAGE-TCR-T cells were 
transferred into patients, there were objective responses against the target as well as 
serious adverse events leading to death in two patients. The TCR transduced T cells 
recognized MAGE-A12 in brain tissue (134). Further experimentation with modified 
MAGE-TCR-T led to severe cardiac toxicity and additional morbidity (135,136). This 
shows the extremely potent nature of redirecting T cells against antigens not well 
defined.  
Transducing T cells with designer genes provides a powerful tool to generate T cells 
with tumor specificity as described above. Unfortunately, one of the main 
mechanisms that tumors employ to evade T cell elimination is downregulation of 
MHC (137). Chimeric antigen receptor (CAR) bypass this mechanism of 
immunoevasion by endowing T cells with antibody-specific binding of targets on the 
cell surface (138). To activate T cells CARs have intracellular signaling domains 
such as CD3- ζ, CD28, 4-1BB, OX40 among others (129). The correct combination 
of activating signaling domains is under discussion, but it is clear that addition of 
second signal activation domains lead to increased persistence and T cell function in 
vivo (139). CAR-T cells have been in development for more than twenty years. Much 
progress has been made in this time, including the successful application in 
hematological malignancies. 
The treatment of B-cell malignancy in both children and adults with CAR specific for 
B cell surface markers has proven to be quite effective. The first success with CAR-T 
was achieved in a patient with B-cell advanced follicular lymphoma who was treated 
with CD19-CAR-T and underwent dramatic regression (140). This was followed up 
by the treatment of a CLL patient, where CD19-CAR-T was transplanted at a 
relatively low dose of 1.5x105 cells per kg but expanded more than 1000-fold. The 
patient went into remission soon after therapy (141). The second success was in the 
application of CD19-CAR-T in ALL patients, where potent effects were seen initially 
in treatment, though eventually one ALL patient escaped the CD19 specificity and 
progressed (142). The following year an additional study was published where 16 
patients with B-ALL were treated with CAR-T. 88% of patients went into complete 
remission and were moved to standard-of-care allogeneic HSCT (143). In a phase I 
clinical trial run by the NIH, CD19-CAR-T could be manufactured within 11 days and 
they reported that all toxicities associated with therapy were reversible, albeit still 
quite severe (144).  
The success of CD19-CAR-T has energized the field of ACT, especially with the 
adoption of this therapy by pharmaceutical companies such as Novartis, but this 
success may be limited to therapy for leukemia. One of the benefits of targeting this 
disease and particularly the antigens CD19 and CD20 is their constant re-
presentation in the form of healthy B cells to the CAR-T. Elimination of B cells in 
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these patients comes with considerable adverse events resulting from humoral 
immunity, and requires antibody replacement therapy for the foreseeable future for 
those treated with CD19-CAR-T. Nonetheless, this may be an advantage, as this will 
ensure long-lived protection from progressing disease. Transferring CD19-CAR into 
induced pluripotent stem cells provides a proof of concept for generating an unlimited 
source of CAR-T. These CAR-T were characterized by their similarity in phenotype 
to γδ T cells and were able to inhibit tumor growth (145). CAR-T have the potential to 
remodel the tumor microenvironment. CAR-T are able to activate TAM into anti-
tumor macrophages that use NO to lyse tumor cells. GM-CSF and IFN-γ produced 
by CAR-T were found to be responsible for this activation and inhibition of ovarian 
tumor growth (146). To further facilitate the activation on tumor resident 
macrophages the CAR-T cells have been modified to express IL-12 under minimal 
NFAT promoter. IL-12 being present in the tumor led to regression of tumors that 
were not expressing the CAR specific antigen due to macrophage lysis of tumors 
(147). 
In the treatment of solid tumors CAR therapy success has been less successful. The 
first trials with solid tumor CAR therapy included targeting carbonic anhydrase IX 
(CAIX), CD171, FR-α and GD2. For the treatment of renal cell carcinoma with CAIX-
CAR-T no clinical benefit was found. Neuroblastoma patients receiving CD171-
specific CAR-T had persistence of T cells for 6 weeks but only one patient had a 
partial response that relapsed once CAR-T were no longer detectable. The treatment 
of ovarian cancer with FR-α also saw no anti-tumor activity. Furthermore, utilizing 
HER2-CAR-T containing CD28 and 4-1BB co-stimulatory domains had immediate 
on-target off-tumor toxicity when transferred into the patient (148,149). This CAR 
therapy induced cytokine storm that precipitated the death of the patient (150). A 
more positive result was found for GD2-CAR-T, while initially not showing any direct 
effect in a long term follow-up study found that low-levels of CAR-T survived up to 
192 weeks and mediated a significant survival benefit (151). This strongly suggests 
that more refined control CAR-T, and a shift of focus away from CAR co-stimulatory 
domain modification is required for successful solid tumor therapy.  
2.1.3.3 NK adoptive cell therapy 
While T cells are potent killers when they recognize their cognate antigen, they 
require specificity to function. As discussed above, it is possible, through complex 
ex-vivo manipulation, to endow tumor specificity. One of the first clinical trials with 
adoptive lymphoid cells was done but culturing cells in IL-2, these were termed 
lymphokine-activated killer (LAK) cells and after transfer in a patient led to a 
response in 20% of the patients following re-infusion (152). These LAK cells contain 
a high proportion of NK cells. NK cells, in contrast to T cells, require no antigen 
specificity and are therefore an interesting modality for adoptive cell therapy. This 
approach has demonstrated success with hematological malignancies. In other 
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malignancies it is not yet effective (153). With regard to NK cell function in the 
context of stem cell transplant, it has been shown that KIR mismatch increases the 
NK cells activation against their target, leading to improved lysis of leukemia (154). 
NK cells transferred in patients previously treated with high dose chemotherapy 
increased engraftment and serum concentrations of IL-15 (155). 
2.2 ACTIVE IMMUNOTHERAPY 
Inducing an immune response to 
antigens in vivo is the essence of active 
immunotherapy. The pillars of active 
cancer immunotherapy include 
modalities such as DC vaccination, 
peptide vaccination as well as nucleic 
acid based vaccination (157).  
2.2.1 Dendritic Cell Vaccination 
Dendritic cells are at the core 
vaccination. These cells are responsible 
for driving immunity against antigens in 
all vaccine strategies, and since their 
discovery by Ralph Steinman have been 
the focus of intense investigation. To 
date there is one FDA approved 
dendritic-cell-based vaccination for 
humans, sipuleucel-T. This vaccine has 
been approved for use in minimally symptomatic metastatic castration-refractory 
prostate cancer. Patients treated with sipuleucel-T have a modest increased in 
median survival of a little more than four months compared to placebo group 
(158,159). Sipuleucel-T is considered a DC vaccination, but it is a product derived 
from leukapheresis where granulocytes, lymphocytes and low-density monocytes 
are removed, leaving behind dendritic-cell precursors. These are then washed and 
pulsed with a fusion protein consisting of prostatic acid phosphatase (PAP) and GM-
CSF. For 40 hours they are incubated in serum/cytokine free medium prior to 
infusion into patients (160). In contrast to many other clinical DC trials the sipuleucel-
T vaccination product does include ex-vivo maturation of the DCs (161).  
Metastatic melanoma is one of the first tumor types with well-described tumor 
associated antigens (162,163). This allowed for the development of therapies 
specifically eliciting responses to these antigens. By pulsing DCs with peptides, 
Melan-A, gp100, tyrosinase among other melanoma antigens prior to intravenous 
injection four out of 14 of the patients were able to mount a detectable antigens 
specific response and two had measurable anti-tumor effects. The DCs were 
Edward Jenner laid the foundation for 
vaccination. The term “vaccine” was coined by 
his contemporary and fellow vaccinologist 
Louis Pasteur in tribute to the first vaccine 
being derived from cowpox. Edward made the 
observation that milkmaids who had 
contracted cowpox would not suffer from 
smallpox. To test this he vaccinated his 
gardeners’ son, James Phipps, by inserting 
fluid from a cowpox lesion into his skin. The 
boy had a mild reaction to the vaccination. Six 
weeks after vaccination Edward took fresh 
smallpox pustule material and inoculated the 
boy. Even after repeated challenges James 
did not present any disease. He late 
exclaimed: “I hope that some day the practice 
of producing cowpox in human beings will 
spread over the world - when that day comes, 
there will be no more smallpox.” The WHO 
declared smallpox eradicated in 1980.(156) 
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generated from CD34+ cells, and matured into DCs by culture in cytokine cocktails 
including IL-4/GM-CSF followed by TNF-α (164). In a similar study, DCs derived 
from CD34+ progenitor cells pulsed with melanoma antigens generated responses in 
16 out of 18 patients. In this setting immunogenic antigens, KLH and Flu peptides, 
were pulsed along with melanoma antigens on the DCs. The two patients who did 
not react to melanoma antigens or control antigens had rapid progression of 
disease, while all other patients had an immunological response to at least one of 
the melanoma antigens. In this study overall immunity to melanoma antigens was 
associated with improved clinical outcome (165). A target for immunotherapy that 
remains intriguing is the unique tumor antigen expressed by B cell lymphomas (166). 
B cell lymphomas can be targeted based on their idiotype (Id), the unique variable 
regions of the clonal immunoglobulin. In the case of B-cell lymphoma this is 
expressed on all cells of the disease, as it is clonal in nature. DCs were generated 
from PMBC purified by leukapheresis and pulsed with Id-purified proteins together 
with an immunogenic carrier protein KLH. DCs were reinfused into patients and were 
able to generate cellular or humoral responses in 65% of patients. Six patients who 
did not have direct benefit were boosted with Id-KLH-DC vaccines, of which two had 
complete response and one had a partial response (167). Proceeding with 
leukapheresis to procure PBMC from which generate DCs, particularly when 
harvesting monocytes from which to generate DCs, in cancer patients comes with 
the inherent issue of co-purifying monocytic MDSC that inhibit maturation of DCs 
(168). Additionally, GM-CSF used to mobilize CD34+ cells from the bone marrow is 
able to recruit MDSC(169). To overcome the recruitment and isolation of MDSC, but 
also to initiate a type I interferon centric type of immune response, pDCs have been 
used to vaccinate metastatic melanoma patients. Via apheresis pDC were directly 
isolated from patients using magnetic bead sorting based on pDC cell surface 
marker BDCA4. Melanoma antigens were pulsed onto DCs in combination with 
FSME-IMMUN for activation of pDC. The patients were injected subcutaneously 
and pDCs were able to migrate to multiple lymphnodes. These patients had a 
overall survival of 22 months which was significantly improved when compared to 
historical controls that had an overall survival of 7.6 months (170). 
With innumerable DC therapies ongoing, and 43 clinical trials being completed last 
year alone, interest in using this modality of immunotherapy remains strong (161).  
2.2.2 Peptide Vaccination 
Peptide vaccinations rely upon the knowledge which antigens are expressed by the 
tumors. All different classes of tumor-associated antigens have been targets of 
vaccination with the most impressive results being generated in peptide or protein 
vaccine approaches using non-self tumor specific epitopes. Vaccination against non-
self peptides evades the central tolerance trimming of potential anti-tumor specific T 
cells. HPV16-induced gynecological carcinomas are a prime target for this mode of 
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vaccination. These develop from the premalignant states that are caused by high-
risk types of HPV. When patients in this premalignant state are vaccinated with 
overlapping 25-35-mer peptides covering HPV16 E6 and E7 proteins 9 out of 19 
patients had complete remissions of their disease (171). When long-peptide 
vaccination was used in advanced gynecological carcinomas, T cell responses were 
elicited, but these were restrained by tumor mediated immune suppressions so while 
it was possible to elicit a response no direct clinical effect was noted (172). 
Melanoma, and melanoma-associated antigens have also been used for peptide-
based vaccination. TAA gp100 has been used as a target of peptide vaccination. In 
a clinical trial commenced after the discovery of this TAA, two 9-mer peptides were 
mixed with IFA and patients were vaccinated thrice in combination with high dose IL-
2. Surprisingly, 42% of 31 patients had objective responses (173). In a follow-up 
phase-III trial, comparing IL-2 with vaccination using gp100 peptides combined with 
IL-2, a less stellar response was noted with only 16% response rate. This was still 
significantly higher than IL-2 alone which had a response of 6% with 11.1 months 
overall survival compared to 17.8 with peptide vaccination (174). In RCC, another 
immunogenic tumor, vaccination with a multi-peptide vaccine IMA901 which contains 
epitopes for antigens such as Cyclin D1 and MUC1 was able to generate responses 
to multiple epitopes (175). This vaccine, in combination with cyclophosphamide, 
elicited immune responses that were associated with clinical benefit, particularly in 
patients with low suppressive cell populations (176). 
While peptide vaccines get to the heart of vaccination they must overcome hurdles 
that other modes of vaccine do not need to overcome. As DCs remain the lodestone 
of vaccine strategies, injection with peptide alone would generate a weak or possibly 
toleragenic response, hence the requirement of adjuvants to generate “danger 
signals” in DCs. These include adjuvants such as montanide, incomplete Freund’s 
adjuvant, monophosphoryl lipid A, BCG as well as imiquimod that are able to 
activate PRRs through various mechanisms and activate DCs (177). Additionally, 
fusion protein-peptides that contain DC ligands have been developed to ensure that 
the peptide is presented by APCs which is optimally effective to deliver antigen 
(178). A MUC1 fusion protein based vaccine approach targeting mannose receptor 
in the setting of stage II breast cancer has shown remarkable effect. Out of 16 
patients vaccinated only two had a recurrence, while in the placebo group the 
expected recurrence rate of 60% in 15 patients was noted (179). Further augmenting 
epitope responses can be achieved through modification of single or multiple amino 
acids in the peptides used for vaccination. This was indeed already the case for the 
gp100 vaccinations where a threonine was replaced with a methionine led to 
increase overall responses in patients (173). Modification of other melanoma 
antigens has led to increased binding to MHC and directly led to increased levels of 
IFN-γ production in T cells and increased anti-tumor immune response (180).  
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2.2.3 Nucleic Acid Vaccination 
 
With nucleic acid vaccination we take an extra step further from directly inducing 
immunity by DCs primed ex vivo and peptides loaded onto DCs in vivo to genetic 
information encoding TAAs. With the advent of molecular biology, the manipulation 
of nucleic acids to express the desired antigens, fusion proteins, cytokines or other 
immunostimulatory proteins becomes accessible and feasible. In addition, to being 
especially suited to manipulation, nucleic acids are innately immunogenic, as they 
are natural “danger signals”. While peptide and protein vaccines rely on adjuvants, 
nucleic acids are their own adjuvant and are able to bind to the many DAMP binding 
PRRs described above (181,182).  
 
The delivery of nucleic acids for vaccination can be done using various vectors, 
including viral, bacterial, naked plasmid DNA or naked RNA. Initial findings for the 
use of DNA vaccines against viral antigens was that the therapy was well-tolerated, 
with no integration of DNA into the genome, no autoimmunity and no tolerance, and 
was able to induce both cellular as well as humoral immunity in patients (183). DNA 
vaccines have generally been delivered either intramuscularly or intradermally. In 
both cases antigens are presented in either a direct or indirect route. Antigen 
encoding DNA delivered directly into DC cells allows for direct presentation of TAA 
epitopes. APCs can also collect antigens through cross-presentation facilitated by 
the uptake of DNA by keratinocytes or myocytes. Thus DCs are able to elicit both 
CD4+ as well as CD8+ T cell responses (184).  
 
The first attempt at utilizing DNA vaccines was targeting immunogenic antigens such 
as those found in influenza. Mice vaccinated with nucleoprotein encoding DNA 
mounted cytotoxic CD8+ T cell as well as antibody responses (185). This provided 
the basis of expanding DNA vaccination to tumors. The first DNA vaccine targeting 
human tumors was in B-cell lymphomas targeting the Id region. Hawkins et al. were 
able to show that it was possible to easily generate patient-specific DNA vaccines 
that would produce antigen that would be recognized by the patients’ immune 
system (186). Using this technology a phase I study was set up to test the safety 
and feasibility of DNA vaccines targeting Id. The Id was fused to mouse Ig constant 
regions in a plasmid DNA vaccine delivered using a gene-gun. Six out of 12 patients 
were able to mount humoral or cellular anti-Id responses though no clinical response 
was observed (167). Other hematological malignancies could be targeted through 
vaccination against WT1 tumor antigen using rationally designed DNA vaccines. In 
HHD mice, highly potent CTLs were generated that were able to kill WT1 expressing 
tumor cell lines (187). As with peptide vaccines, DNA vaccines have been utilized to 
generate responses against melanoma antigens. In a study to compare xenogeneic 
responses, 18 stage III and IV melanoma patients were randomized into groups 
where either three vaccines with mouse tyrosinase was followed by three vaccines 
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with human tyrosinase or vice versa. Xenogeneic vaccination had no impact, but 
overall seven out of 18 patients generated T cell responses to native tyrosinase 
peptide. When, compared to historical controls, patients on trial had a median 
survival of 42 months compared to 36 months (188). DNA vaccination using plasmid 
DNA encoding HER2/neu in combination with IL-2 and GM-CSF as adjuvants, was 
able to generate both humoral and cellular immunity in metastatic breast cancer 
patients, though once again no clinical benefit could be demonstrated (189).  
 
Some successes have been recently made with DNA vaccines. A DNA vaccine 
approach targeting MAM-A, a TAA expressed by 40-80% of primary breast cancers, 
was delivered IM with a Needle Free Biojector and patients were able to generate de 
novo responses to this MAM-A. Vaccination was able to induce CD8+ T cell antigen 
specific IFN-γ response in eight out of eight HLA-A2 patients. Impressively, at six 
months 53% of patients were progression-free while 33% of the patients not meeting 
the HLA-based inclusion criteria for the vaccine remained progression free (190). 
DNA vaccines in stage III HPV-positive cervical intraepithelial neoplasia patients 
were able to elicit CD8+ T cell responses against E6/E7 that resulted in complete 
clinical regression of lesions and viral clearance. DNA vaccines were delivered via 
intramuscular electroporation generating potent multifunctional T cell responses 
(191). DNA vaccination has also been tested in prostate cancer, eliciting CTL and 
antibody response has been possible but was not effective clinically (192,193). 
Combining immune-checkpoint blockade antibodies together with vaccination is able 
to release anti-tumor vaccine generated immunity. This has been shown to be the 
case for PD-1 and PD-L1 checkpoint blockade in combination with prostate cancer 
antigen DNA vaccine SSX2 (194). 
 
A platform of nucleic acid based vaccination that is resurging to prominence is the 
delivery of in vitro transcribed (IVT) RNA. After an extended hiatus, due in part to 
perceived instability, RNA vaccines are showing some unique advantages over 
DNA-based vaccination. Namely that IVT RNA does not need to enter the nucleus to 
be functional, and is immediately translated upon cellular uptake. IVT RNA based 
vaccines are also transiently active and metabolically degraded in a short amount of 
time (181,195). In addition, very low doses of RNA, in combination with α-virus 
replicon technology, are able to generate virus specific antibodies and T cells. This 
would allow for improved scale up from rodents to humans (196). The ease of 
manipulation of nucleic acids allowed for the generation of Id patient specific DNA 
vaccines, and now RNA vaccines are being utilized for the generation of neo-antigen 
based vaccines. This is a clinical trial to keep an eye on for the potential therapeutic 
application of future cancer vaccines (197).   
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3 AIMS OF THE THESIS 
The general aim of this thesis is to progress the fields of both passive and active 
cancer immunotherapy. In recent years both have been making great strides in 
therapeutic outcome for patients. While progress is encouraging, many obstacles 
have not been properly addressed. In this thesis I address the hurdles of tumor 
mediated immune suppression in passive immunotherapy as well as furthering the 
understanding and boosting active immunotherapeutic reaction against known as 
well as novel tumor antigens. 
Strengthening the pillar of passive immunotherapy 
 Paper I. Catalase protects tumor redirected T cells from oxidative 
stress. Tumor cells and associated suppressive cells have the capacity to generate 
abnormally large quantities of reactive oxygen species that lead to oxidative stress 
and immune dysfunction. We modified T cells ex-vivo with chimeric antigen 
receptors, to endow them with tumor specificity, as well as with catalase to offer 
protection from oxidative stress that allows modified T cells to remain functional 
under oxidative stress. 
Strengthening the pillar of active immunotherapy 
 Paper II. Intradermal DNA vaccine induced anti-tumor immunity 
requires NF-κB. Vaccination with antigen encoding DNA is able to elicit a specific 
cytotoxic T cell response. The mechanism with which this immunity is established 
was explored in multiple knockout mouse models. We were able to identify that 
some expected pathways were not players, and the majority of anti-tumor activity 
rested on NF-κB activation. 
 Paper III. Delivery of a genetic adjuvant boosts anti-tumor 
immunity. Based on the previous findings, we strove to increase anti-tumor CTL 
responses to antigen encoded by the DNA through the addition of plasmid DNA 
encoding a genetic adjuvant. This led to a type I IFN dependent increase in tumor 
specific CTLs that were able to increase survival in tumor challenged mice. 
 Paper IV. Protection against metastatic cancers could be induced 
by vaccination targeting Cripto-1. The success of cancer vaccines rests on the 
antigens that are in the arsenal of immunotherapists to utilize for vaccination. We 
developed a cancer vaccine that is able to elicit adaptive immune responses against 
Cripto-1 leading to decreases in metastatic spread as well as inhibiting the growth of 
cancer stem cells.  
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4 RESULTS AND DISCUSSION 
4.1 PROTECTING TUMOR REDIRECTED CAR-T CELLS FROM ROS 
Co-expressed catalase protects chimeric antigen receptor-redirected T cells 
as well as bystander cells from oxidative stress-induced loss of anti-tumor 
activity 
Manuscript 
Tumor infiltrating lymphocytes are associated with better prognosis in a variety of 
cancer types. Therapy using TIL expanded ex-vivo has been established as a 
remarkably effective passive-immunotherapy approach for metastatic melanoma 
patients. This highlights the potent nature of adoptively transferring lymphocytes, but 
unfortunately it is not always possible to generate TIL for each patient, particularly 
TIL that are reactive to their malignant clone. Modification of T cells with CAR ex-
vivo, a trans-membrane fusion protein that endows T cells with tumor specificity as 
well as activation potential, is an alternative to enriching tumor reactive T cells from 
TIL. CAR modified T cells have been successfully applied to acute as well as chronic 
lymphocytic leukemia, and may soon become a replacement for standard therapy for 
this disease. Treating solid tumors with CAR-modified T cells has proved to be less 
effective. It is not only required of the T cells that they recognize and target the 
tumor; they must also be able to survive and retain their function in the tumor 
microenvironment. One of the factors leading to immune-dysfunction in the tumor 
microenvironment is the high level of oxidative stress that are encountered by the 
transferred lymphocytes. ROS production is not exclusively the domain of the tumor 
cells but also myeloid derived suppressor cells, and regulatory T cells as well as 
granulocytes recruited by the tumor. In this study we attempted to relieve the burden 
of oxidative stress by endowing CAR redirected T cells with catalase. 
We confirmed that the retroviral CAR and catalase encoding bi-cistronic expression 
vector transduced T cells and lead to significant increases in catalase activity. T cells 
transduced with CAR and catalase (CAR-CAT) were found to have lower basal 
oxidative stress than T cells transduced with only CAR. CAR-CAT T cells were able 
to maintain a reduced state during activation with mitogens while CAR T cells 
became stressed. The stress induced by H2O2 led to dysfunction in CAR T cells but 
not in CAR-CAT T cells. This was found to be the case for both proliferation as well 
as specific cytotoxic tumor lysis by the T cells. In addition to a direct benefit to the 
CAR-CAT T cells, we found the these transduced T cells were able to mediate a 
beneficial bystander effect; leading to reduced bystander lymphocytes which were 
able to maintain lower oxidative state as well as preventing loss of CD3-ζ. In the 
case of bystander NK cells, CAR-CAT T cells were able to maintain NK cell cytolytic 
function. 
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The tumor microenvironment is a complex mix of cells, signaling and of constant 
flux. It is in this environment that CAR transduced T cells must enter and commence 
their elimination of the tumor mass. Researchers have long been struggling to 
optimize the CAR fusion protein directly. The discussion between whether CD28, 4-
1BB, OX40 or other co-stimulatory fusion combinations has dominated the 
landscape of CAR modified T cells. With this work we attempt to steer the 
conversation on adoptive T cell therapy in the direction of addressing the other 
obstacles present in the tumor microenvironment.  
In the tumor microenvironment, one of the hurdles that needed to be addressed is 
oxidative stress. The CARs used in this study were directed at CEA and HER2, both 
tumor antigens expressed commonly on a variety of breast cancer and colorectal 
cancer. Both these tumors are typified by their high ROS production and associated 
oxidative stress; lymphocytes present in both diseases have been found to have 
high levels of oxidative stress.  We revealed that by co-expressing catalase in T cells 
together with CARs led to reduced lymphocytic oxidative stress and maintained T 
cell functionality. In the case of adoptive cell transfer, there is a requirement for rapid 
expansion of cells ex-vivo, typically leading to the generation of effector and effector 
memory T cells, both subsets of T cells more susceptible to oxidative stress than 
their naïve T cell counterparts. We also found that non-transduced bystander cells 
were protected from oxidative stress when co-cultured with CAR-CAT transduced T 
cells. In the tumor microenvironment ROS has an extremely detrimental effect on NK 
cells, and may be one of the largest factors to their nearly non-essential role in most 
tumors. Combining tumor redirected CAR T cells with transgenic expression of 
molecules that lead to resistance of adoptively transferred cells to the suppressive 
tumor microenvironment may bring about the success of this therapy beyond the 
scope of its use now.  
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4.2 NF-ΚB LINKS DERMAL DNA VACCINATION TO IMMUNITY 
NF-κB activation during intradermal DNA vaccination is essential for eliciting 
tumor protective antigen-specific CTL responses 
Human Vaccines & Immunotherapeutics 2013, 9:10, 2189-2195 
Activating a tumor specific cellular adaptive immune response has been a long-
standing goal in the field of cancer-vaccines. DNA vaccines provide an interesting 
platform for the discovery as well as delivery of novel tumor associated antigen 
based vaccines (198). Delivery of DNA vaccines has found two main sites of 
interest, namely intramuscular and intradermal, and with the assistance of 
electroporation leading to increased CTL responses to the encoded antigens 
(199,200). Delivery of DNA to the dermis is of particular interest due to resident 
APC, both Langerhans cells as well as dermal DCs, present at this site. These cells 
are proficient at processing the antigen as well as migrating to lymphoid organs and 
eliciting antigen specific responses (201). The activation of resting DCs is mediated 
through potentially a plethora of pathogen-recognition receptor. DNA found in the 
cytosol, such as after electroporation based DNA vaccine delivery, is a potent 
danger associated molecular pattern leading to the triggering of NF-κB as well as 
IRFs. Improving the efficacy of DNA vaccines requires a more thorough 
understanding of the pathways and transcription factors involved in eliciting a 
protective anti-tumor immune response.  
DNA vaccines encoding antigens, either highly immunogenic model antigen 
ovalbumin (OVA) or tumor associated antigen tyrosinase related antigen 2 (TRP2), 
were delivered using intradermal electroporation. Cytotoxic T lymphocyte responses 
were evaluated using intracellular cytokine staining as well as in vivo cytotoxicity 
assays. Type I interferons are one of the key cytokines responsible for linking innate 
and adaptive immunity; this link is laid through the common IFN-α receptor as well 
as through the activation of transcription factor IRF3. IFN-α receptor and IRF3 
knockout mice showed no decrease in peripheral blood activated CTLs, nor was the 
function of CTLs impaired in IFN-α receptor knockout mice. We evaluated the role of 
classical bacterial DNA sensor TLR9 and its adaptor protein MyD88 to mediate a 
role in establishing CTL based immunity, but found neither to play a role in either 
eliciting CTLs or dampening their function. Inflammatory cytokines IL-1 and IL-18 
have been described to be regulated in part by AIM2, a cytosolic DNA sensor that 
activates caspase-1. In IL-1/IL-18 KO mice vaccination was not found to decrease 
CTL induction or efficacy compared to WT mice. NF-κB, a potent regulator of cell 
survival and inflammation, on the other hand was found to be activated by DNA 
vaccination and to be responsible for mediating TRP2 specific CTL responses. Most 
importantly, the decreased responses by inhibition of NF-κB signaling abrogated the 
anti-tumor response generated by DNA vaccination.  
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While it is not wholly surprising that NF-κB can play such an essential role in eliciting 
immunity, our findings that type I interferon were not required was surprising. The 
field of DNA-sensing innate immune receptors has expanded enormously in the past 
few years, including many new molecules and pathways, but essentially leading still 
to either the activation of IRFs or NF-κB. Previous studies have shown that in TBK-1, 
IRF3 and IFN-α receptor pathway knockout mice DNA vaccine elicited CTL 
responses were almost completely eliminated (202,203). These findings are in stark 
contrast to the results generated in our model, and yet can be reconciled due to the 
fact that delivery of DNA in those studies was done intramuscularly. It is not 
unreasonable to consider that the location of vaccine delivery will have an impact on 
antigen immune responses. Indeed, α-virus replicon-based vectors, which lead to 
the production of large amounts of cytosolic RNA, were hampered by type I IFNs 
when delivered intradermally (204). Activation of NF-κB in DCs leads to the 
production of potent inflammatory cytokines, including IL-12, IL-6 and TNF-α, up-
regulating secondary signaling, including CD80 and CD86, as well as increasing 
survival, by regulating BCL-2, Bcl-XL among others (205). Uncovering the role of 
these transcription factors opens up the field to direct improvement of DNA vaccines.  
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4.3 DAI BOOSTS DNA VACCINE BASED ANTI-TUMORAL IMMUNITY 
DAI (DKN-1/ZBP1) as a Genetic Adjuvant for DNA Vaccines that promotes 
effective antitumor CTL immunity 
Molecular Therapy 2011, 19:3, 594-601 
DNA vaccines, while an attractive choice for antigen delivery due to its safety and 
ease of production, have yet to have the same impact in the clinic as has been 
shown in animal models (182). Tumor specific CTLs are implicated in favorable 
clinical prognosis of cancer patients. Eliciting a CTL response potent enough 
remains challenging for DNA vaccination; there are many underlying issues for these 
frail immune responses, one of which is that tumor-associated antigen epitopes 
detectable by T cells are normal non-mutated self-antigens that are either negatively 
selected against or become T regulatory cells. To ameliorate these issues proper 
delivery of DNA vaccines and strong adjuvants are necessary to generate a potent 
anti-tumor immunity. Clinical trials comparing electroporation of DNA vaccines to 
standard delivery have been able to show that this method of delivery to be much 
more superior than without electroporation. The co-delivery of cytokines, and even 
co-delivery of cytokine encoding DNA, indicate the importance of generating the 
correct immune context to induce potent CTLs (206). In this study we look upstream 
of these cytokines and endeavor to harness a cytosolic DNA sensor, DAI, to engage 
maturation of dermal DCs and activation of T cells through its co-delivery with an 
antigen encoding DNA vaccine.  
DNA vaccine delivery via intradermal electroporation has been shown to induce the 
transcription of many pro-inflammatory genes. We found that in addition to these 
already increased levels, co-administration with DAI encoding plasmid DNA (pDAI) 
significantly increased type I IFN gene expression as well as markers related to DC 
maturation and T cell activation. Co-delivery of pDAI with antigen-encoding plasmid 
DNA stimulated increased in-vivo proliferation, antigen specific cytotoxicity and ex-
vivo antigen specific cytokine production. Tumor associated antigen vaccination in 
combination with pDAI enhanced anti-tumor responses significantly, endowing 
challenged mice with increased survival. Mice that survived the primary challenge 
were re-challenged and found to be protected by a memory response that was not 
present in TAA-DNA vaccinated mice alone. Evaluation of antigen specific T cells 
revealed that using pDAI in combination with antigen encoding DNA for vaccination 
significantly increased the percent of effector memory (CD44high CD62Llow) and 
central memory cells (CD44high CD62Lhigh) T cells; this corresponded nicely with 
increased survival after tumor re-challenge. Additionally, we evaluated the 
mechanisms involved with the adjuvanting effect of pDAI co-delivery and found them 
to be mediated by both NF-κB as well as type I IFNs. 
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In our previous study we found that type I IFNs were dispensable to tumor specific 
CTL responses elicited by DNA vaccines. We speculated that by introducing an 
intracellular PRR as a genetic adjuvant we would be able to harness a wide variety 
of proinflammatory signaling molecules activated by PRRs to enhance the DNA 
vaccine induced response. It is important to note that previous studies have 
employed encoding cytokines on plasmid DNA to adjuvant DNA vaccine responses 
(207,208). These have shown increased anti-tumor effect, on the other hand, these 
strategies may lead to the recruitment of suppressive T regulatory as well as myeloid 
suppressor cells (209,210). While employing an upstream regulator of a plethora of 
inflammatory responses we can abrogate the recruitment of suppressive cells and 
induce a potent anti-tumor immunity.   
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4.4 ONCOFETAL PROTEIN CRIPTO-1 IS TARGETABLE BY DNA 
VACCINATION 
Vaccination against tumor-associated antigen Cripto-1 elicits a protective 
immune response to metastatic melanoma and breast cancer stem cells 
Manuscript 
Vaccination against pathogens has protected the lives of billions of people. Using 
this treatment modality to treat cancer patients has left much to be desired, as most 
responses generated in patients have been underwhelming at best. Though 
immunologists should remain steadfast in their resolve to generate vaccine induced 
responses potent enough to mediate protection in patients. In the previous work we 
have demonstrated a method to enhance CTL responses, but development on 
targeting novel antigens is required as well. To date many tumor associated 
antigens, such as MAGE-A, gp100, Ny-ESO-1, Tyrosinase and HER2 to name a 
few, have been targeted by vaccination but have been met with limited success 
(211). It may very well be that these antigens, while up-regulated on bulk tumor, 
were not the optimal targets for the application of cancer vaccines. Cripto-1 (CR), a 
small cell surface glycoprotein, is an interesting target in that it has been shown to be 
involved in rapid proliferation, angiogenesis as well as epithelial-mesenchymal 
transition (212). Additionally, breast cancer patients with high levels staining for CR 
have poor prognosis (213). Interestingly, CR has been identified on cancer stem 
cells as well (214). These are small populations within the tumor mass responsible 
for generating the daughter cells that drive tumor growth. Additionally, cancer stem 
cells are resistant to classical cancer therapies, including radiation, chemo and 
surgical therapy. These attributes constitute the hallmarks of progressive disease 
and targeting these pathways with vaccination may have a greater impact than 
targeting general tumor-associated antigens. 
Mice were vaccinated using plasmid DNA encoding for mouse CR (mCR). 
Prophylactic vaccination in C57BL/6 mice reduced B16F10 transplantation growth as 
well as increasing survival of vaccinated mice. More impressive results were 
obtained when vaccinated mice were challenged intravenously, significantly reducing 
lung metastasis. We identified three potential epitopes by stabilizing MHC class I 
molecules on RMA-s cells. Two of the epitopes were able to stimulate ex-vivo 
peripheral blood lymphocytes to produce IFN-γ and TNF-α. CD8+ T cells isolated 
from vaccinated mice produced IFN-γ upon co-culture with B16F10 as well as 
stimulation with mCR16-25. To explore whether mCR vaccination would be effective in 
additional models, BALB/c mice were vaccinated and we found that they were able 
to produce antibodies specific for mCR. When challenged with a spontaneously 
metastasizing breast cancer model the vaccination was able to very significantly 
reduce the metastatic index by 6 fold, while the effect on tumor mass was a 
significant reduction of 1.5 fold. To evaluate the effect of vaccination on cancer stem 
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cells (CSCs), a tumor cell line expressing low levels of mCR was cultured in 
mammospheres. Each progressive passage on low attachment plates increased 
mCR expression allowing vaccination against the target to decrease tumor growth as 
well as improving survival. In a therapeutic setting, BALB-neuT mice were 
vaccinated in week 10, when female mice typically already have developed in situ 
carcinoma. Vaccination in this setting significantly reduced metastatic burden. 
In this study we show that vaccination against CR induces a cellular and humoral 
responses in a variety of mouse models. These responses are able to inhibit tumor 
growth, though this was not found to be the case in the BALB-neuT mice. While the 
vaccination was not able to restrain solid tumor growth, it was able to have a very 
large impact on the spread of metastatic disease. In addition to halting metastatic 
spread, vaccination of mice against CR endowed mice with anti-tumor immunity that 
was able to hinder the growth of transplanted cancer stem cells. CSCs have been 
shown to have increased expression of CR in melanoma, prostate and breast cancer 
(215-217). CSCs in breast cancer have high metastatic potential. This highlights the 
efficacy of anti-tumor immunity against small groups of cells that are essential to 
eliminate to increase survival of cancer patients. 
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5 FUTURE PILLARS OF CANCER IMMUNOTHERAPY 
With growing success of passive immunotherapies, and the increasingly positive 
results from active immunotherapy trials, there is a renaissance occurring in cancer 
immunotherapy that is translating to novel treatments that, in contrast to many 
classical therapies, are able to cure cancer patients. But, of course we are in the field 
of cancer research, and while not all cancer patients are treatable we must pursue 
improvements. There are innumerable ways forward, but I will highlight a couple that 
I find promising. 
5.1 HARNESSING THE POTENCY OF ADOPTIVE CELL TRANSFER 
Adoptive cell therapy, particularly in the form of CAR redirected cell therapy, is 
coming into the main stream. With companies such as Novartis investing in large-
scale production facilities (buying out Dendreon), we should soon see CD19-CAR-T 
treatment for the masses. Of course, harnessing the potent cytolytic potential of T 
cells has worked well for hematological malignancies; it is yet to be similarly 
successful in solid tumors.  
Modifying T cells through the use of viral vectors and transposons allow for further 
modification beyond delivery of CAR. In our study we transferred catalase to offer 
protection from the suppressive tumor microenvironment. This concept is being 
pushed forward in our lab at the moment with delivery of TRX1 and silencing of 
KEAP1 to further facilitate protection from oxidative stress. This is of course just one 
aspect of immunosuppression that can be targeted; already a double-negative 
receptor for TGF-β has been shown to covey resistance to T cells from this 
suppressive factor (218). Targeting checkpoint inhibitory molecules is a prime target 
for improvement of ACT, especially in light of clinical success of these antibodies. To 
achieve this various new techniques, such as CRISPR/Cas, ZFN or RNAi, can be 
utilized. Recently, this has been achieved in TIL from melanoma patients in which 
ZFN targeting PDCD-1 gene knocked out 74.8% of the PD-1 encoding gene. This 
led to increased proliferation and enhanced polyfunctional T cells (219).  
Expression of IL-12 in a NFAT regulated manner in both CAR as well as TIL therapy 
modalities brings potential to remodeling of the tumor microenvironment. In a recent 
clinical trial using TIL with IL-12 production 63% of patients had objective response 
at a TIL transfer rate 10-100 fold less than in typical TIL therapy. Serious adverse 
events clearly indicate that an approach like this requires acute control and 
monitoring (220). In mouse models for CEA, CEA-TRUCK-T (fourth generation 
CAR(147)) have proven to mobilize and re-educate M2 TAM into anti-tumor 
macrophages. This enables the elimination of TAA negative tumors along with 
positive tumors (221).  
Finally, adoptive T cell transfer is a modality that has shown to be potentially fatal. It 
is important to harness these potent cytolytic cells, and it should be reasonable to 
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consider building in kill switches (222) or utilize RNA electroporation of T cells. This 
would minimize on-target but off-tumor adverse events. 
5.2 EXPLOITING WINDOWS OF OPPORTUNITY 
The official acceptance of vaccination, particularly the approval of sipuleucel-T as a 
therapy for prostate cancer by the FDA, is a boon to field of cancer vaccines. It 
shows that there is certainly room for vaccination in our field. The demise of the 
company producing the sipuleucel-T vaccine also highlights the enormous hurdles 
needed to be overcome by cancer vaccines. Sipuleucel-T vaccine induces a 
measurable immune response in most patients, but again, this immune response 
was only able to show a very limited increase in survival. In our work we have tried to 
address some of these issues, but there is much more room for strengthening this 
pillar of cancer immune therapy. 
The first, most obvious room for improvement is finding the window of opportunity for 
vaccination, particularly when considering that ten vaccines should be given against 
hepatitis B, rotavirus, diphtheria, influenza and many others before children have 
become one year of age. Additional vaccines and booster shoots are given up to 18 
years, as recommended by the CDC. Of interest is the HPV vaccine, which is 
recommended to be initiated at a range of 11-12 years old though may be taken in 
females from 13-26 (223). The goal of HPV vaccination is to prevent the 
development of virus induced cancers. Vaccination at this stage in the life cycle of 
humans is due to the ability of younger children to develop potentially life long 
immunity against a large variety of diseases. At the moment, therapeutic vaccination 
is the only option available for inducing immunity against cancer. Cancer is often 
considered a disease of the elderly, there are of course tragic exceptions, but 
nonetheless 36% of all cancer cases are diagnosed in people above 75 years of 
age. Age comes with natural immunosenescence. The nature of immunosenescence 
is such that innate immunity is compromised; HSCs are less active and have a 
skewed preference towards generating myeloid cells (224), a marked reduction in 
the ability of neutrophils and DCs to phagocytose (225). Immunosenescence leads 
to changes in adaptive immune responses as well; T-cell diversity is compromised 
with expansions being only clonal in nature (226). Dysfunction in innate immunity 
leads to dysfunction in adaptive immunity (225).  
These issues are compounded when taken in the context of cancer patients, where 
the tumor induces a systemic immune suppression. In the context of vaccination, 
MDSC have found to be inversely correlated to response (227). In addition to the 
prognostic value of MDSC to response in RCC patients, the burden of Tregs was an 
additional prognostic marker. Depletion of Tregs by cyclophosphamide increased 
overall survival in patients (176). Taken together, this makes a strong argument for 
the window of opportunity being when the prospective cancer patient is treated with 
vaccination at a younger age. A truly prophylactic anti-cancer vaccine would be able 
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to enhance immune surveillance and reduce cancer development. A promising 
direction is being taken in the vaccination against MUC1 in patients with pre-CRC 
lesions (228). Cervical cancer is a cancer that may also be an appropriate vaccine 
candidate in this context, it can have visible pre-malignant stages which allow for 
vaccination to be applied in a relatively healthy patient (229). Pre-malignant cervical 
cancers have a 30% chance of becoming invasive cancers (230). A DNA vaccine 
has recently shown promising results (190), building upon the success of long-
peptide vaccines (171). Additionally for other cancers such as malignant melanoma, 
metastatic breast cancer and colorectal carcinoma pre-malignant stages are 
frequently identified and would provide many opportunities for inducing immunity in 
non-suppressed, younger patients (231).  
When therapeutic vaccination becomes a necessity, combination therapy must be 
used to force a window of opportunity. Potential for combinations is nearly endless, 
and many arguments could be made for all. Briefly, surgery has been shown to 
reduce MDSC in breast cancer models (232) as well as CRC patients, where Tregs 
were additionally reduced (233). Targeting of Tregs can be done with anti-CD25 to 
augment peptide based vaccination (234). In combination with chemotherapy, 
peptide based vaccine strategies synergize to produce robust TNF-α and IFN-γ 
leading to reduction of MDSC and increased survival (235). Cyclophosphamide has 
been shown to reduce Treg levels and increase effectiveness of vaccines (176), but 
may also have a detrimental effect on anti-tumor immune compartments by 
recruiting MDSC (236). Exposure of tumors to ionizing irradiation reduces MDSC 
and changes suppressive immune infiltrate to an immunogenic one (237). 
Additionally targeting MDSC can be done in a novel manner by targeting their 
metabolism by inhibiting fatty acid oxidation. The delivery of etomoxir, an inhibitory of 
fatty acid oxidation, allowed for increased efficacy of vaccination against tumors 
(238). TAMs are potentially another cell population that either needs to be 
reprogrammed or eliminated. This can be done by targeting CSF-1R (239) or 
through the vaccination response itself. Vaccine induced T cells have a direct effect 
on being able to shape macrophages from an M2 to M1 phenotype, and these 
interactions and changes of the tumor microenvironment are essential to the 
success of peptide based vaccination (240).  
Finally, antigens are a major consideration for vaccination and which to target is 
central to each application. Neoantigens pose an interesting opportunity for 
vaccination in a therapeutic setting as theoretically they are novel and central or 
peripheral tolerance will not hinder their immunogenicity. Many trials are ongoing, 
both as vaccines but also for adoptive cell therapies, attempting to harness these 
antigens. But while this therapy may not suffer from tolerance, it will suffer economic 
hardships as the feasibility of generating neoantigen therapies are beyond the 
means of many. Driver mutations provide interesting alternatives to patient specific 
neoantigen vaccines or adoptive cell therapy. Such a mutant has been described in 
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the protein IDH1 that is expressed by a large majority of grade II or III gliomas. 
Vaccination with long peptides in this case is applicable to a wide variety of patients 
while still having the advantage of being a neoantigen (241,242). Additionally, while 
neoantigens may provide the foundations of a new pillar of cancer immunotherapy, it 
is key to consider that recent findings have once again highlighted that central 
tolerance may not be as eager to eliminate self-reactive T cells as previously 
expected (243). 
The pillars of cancer immunotherapy are being built upon a solid foundation of 
oncology and immunology provided by decades of dedicated researchers. Many 
aspects of these cancer immunotherapies will continue to evolve in the coming 
decades, pushing the boundaries of which diseases are treatable and how well the 
patients will respond to immunotherapeutic treatments. I am looking forward to future 
where we can vaccinate and transfer anti-tumor immunity to protect and cure cancer 
patients. I hope that my contribution of mortar, stones and rubble have helped 
solidify and strengthen the pillars of cancer immunotherapy.  
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Abstract 
 
Treatment of cancer patients by adoptive T cell therapy has yielded promising 
results. In solid tumors, however, T cells encounter a hostile environment, in 
particular with increased inflammatory activity as a hallmark of the tumor 
milieu that goes along with abundant reactive oxygen species (ROS) that 
substantially impair anti-tumor activity. We present a strategy to render anti-
tumor T cells more resilient towards ROS by co-expressing catalase along 
with a tumor specific chimeric antigen receptor (CAR) in order to increase 
their anti-oxidative capacity by metabolizing hydrogen peroxide (H2O2). In 
fact, T cells engineered with a bi-cistronic vector that concurrently expresses 
catalase (CAR-CAT) along with the CAR performed superior over CAR T cells 
as they showed increased levels of intracellular catalase and had a reduced 
oxidative state with less ROS accumulation in both the basal state and upon 
activation while maintaining their anti-tumor activity despite high H2O2 levels. 
Moreover, CAR-CAT T cells exerted a substantial bystander protection of 
non-transfected immune effector cells as measured by CD3ζ chain expression 
in bystander T cells even in presence of high H2O2 concentrations. Bystander 
NK cells, otherwise ROS-sensitive, efficiently eliminate their K562 target cells 
under H2O2-induced oxidative stress when admixed with CAR-CAT T cells. 
This approach represents a novel means for protecting tumor-infiltrating cells 
from tumor-associated oxidative stress-mediated repression.  
 

 
 
 
 
Introduction 
 
Tumor infiltrating lymphocytes (TILs) have long been recognized as a 
prognostic factor for cancer patients in a variety of tumor types (1). This has 
spurred the development of adoptive cell therapy with TILs, which in 
combination with non-myeloblative lymphodepletion regimens has resulted in 
some remarkable clinical response rates in metastatic melanoma patients (2, 
3). Isolation and expansion of TILs from cancer patients is however not 
feasible for all tumor types, and genetic transfer of tumor specificity with T cell 
receptors (TCR) and chimeric antigen receptors (CAR) into T cells from 
peripheral blood is an attractive alternative. Similar to conventional T cells, the 
limitation of TCR transduced T cells are in their inability to recognize tumors 
that have down- regulated their MHC-class I molecules (4, 5). CARs 
circumvent this by providing specificity by a single chain fragment of a 
variable antibody region specific for a surface tumor antigen. CARs activate T 
cells through intracellular signaling domains such as CD3ζ which is improved 
by costimulation including CD28 or 4-1BB (6). Recently, transfer of such 
“second generation” CAR T cells targeting CD19 positive B cell lymphoid 
leukemia has shown encouraging clinical results in treating patients with bulky 
tumors (7-10). Though these results are galvanizing the field of adoptive cell 
therapy, clinical trials focusing on solid tumors have seen less success (11-
13). The challenge for T cell based therapies of solid tumors lays in that T 
cells, in addition to reaching their targets, are required to survive and function 
within the unfavorable tumor microenvironment (TME).  
 
Tumors cells have long been known to have high levels of oxidative stress 
and reactive oxygen species (ROS) which have been shown to play key roles 
in many aspects of tumorigenesis (14). Reactive oxygen intermediaries (ROI) 
and ROS, such as super oxide and hydrogen peroxide, are produced by all 
mammalian cells mainly as part of normal mitochondrial metabolic processes. 
Innate phagocytic immune cells produce high levels of ROS through the 
NADPH oxidase complex as their primary mechanisms of clearing bacterial 
infections. Oxidative stress exists when the balance between ROS production 
and antioxidant function is shifted in favor of ROS. Increased production of 
ROI in tumor cells can be attributed to alterations in metabolic pathways, as 
exemplified by glucose deprivation in breast carcinomas leading to decrease 
in intracellular pyruvate preventing decomposition of ROI (15).  
 
Also tumor-infiltrating immune cells may be responsible for a large part of the 
ROS production. Thus immature myeloid cells found in tumors effectuate their 
suppressive function on the immune system via ROS (16, 17). Cancer 
patients have been found to have increased levels of activated granulocytes 
(18), subsequently defined as granulocytic myeloid derived suppressor cells 
(grMDSCs) (19). High concentrations of ROS can lead to necrotic cell death, 
although there is a window of ROS induced oxidative stress in which 
lymphocytes are still viable but become unresponsive (18). This has been 
linked to blockage of NF-κB activation due to protein oxidation, resulting in 
 
deficient IFNγ, TNFα, and IL-2 production (20, 21).  ROS induced alterations 
in T cell and NK cell functions may also be attributed to the decreased TCR-ζ 
and CD16-ζ chain levels found in tumor bearing patients and mice (22-24), 
which is associated with tumor accumulation of myeloid cells (25).  
 
We have shown that T cells transduced with catalase (CAT) survive and 
function in toxic concentrations of H2O2 (26). To adapt the approach to cell 
therapy we aimed at enhancing persistence and function of tumor- redirected 
T cells in the environment of high oxidative stress. Here, we demonstrate that 
T cells modified with a bi-cistronic expression vector co-expressing the CAR 
as well as catalase (CAR-CAT) produce increased amounts of intracellular 
catalase and have a reduced intracellular oxidative state. This improves 
protection of the CAR-CAT transduced T cells from intrinsic oxidative stress, 
which is a result of T cell stimulation, as well as from extrinsic - especially 
tumor-associated - ROS. Such CAR-CAT T cells are able to lyse tumor cells 
in antigen specific manner under H2O2 induced oxidative stress, under which 
CAR T cells failed to do so. Furthermore, CAR-CAT T cells elicited a 
protective bystander effect allowing neighboring NK cells to kill tumor cells 
within a detrimental environment. CAR-CAT T cells provide a strategy to 
maintain anti-tumor activity of resident and adoptively transferred immune 
cells within the oxidative stress environment of tumors. 
 
 
  
 
Materials and Methods 
 
Cells and Reagents 
HEK293T and SkoV3 cells were maintained in complete RPMI 1640 L-
Glutamine+ medium supplemented with 10% (v/v) FCS, PenStrep (100 U/ml 
penicillin and 100 U/ml streptomycin), 1% MEM non-essential amino acids, 
1mM Sodium Pyruvate and 50 µM 2-Mercaptoethanol (Life Technologies). 
PBMCs were obtained from healthy donors and used for transduction as well 
as the lymphocytic fraction from a healthy leukapheresis donor. These were 
either cultured in activation medium consisting of complete RPMI 1640 
GlutaMAX with the addition of 500 U/ml IL-2 (Proleukin) or stimulation 
medium consisting of complete RPMI 1640 supplemented with 500 U/ml IL-2 
and 100 ng/ml anti-CD3 (Orthoclone OKT3).  
 
CAR engineering of T cells 
T cells were transduced with recombinant retroviruses as described 
previously (27). T cells were purified from healthy donor PBMC followed by 
Pan T cell isolation (Miltenyi biotec) or by leukapheresis followed by elutriation 
and collection of the second fraction containing more than 95% lymphocytes. 
Elutriated lymphocytes were frozen down in 10% DMSO FCS and thawed 
prior to use. Lymphocytes were cultured in stimulation medium for two days 
then transferred to activation medium for four days. In parallel HEK293T cells 
were transfected with retroviral packaging plasmids pCOLT and pHIT60 along 
with a CAR expression vector using JetPrime (Polyplus). Activated 
lymphocytes were co-cultured with virus producing transiently transfected 
HEK293T cells for 48 hours. Transduction efficiency was analyzed by flow 
cytometry with goat F(ab)2 anti-human IgG PE (Southern Biotech) and mouse 
anti-human CD3-APC (BioLegend).  
 
Catalase Detection 
Transduced T cells were sorted using anti-PE MACs (Miltenyi biotec) beads in 
combination with F(ab)2 anti-human IgG PE (Southern Biotech). Sorted CAR 
positive lymphocytes were lysed in Cell Lytic M (Sigma-Aldrich) at a 
concentration of 1x106 cells per 100µL. Protein concentrations of lysates were 
measured using Pierce BCA assay (Thermo Scientific). Catalase activity 
assays were performed as per manufactures instructions after normalization 
based on BCA assay (Life Technologies). To evaluate catalase protein 
expression western blots were performed as follows. 20 µg of lysate were 
loaded into 10% NuPAGE Bis-Tris acrylamide gels (Invitrogen) and run for 45 
minutes at 200 V followed by transfer onto PVDF membrane for 3 hours at 40 
V. Catalase was stained using 1:1000 dilution of rabbit α-human catalase 
(GenScript, A01202), actin was stained using mouse α-beta-actin at a dilution 
of 1:25,000 (Sigma-Aldrich) overnight at 4oC. HRP linked α-rabbit and α-
mouse antibodies were used for secondary antibodies (Cell Signaling 
Technology) and membranes were developed with ECL Prime Western 
Blotting Detection Reagent (GE Healthcare). Intracellular staining and 
detection of catalase  was done using Cytofix/Cytoperm Kit (BD); catalase 
was stained using 2.5 µg/µl of rabbit anti-human Catalase antibody 
(GenScript) followed by anti-rabbit IgG FITC (Pharmingen) conjugated 
antibody. 
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Cell Death Assay 
Lymphocytes were cultured in RPMI 1640 + L-glutamine supplemented with 
500 U/ml IL2 at a concentration of 1x106 cells per ml in the presence of H2O2. 
After 24 hours cells were washed with PBS and then stained with anti-human 
CD3-APC (BioLegend), 7-AAD (BioLegend) and AnnexinV-FITC (BioLegend) 
and acquired on BD LSRII. 
 
Detection of thiols, reactive oxygen species and oxidative state 
Cell surface thiols were evaluated using Alexa Fluor 488-C5-maleimide (Life 
Technologies). Staining was done by washing cells thrice with 4oC PBS 
followed by labeling with 5µM maleimide for 20 minutes at 4oC in the dark. 
Cells were labeled with antibodies prior to acquisition on BD LSRII.  Free 
reactive oxygen species were measured using L-012 luminol probe (Wako 
Chemicals GmbH). 0.5 mg/ml was the final concentration of L-012 in medium 
with cells. Luminescence was measured using (Centro LB 960) plate reader. 
CellROX (Invitrogen) was used to determine intracellular oxidative states. 
1x105 lymphocytes were loaded with 5 µM CellROX for short-term assays or 
0.5 µM CellROX for long-term assays at 37oC for 10 minutes. For basal ROS 
measurements, cells were incubated at 37oC for the indicated duration 
followed by staining with anti-human CD3 PO (BioLegend) and F(ab)2 anti-
human IgG PE (Southern Biotech) prior to acquisition with BD LSRII. To 
stimulate intracellular ROS, cells were activated by phorbol 12-myristate 13-
acetate (PMA) (3 ng/µl) or dihydroxy-napthoquinone (DHNQ) (20 µM) for 2 
hours prior to antibody labeling and acquisition by flow cytometry.  
 
Cytotoxicity and Proliferation assay 
Her2 positive SkoV3 cells were used as targets for Her2 specific CAR 
transduced T cells in standard chromium release assays. K562 were used as 
targets for NK cells. Target cells were loaded with 51Cr (50µCi) (PerkinElmer) 
for one hour there after being washed of excess 51Cr. Target cells were 
incubated for one hour in complete medium prior to being plated out into 96-
well plates together with effector cells at different E:T ratios. Following co-
culture with effector cells for 18 hours 25 µl of supernatant was transferred 
onto LumaPlates (PerkinElmer) and after desiccation were analyzed on the 
Micro-Beta scintillation (TRILUX 1450, PerkinElmer) plate reader.  For 
proliferation, 5 x 103 T cells were seeded in a 96-well U bottom plate and 
stimulated to proliferate with 1µl anti-CD3/CD28 mAB0-coated beads per well. 
Every 24 hours cells were collected by Micro-Beta scintillation counter 
(TRILUX 1450, PerkinElmer) after pulsing with 3H-thymidine (31µCi per well) 
(PerkinElmer) for 4 hours. 
 
  
 
Results 
 
CAR redirected T cells engineered with catalase. 
 
Human peripheral blood T cells from healthy donors were engineered with a 
CAR specific for CEA or Her2 with or without a bi-cistronic cassette to co-
express catalase. Catalase expressing CAR constructs (CAR-CAT) were 
based upon the CEA specific CAR BW431/26scFv-IgG1-CD28-CD3ζ and the 
Her2 specific CAR C6-B1.D2-IgG1-CD28-CD3ζ CAR (27, 28) by inserting the 
full-length human catalase cDNA downstream of the internal ribosome entry 
site (Figure 1A). Non-transduced T cells and T cells modified with a truncated 
NGFR specific CAR (Ctrl-CAR) lacking internal T cell signaling domains were 
used as controls. Retroviral transduction of these constructs into T cells gave 
efficiencies of approximately 55% CAR positive cells (Figure 1B). To 
determine the level of catalase present in the transduced T cells, CAR 
positive and negative cells were sorted from freshly transduced T cells using 
MACs beads specific for the CAR IgG linker region and the catalase recorded 
by Western blot analysis (Figure 1C). No differences were seen in the 
negative fractions of transduced T cells (Supplementary Figure 1A). To 
confirm the function of catalase in CAR positive cells, a catalase activity assay 
was performed on lysates from CAR, CAR-CAT, and Ctrl-CAR sorted cells. 
CAR-CAT transduced T cells were found to contain more than seven-fold 
higher catalase activity than CAR T cells without transduced catalase or Ctrl-
CAR T cells (Fig 1D). Catalase activity was also measured in the lysate of 
CAR negative T cells and found to not to significantly differ between samples 
(Supplementary Figure 1B). Freshly transduced T cells were evaluated for 
their ability to neutralize H2O2. L-012, a ROS sensitive luminol (29)was added 
to T cells prior to addition of 50 µM H2O2. CAR-CAT T cells significantly 
reduced luminescence (Figure 1E) indicating reduced ROS activity in the 
presence of CAT Catalase was recorded in CAR-CAT T cells upon 
permeabilization indicating intracellular localization (Figure 1F).  
 
CAR-CAT T cells display an increased antioxidant capacity against intrinsic 
ROS upon T cell activation  
 
Activation of lymphocytes induces increased mitochondrial activity resulting in 
oxidative stress (30). We next asked if CAR-CAT T cells are more resistant to 
this type of cellular stress especially. Freshly transduced T cells were labeled 
with the oxidative stress indicator CellROX directly after transduction. The 
basal oxidative state was found to be lower in the CAR-CAT T cells compared 
to CAR T cells without transduced catalase (Figure 2A). This was also found 
to be the case after long-term culture (Figure 2B). We additionally stained 
cells with maleimide-alexa-488 and found that the difference between CAR-
CAT and CAR T cells were minimal at 0 mM H2O2, but at 1 mM H2O2 CAR T 
cells were not able to maintain cell surface thiols with a MFI decrease of 20% 
while CAR-CAT maintained cell surface thiols with a decrease of 0.7%. A 
reduced oxidative state in the CAR-CAT T cells compared to CAR only 
transduced cells was also found after co-cultured for 24 hours with SkoV3 
tumor cells (Supplementary Figure 2).  
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T cells encountering antigen at the tumor site will induce oxidative stress in 
the engaged T cells. To simulate this effect we stimulated CellROX labeled T 
cells by incubation with PMA or DHNQ (Figure 2C). CAR-CAT T cells 
displayed a decreased CellROX MFI compared to CAR T cells following PMA 
or DHNQ stimulation, similar to the differences found between their levels of 
basal oxidative states, indicating less oxidative stress of catalase engineered 
T cells upon activation.  
 
CAR-CAT T cells maintain their activity under H2O2 stress 
 
To examine if CAR-CAT transduced T cells were more resistant to high levels 
of oxidative stress cells were cultured in increasing concentrations of H2O2 
(Figure 3A). T cells were freshly transduced and not sorted for CAR T cells. At 
100 µM H2O2 CAR T cells were only 59% viable, which dropped to less than 
30% viability at 200 H2O2. CAR-CAT T cells faired superior retaining their 
viability at 200 µM H2O2.  Of note, activation of T cells for retroviral 
modification itself increased the resistance of T cells to oxidative stress 
compared to non-modified T cells. 
 
Even if adoptively transferred T cells are able to survive in the presence of 
increased ROS levels, maintaining their function with respect to redirected 
cytolysis and amplifications remains crucial for their anti-tumor efficacy. When 
T cells recognize their target antigen they become strongly proliferative, as 
shown for CD19 specific CAR adoptively transferred into CLL patients (31). 
To address this issue we assayed the ability of T cells to proliferate at a level 
of ROS insult at which T cell viability is not affected. Transduced T cells were 
pulsed with 50 µM H2O2 and incubated with anti-CD3 and anti-CD28 beads 
for CAR independent stimulation. At this concentration of H2O2, CAR-CAT T 
cells still maintained their proliferative potential after 4 days compared to 
control T cells (p < 0 .005, Figure 3B). 
 
We asked whether these cells retain their CAR endowed tumor specific 
effector functions. To address this, we studied the ability of Her2 specific CAR 
T cells to lyse the Her2+ SkoV3 ovarian carcinoma cells under oxidative 
stress. CAR mediated specific lysis of SkoV3 cells was almost abolished in 
the CAR T cells at a concentration of 12.5 mM H2O2 , while the CAR-CAT 
transduced T cells efficiently lysed the SkoV3 cells (Figure 3C). Data 
demonstrate the superior capacity of CAR-CAT transduced T cells to maintain 
their tumor-specific cytotoxic function under conditions of oxidative stress 
where this function is lost in non-modified T cells.  
 
CAR-CAT T cells mediate a protective bystander effect  
  
The reduction of ROS by the CAR-CAT T cells may protect also non-modified 
immune cells in their vicinity. To investigate whether CAR-CAT T cells provide 
protection to bystanders, autologous non-modified T cells were stained by 
CellROX. CAR negative cells had decreased CellROX MFI for one hour as 
well as well as overnight staining (Figure 4A). To address whether this would 
be the case when oxidative stress was introduced, autologous T cells were 
labeled with CFSE and admixed with CAR or CAR-CAT engineered 
 	
lymphocytes. CAR-CAT bystander cells maintained basal oxidative stress 
level, while those admixed with CAR had increased oxidative stress (Figure 
4B). Additionally, the level of surface thiols in CAR-CAT negative autologous 
T cells was reduced when compared to CAR negative autologous T cells 
(Figure 3C). The results showed that these non-transduced T cells co-cultured 
together with the CAR-CAT transduced cells had a reduced oxidative state 
when compared to their counterparts co-cultured together with CAR T cells. 
The supernatant had a five-fold increase in catalase activity in CAR-CAT T 
cell culture compared to from the supernatant of CAR T cells (Figure 4D). We 
conclude that CAR-CAT T cells released catalase in substantial amounts 
which reduced the oxidative state of co-cultured cells. 
 
Intracellular oxidative stress, induced directly by the cancer cells or by 
immune-suppressive cells infiltrating the tumor lesion, can regulate T cell 
functions by reduingthe CD3-ζ making TCR mediated T cell activation less 
efficient (22, 32). We therefore studied if the CAR-CAT T cells, in a bystander 
fashion, could protect the non-transduced T cells from this detrimental 
repression. To simulate the situation, transduced and non-transduced T-cells 
were co-cultured, subjected to H2O2 insult and then stained for CD3-ζ. 
Exposure to H2O2 decreased of CD3-ζ in the non-modified T cells when co-
cultured with non-modified or CAR modified T cells. In contrast, co-incubation 
with CAR-CAT T cells maintained CD3-ζ levels of bystander T cells (Figure 
4E). In the third donor, no decrease in CD3-ζ was detected in bystander T 
cells (data not shown).  
 
Tumor infiltrating lymphocytes also include NK cells which are sensitive to 
H2O2 induced inactivation (33). To address whether the CAR-CAT T cell 
mediated bystander effect is protective for NK cells in the near vicinity of the 
transduced T cells, NK cells were admixed with transduced T cells at a ratio of 
two transduced T cells to one NK cell and the cytolytic capability of the NK 
cells was assessed against K562 target cells under increasing concentrations 
of H2O2. In the absence of oxidative stress, there was no difference in NK cell 
mediated cytotoxicity against K562 co-cultured with CAR-CAT, CAR or Ctrl-
CAR T cells (Fig 4F). In contrast, when exposed to increasing levels of H2O2, 
the NK cells co-incubated with CAR-CAT T cells were consistently more 
efficient in killing the K562 cells than NK cells co-cultured with CAR, Ctrl-CAR 
transduced or non-transduced T cells. We conclude that CAR-CAT T cells 
protect in trans both T and NK cells from oxidative stress mediated 
repression.  
 

Discussion 
 
Adoptive therapy with CAR modified T cells offers a powerful therapy for a 
variety of malignant entities. This has been realized for the treatment of 
hematological tumors such as CLL and ALL (9, 31); treatment of solid tumors, 
however, faces additional hurdles and needs further optimization (6). The 
stroma of solid tumors constitutes a barrier that actively suppresses the 
function of the adoptively transferred T cells by various immune suppressive 
mechanisms including mediators such as ROS, arginase, IDO, and PGE2 (34, 
35). In this study we demonstrate that redirected T cells, engineered to target 
tumor cells by a CAR specific for a cell surface antigen, can be protected from 
ROS induced oxidative stress by co-expressing catalase.  The CARs used in 
this study are specific for Her2 and CEA, respectively, and have been shown 
to eliminate tumor cells with the respective targets in a specific fashion (28, 
36). The Her2 or CEA are highly expressed in a variety of breast cancer and 
colorectal cancer (CRC) lesions, respectively (37, 38), both of which have 
increased ROS production and local oxidative stress (15, 39). In CRC, 
oxidative stress promotes proliferation of tumor cells while being insufficient to 
cause cell death (40). Carcinoma infiltrating lymphocytes have experienced 
high levels of oxidative stress as measured by 8-OHdG staining (39).  Also 
breast cancers have high levels of oxidative stress, being a driving factor in 
breast cancer progression. Accordingly, lymphocytes from breast cancer 
patients exhibit increased oxidized DNA levels as compared to healthy donor 
lymphocytes (41). Interestingly, when reducing oxidative stress in aggressive 
breast cancer tumors are sensitized to chemotherapy (15). This ROS feature 
of both cancer types provides the rationale for a potentially beneficial effect of 
co-expressing catalase in CAR transduced T cells homing to these tumors.  
 
We revealed that co-expressing catalase in CAR T cells allowed for a reduced 
oxidative state in engineered T cells, an effect that remained when cells were 
activated by TCR/CD3 engagement or while co-cultured with tumor cells. A 
reduced oxidative state is essential for maintaining T cell function in the long-
term. This is particularly of clinical relevance in the setting of adoptive cell 
therapy where the transplanted T cells are thousand fold expanded ex vivo 
prior to transfer and entering the tumor tissues. T cell subsets are differentially 
affected by ROS, particularly CD8+ T effector memory cells being more 
susceptible to ROS induced cell death and loss in function than their naïve T 
cell counterparts (21). These memory cells are essential for providing a better 
clinical outcome in CRC patients (42).  
 
The tumor tissue is infiltrated with a large number of immune cells, most of 
which are not of lymphoid but of myeloid origin. These macrophages, 
monocytes, granulocytes and myeloid derived suppressor cells (MDSCs) 
produce ROS and thus suppress the lymphoid anti-tumor immune response. 
Activated infiltrating granulocytes in particular inactivate T cells, and addition 
of ROS scavengers was able to rescue their function (18). MDSCs are potent 
producers of ROS, mainly through the activation of the NOX2 pathway leading 
to the production of super oxide, and have been shown to exert some of their 
suppressive function through this pathway (17). High catalase activity in those 
 
tumor targeting lymphoid cells upon transgenic catalase expression provides 
a strategy to resist ROS mediated repression in the tumor tissue. 
 
In patients, CAR transduced T cells are able to clear large tumor burdens, 
sometimes leading to tumor lysis syndrome (8). We confirmed the high 
efficacy of the CAR transduced T cells in cytotoxicity assays. CAR-CAT T 
cells retained their ability to lyse Her2 positive tumor cells under conditions of 
oxidative stress, while this ability was lost in control CAR T cells. Furthermore, 
50 µM H2O2 affected the capacity of control T cells and CAR T cells to 
proliferate in response to a strong proliferative stimulus while CAR-CAT 
transduced T cells retained proliferative capacity (Figure 3B). We conclude 
that genetically modified T cells which over-express catalase resist oxidative 
stress to certain levels which may be sufficient to induced remain functional 
upon entering the tumor stroma.  
 
Protecting tumor infiltrating T and NK cells from ROS mediated inactivation 
would maintain their anti-tumor activity, the latter cells attacking those cancer 
cells which lack the particular tumor-associated antigen recognized by 
redirected T cells. In line with this concept we found that CAR-CAT T cells 
were capable of reducing the oxidative state of bystander T cells. Under these 
conditions NK cells are enabled to execute their anti-tumor response. This 
bystander effect was likely mediated by the catalase present in the 
supernatant of CAR-CAT T cells. We showed that T cells engineered with 
CAR and catalase preserved CD3-ζ levels of the bystander T cells (Fig 4E). 
This may result in more efficient tumor elimination, including of cancer cells 
lacking CAR targeted antigens. Protecting bystander immune cells in trans by 
catalase engineered T cells may thereby indirectly provide a benefit in the 
therapy of solid tumors. In addition to CAR redirected T cells themselves, 
tumor infiltrating lymphocytes, which are inactivated by ROS producing 
stroma cells may become reactivated when ROS induced 
immunosuppression is removed. Increased oxidative stress decreases 
TCR/CD3ζ expression in T cells inhibiting their TCR mediated effector 
functions. In cancer patients CD3ζ is often down regulated in tumor infiltrating 
T cells, accompanied by loss of cytolytic activity as well as loss of proliferative 
potential (23, 32, 43). In gastric carcinoma, the five year survival of patients 
was significantly improved when TILs maintained normal levels of CD3-ζ 
expression (44), underlining the therapeutic potential in sustaining function of 
infiltrating immune cells in a ROS mediated immune repressive environment.  
Due to their high sensitivity towards oxidative stress, intra tumor activity of NK 
cells is likely compromised (45), particularly of the cytotoxic CD56 dim NK cell 
subset (33). We found Data indicate that the bystander effect of CAR-CAT T 
cells extended also to NK cells and rescued their cytolytic ability at high H2O2 
concentrations (Fig 4F). Beyond this, CAR-CAT T cells are able to modify the 
suppressive cells in the tumor tissue. MDSCs require high levels of ROS to 
retain their suppressive phenotype; in absence of ROS immature MDSCs 
differentiate into non-suppressive monocytes (17) which, together with other 
mechanisms, finally may result in a global change in the immune surveillance 
of cancer.  
 
 
The approach of combining tumor redirected CAR T cells with the transgenic 
expression of molecules that modulate the oxidative state in the tumor milieu 
may be extended to several other categories of molecules which counteract T 
cell function such as arginase-1, IDO or iNOS. Additionally, other strategies to 
reduce tumor immunosuppression, for example by co-engineering T cells with 
TGF-β dominant negative receptor have shown impressive results(46) and 
suggest that targeting these suppressive mechanisms may be essential to 
improving T cell based therapies(6). Our data imply that the strategy to target 
ROS may improve both the antigen- specific and antigen-independent tumor 
elimination, resulting in a more rapid and efficacious tumor elimination which 
likely improves the outcome of adoptive T cell therapy of cancer. 
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Figure Legends: 
 
Figure 1. Design of bicistronic expression vector for chimeric antigen 
receptors and catalase expression. (A) Schematic diagram depicting the two 
sets of CAR used. (B) PBMC from healthy donors were cultured for a four 
days and transduced using either bicistronic retroviral expression vectors for 
CAR and catalase or retroviral expression vector for CAR alone. Expression 
of CAR on transduced T cells was assessed by staining with PE conjugated 
F(ab)2 anti-human IgG that binds to the extracellular FC region of the CAR 
and APC-conjugated anti-CD3. PE conjugated isotype antibody were used to 
confirm lack of non-specific binding. CAR cells were gated on lymphocyte 
population in FSC and SSC prior to gating CAR positive cells. (C) Protein 
lysates from MACs sorted transduced T cells were analyzed by western-blot. 
Relative protein expression was determined by ImageJ analysis of the 
intensity of the bands from the western blot. (D) MACs sorted lysates were 
used to measure catalase activity. (E) Luminescence from 105 transduced or 
non-transduced cells was measured after adding L-012 and H2O2. (F) 
Transduced T cells were perimabilized and rabbit polyclonal anti-human 
catalase antibody was used to stain for intracellular catalase. FITC conjugated 
anti-rabbit IgG antibody was used to analyze the samples with flow cytometry. 
Data are presented as means ± SD, *** P < 0.005 by students T-test using 
GraphPad 5. 
 
Figure 2. Oxidative state is reduced in CAR-CAT T cells compared to CAR T 
cells. (A) Directly after co-culture with HEK293T cells, transduced T cells were 
labeled with CellROX (5µM) in complete medium. (B) After short-term one-
hour culture, or long-term 18 hr culture, cells were labeled with PE anti-human 
IgG and Pacific Orange anti-human CD3 and samples were acquired on BD-
LSR2. (C) To induced oxidative stress, freshly transduced T cells were loaded 
with CellROX and stimulated with PMA (3µg/ml) and DHNQ (20µM) for two 
hours before acquiring samples by flow cytometry. Samples were analyzed 
using FlowJo.  
 
Figure 3. CAR-CAT T cells maintain viability and functionality under H2O2 
induced oxidative stress. (A) After transduction with CAR or CAR-catalase T 
cells were re-suspended to 2 x 105 in 200 µl complete medium RPMI 
containing 10% FCS and exposed to increasing concentrations of H2O2. After 
24 hrs cells were stained with AnnexinV-FITC and 7AAD and analyzed by 
FACs. (B) 50µM H2O2 was used to induce oxidative stress in 5 x 103 
engineered or non-modified T cells being stimulated with CD3-CD28 
proliferation beads for four days and cell proliferation was measured by 3H-
thymidine incorporation for 4 hrs. (C) Transduced T cells were used as 
effectors for targeting Her2 positive tumors at an E:T ratio of 1:2. Freshly 
transduced T cells were cultured overnight with increasing concentrations of 
H2O2 to induce oxidative stress. After 18 hrs target cells were labeled with 
51Cr and transferred into effector cell containing wells. Supernatant was 
collected after 24 hr co-culture and transferred to LumaPlates and read out on 
MicroBeta. The percent specific lysis was calculated using the following 
formula: (CPMsample –CPMspontaneous)/(CPMmaximum – CPMspontaneous). Data are 
 
presented as means ± SD, ** P < 0.005 by 2 way ANOVA using GraphPad 5 
for B and C between CAR and CAR-CAT.  
 
Figure 4. A bystander effect is mediated by CAR-CAT T cells towards non-
modified T and NK cells. (A) T cells were labeled with CellROX for both a 
short-term and long-term staining and CellROX MFI on CAR negative T cells 
was determined after cells were acquired by FACs. (B) Healthy donor 
autologous T cells were CFSE labeled and admixed with transduced T cells 
followed by staining with antibodies and CellROX and acquired by flow 
cytometry. (C) CAR-CAT and CAR negative cells were labeled with maleimide 
and surface thiols were evaluated. (D) Supernatants were collected from 
transduced T cells and non-transduced and tested for catalase activity. (E) 
H2O2 was used to induce oxidative stress in T cell culture for two hours prior 
to staining. 2 x 105 cells were stained for CD3-ζ using FITC conjugated anti-
CD3-ζ after permiabilization with 0.25% PFA and Digitonin. Cells were 
acquired by FACs and change in CD3ζ MFI was calculated by: CD3ζ MFI(XµM 
H2O2) – CD3ζ MFI(0µM H2O2) gated on the CAR negative fraction. (F) NK cells 
were co-cultured with engineered T cells at a ratio of 2:1 CAR T cell to NK cell 
overnight under oxidative stress induced by different concentrations H2O2. 
K562 target cells were loaded with 51Cr and added to the NK/T cell mix after 
H2O2 co-culture at a ratio of 1:1 NK cell to K562. 25µl of supernatant was 
transferred to LumaPlates and read out on MicroBeta. Data are presented as 
means ± SD, * P < 0.05 by 2 way ANOVA using GraphPad 5 for C between 
CAR and CAR-CAT. 
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Introduction
Vaccinations have been an essential part of basic medical care 
for over a century, providing protection to various diseases and 
pathogens. Traditionally inactive or attenuated viruses have 
been used to establish humoral and cellular immunity. Since the 
advent of molecular biology and the ease of DNA manipulation, 
it has been proposed to use DNA as a vehicle of immunization.1 
Different techniques have been developed to establish immunity 
against DNA-encoded antigens (Ag). Intramuscular and intra-
dermal (i.d.) injections of naked DNA followed by electropora-
tion (EP) greatly increases the ability of DNA vaccines to elicit 
cellular immune responses including cytotoxic CD8+ T lympho-
cytes (CTL).2,3 Cancer vaccines able to elicit strong antigen-spe-
ciﬁc CTL responses that are effective at eliminating tumors are 
highly desired for achieving favorable clinical outcomes.1,4,5
Mature activated antigen presenting cells (APC), such as 
dendritic cells (DC) are essential for establishing effective CTL 
responses. DNA vaccines can target sentinel APCs, such as 
DNA vaccines have been shown to elicit tumor-protective cytotoxic T lymphocyte (CTL) immunity in preclinical models, 
but have shown limited efficacy in cancer patients. Plasmids used for DNA vaccines can stimulate several innate immune 
receptors, triggering the activation of master transcription factors, including interferon regulatory factor 3 (IRF3) and 
nuclear factor κ B (NF-κB). These transcription factors drive the production of type I interferons (IFNs) and pro-inflammatory 
cytokines, which promote the induction of CTL responses. Understanding the innate immune signaling pathways triggered 
by DNA vaccines that control the generation of CTL responses will increase our ability to design more effective vaccines. 
To gain insight into the contribution of these pathways, we vaccinated mice lacking different signaling components with 
plasmids encoding tyrosinase-related protein 2 (TRP2) or ovalbumin (OVA) using intradermal electroporation. Antigen-
specific CTL responses were detected by intracellular IFN-γ staining and in vivo cytotoxicity. Mice lacking IRF3, IFN-α 
receptor, IL-1β/IL-18, TLR9 or MyD88 showed similar CTL responses to wild-type mice, arguing that none of these molecules 
were required for the immunogenicity of DNA vaccines. To elucidate the role of NF-κB activation we co-vaccinated mice 
with pIκBα-SR, a plasmid encoding a mutant IκBα that blocks NF-κB activity. Mice vaccinated with pIκBα-SR and the TRP2-
encoding plasmid (pTRP2) drastically reduced the frequencies of TRP2-specific CTLs and were unable to suppress lung 
melanoma metastasis in vivo, as compared with mice vaccinated only with pTRP2. Taken together these results indicate that 
the activation of NF-κB is essential for the immunogenicity of intradermal DNA vaccines.
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Langerhans cells and dermal DCs, that are proﬁcient in process-
ing the DNA-encoded antigen and migrating to lymphoid organs 
to elicit Ag-speciﬁc T and B cell responses.2,3,6 Skin-resident 
APCs are well suited to recognize pathogen-associated molecular 
patterns (PAMPs) such as double stranded plasmid DNA used 
for DNA vaccines. Pattern recognition receptors (PRRs), such 
as Toll like receptors (TLRs), present mostly in APCs detect 
PAMPs and trigger signaling pathways that activate master tran-
scription factors, including interferon regulatory factors (IRF) 
and nuclear factor κ B (NF-κB). The resulting production of 
type I interferons (IFNs), proinﬂammatory cytokines and che-
mokines promotes DC maturation that in turn generate CTL 
responses linking innate to adaptive immune responses. TLR9 
recognizes DNA containing unmethylated CpG motifs from 
bacterial and viral DNA present within the endosomal compart-
ment.7 Cytosolic DNA sensors include DExD/H box helicases 
(DHX9/36),8 DNA-dependent activator of IFN regulatory fac-
tors (DAI),9 absent in melanoma 2 (AIM2),10 meiotic recombi-
nation 11 homolog A (MRE11),11 gamma-interferon-inducible 
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signiﬁcant differences in TRP2-speciﬁc CTL frequencies could 
be found between IFNαR−/− and WT mice (Fig. 1C). To further 
conﬁrm these results, the role of IRF3, a key transcription factor 
driving type I IFN expression resulting after ligation of cytosolic 
DNA sensors, such as DAI and IFI16, was examined. IRF3−/− 
mice were able to generate CTL responses as strong as WT mice 
after vaccination with the TRP2-encoding plasmid (Fig. 1D). 
These results demonstrate that type I IFN/IRF3 signaling axis is 
not required for the ability of intradermal DNA vaccines to elicit 
antigen-speciﬁc CTL responses.
TLR9 and MyD88 do not mediate the generation of CTL 
responses after intradermal DNA vaccination. Plasmid DNA 
produced in the gram-negative bacteria E. coli contains unmethyl-
ated CpG motifs that could activate TLR9 and downstream signal-
ing pathways through the adaptor protein myeloid differentiation 
primary response gene 88 (MyD88), which functions as a central 
adaptor protein for other TLRs (except TLR3) and the DNA sen-
sor DHX9.21 This led us to speculate that TLR9-mediated innate 
immune activation could possibly contribute to the speciﬁc adap-
tive CTL responses elicited by intradermal DNA vaccination. To 
determine if this was indeed the case, TLR9−/−, MyD88−/− and WT 
mice on C57BL/6 background were vaccinated, as described above, 
with the OVA-encoding plasmid. Vaccination generated levels of 
OVA-speciﬁc IFN-γ producing CTLs that were similar between 
the three groups (Fig. 2A). To conﬁrm the functionality of the 
CTLs generated, in vivo cytotoxicity was tested, demonstrating 
that cytotoxic potential of OVA-speciﬁc CTLs was intact in TLR9 
and MyD88 KO mice as compared with wild-type mice. In both 
cases, there was no signiﬁcant difference in the OVA-speciﬁc kill-
ing between KO mice and wild-type mice (p = 0.75 and p = 0.98 
respectively) (Fig. 2B). Similar results were obtained when the less 
immunogenic TRP2 antigen was tested in these TLR9, MyD88 
KO models. TRP2-speciﬁc CTL frequencies were not different 
between wild-type and KO mice (Fig. 2C), indicating that TLR9 
and downstream MyD88-dependent signaling are not required for 
the generation of CTL responses elicited by i.d. EP DNA vaccines. 
A different proinﬂammatory pathway that can contribute to the 
immunogenicity of DNA vaccines is the inﬂammasome. AIM2-
mediated DNA sensing can trigger inﬂammasome activation, 
leading to the activation of caspase-1 and the catalytic cleavage of 
pro-forms of the pro-inﬂammatory cytokines IL-1β and IL-18 into 
their active secreted form. Given the observed high expression of 
the inﬂammasome protein AIM2 in skin,22 we studied whether 
IL-1β−/− IL-18−/− mice were able to mount similar CTL responses 
as WT mice. We found that intradermal electroporation induced 
similar speciﬁc CTL responses between the KO and WT mice 
measured as IFN-γ producingCTLs (Fig. 2D) and in vivo cyto-
toxicity (Fig. 2E).
Suppression of NF-κB during intradermal DNA vaccina-
tion decreases CTL responses and impedes tumor rejection. 
Most DNA-sensing PRR (DAI, IFI16, AIM2, DHX9) signaling 
pathways converge in the activation and nuclear translocation 
of NF-κB to drive the expression of proinﬂammatory transcrip-
tional targets. To investigate the role of this pathway, we used a 
plasmid encoding the IκBα-super repressor (IκBα-SR), which 
functions similarly to endogenous IκBα in its ability to bind and 
protein 16 (IFI16),12 leucine rich repeat ﬂightless-interacting 
protein (LRRFIP1),13 probable ATP-dependent RNA helicase 
DDX4114 and RNA polymerase III,15 which transcribes dsDNA 
into double stranded RNA leading to RIG-I activation. However, 
which of these DNA-sensing signaling pathways promotes the 
maturation of APCs after DNA electroporation leading to the 
generation of CTL responses is not fully understood, especially 
for intradermal vaccination. Understanding the innate immune 
mechanisms involved in this process will increase our capacity to 
design more potent DNA vaccines.
In the following study, we explored the mechanisms involved 
in the induction of CTL responses elicited by intradermal DNA 
electroporation resulting in tumor protection. INF-α and tran-
scription factor IRF3, previously identiﬁed as a key signaling path-
way for establishing response to DNA vaccines, were not required 
for the induction of CTL responses by intradermal DNA vacci-
nation. Furthermore, the generation of CTL responses was found 
to be independent of the classical TLR9 DNA sensing pathway 
and any other MyD88-dependent proinﬂammatory pathway. 
Lastly, we demonstrate that NF-κB acts as a master transcription 
factor that is essential for inducing antigen-speciﬁc CTLs and in 
providing protection against in vivo tumor challenge.
Results
Type 1 interferons are not required for intradermal DNA vaccine-
induced CTL responses. DNA-sensing PRRs, including TLR9 
and cytosolic DNA sensors, can trigger the production of type I 
IFNs, which are an important bridge between innate and adaptive 
immunity by promoting APC maturation and induction of T cell 
responses.17,18 Moreover, type I IFNs have been found to be essential 
for the immunogenicity of DNA vaccines delivered intramuscularly 
in a TLR9-independent fashion.19,20 To determine whether type 
I IFNs are also essential in establishing CTL immunity after 
intradermal DNA electroporation, wild type (WT) and IFNαR−/− 
mice on the 129sv background were immunized with the plasmid 
encoding the model antigen ovalbumin (OVA). In contrast 
to previous studies, CTL responses measured after the second 
immunization in peripheral blood from IFNαR−/− mice were not 
reduced compared with WT mice (Fig. 1A). To test whether the 
effector function of elicited CTLs was impaired in IFNαR deﬁcient 
mice, an in vivo cytotoxicity assay was performed. Vaccinated mice 
were adoptively transferred with CFSEhigh and CFSElow labeled 
splenocytes pulsed with OVA and control peptides, respectively. 
Flow cytometry analysis of lymph nodes from recipient mice showed 
that killing of CFSEhigh labeled OVA peptide pulsed lymphocytes 
was not signiﬁcantly different between WT and IFNαR−/− mice 
(p = 0.19), conﬁrming the establishment of functional OVA-
speciﬁc CTL immunity (Fig. 1B).
Unlike OVA, tumor antigens are poorly immunogenic and 
induction of CTL responses against such antigens is controlled by 
diverse mechanisms of tumor-associated self-tolerance. To iden-
tify if the strong immunogenicity of OVA was the reason for the 
vital CTL responses observed regardless of the deﬁciency in type 
I IFN signaling, mice were vaccinated with a vaccine encoding 
the melanoma antigen tyrosinase-related protein 2 (TRP2). No 
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Finally to conﬁrm that the reduced TRP2-speciﬁc CTL 
responses would have an impact on the ability of intradermal 
DNA vaccination to confer tumor protection, the B16F10 mouse 
melanoma lung metastasis model was used. Mice were vacci-
nated with either control plasmid, pTRP2 or co-vaccinated with 
pTRP2 and IκBα-SR encoding plasmid as described above; 
14 d after the second immunization were challenged with 105 
B16F10 cells injected i.v. Three weeks after the challenge, lungs 
were excised and the melanoma metastatic foci were enumer-
ated (Fig. 3C). Accordingly, signiﬁcantly decreased melanoma 
metastasis was observed in mice vaccinated with TRP2 encoding 
plasmid, whereas mice co-electroporated with both pTRP2 and 
pIκBα-SR were unable to suppress melanoma formation. Note 
that electroporation with the IκBα-SR encoding plasmid did 
not affect lung metastasis when administrated by itself (data not 
shown). In conclusion, these results indicate that the activation of 
NF-κB during intradermal DNA vaccination is essential for the 
induction of CTL-mediated tumor protective immunity.
block NF-κB, but carries mutations that prevent its phosphory-
lation and subsequent degradation and, as consequence, stably 
impedes the translocation of NF-κB to the nucleus.23 Thus, this 
plasmid allows blocking of NF-κB activation speciﬁcally at the 
vaccination site in the context of DNA vaccines.24 To test the 
activation of NF-κB during DNA vaccination, a NF-κB lucifer-
ase reporter plasmid was i.d EP into the hindquarters of mice as 
done with DNA vaccines. In vivo luciferase activity was detected 
six hours after intradermal electroporation, which is indicative 
of early NF-κB activation. As expected, when the functionality 
of IκBα-SR was evaluated, co-electroporation with the IκBα-SR 
encoding plasmid showed decreased in vivo bioluminescence 
(Fig. 3A). To test the ability of NF-κB activation during intra-
dermal DNA vaccination to mediate speciﬁc CTL antitumor 
responses, mice were vaccinated with the TRP2–encoding plas-
mid and pIκBα-SR. This led to a stunning decrease in IFN-γ 
producing CD8+ T lymphocytes as compared with mice vacci-
nated with pTRP2 alone (Fig. 3B).
Figure 1. Type 1 interferons are not required for generating CTL responses. Wild-type (WT) and IFNαR−/− mice on 129sv background were vaccinated 
twice with the OVA-encoding plasmid pOVA. The percentages of IFN-γ producing CD8+ T lymphocytes were detected after in vitro stimulation with 
OVA and control peptides (A). In vivo cytotoxicity was measured by quantifying OVA pulsed CFSEHigh labeled target cells and compared with control 
pulsed CFSELow labeled cells in WT and IFNαR−/− mice vaccinated with pOVA. The mean percentage ± SEM of specific killing for each case is indicated 
(B). Tyrosinase-related protein 2 (TRP2) encoding DNA was used to vaccinate WT and IFNαR−/− 129sv mice. IFN-γ producing CD8 T lymphocytes were 
measured after in vitro stimulation with TRP2 and control peptides (C). WT and IRF3−/− mice on C57BL/6 background were vaccinated with TRP2-en-
coding plasmid and the percentages of IFN-γ-producing CD8 T cells were measured by flow cytometry after in vitro stimulation with TRP2 and control 
peptides (D). Bars indicate the mean ± SEM.
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RNA-PolIII, and LRRFIP1 trigger the production of type I IFNs 
primarily via TBK1-dependent activation of IRF3, whereas TLR9 
and DHX9 can signal through MyD88 to activate IRF7. Type I 
IFNs lead to the maturation of DCs, inducing an increased expres-
sion of MHC molecules and costimulatory molecules, such as 
CD80 and CD86.18 Importantly, type I IFNs also provide the “third 
signal” needed for CD8+ T cells to undergo clonal proliferation 
and differentiation into CTLs.17,25,26 The importance of the type I 
IFN signaling, in particular the TBK-1/IRF3-dependent pathway, 
for innate immune recognition of DNA vaccines has been estab-
lished by studies showing that adaptive immune responses elicited 
by DNA vaccination are almost completely abrogated in mice lack-
ing the components of this cascade.19,20,27 Ishii et al. found that 
IFNαR−/− and Tbk1−/− mice were not able to generate LacZ speciﬁc 
CD8+, as measured by MHC tetramers, or stimulate antigen-spe-
ciﬁc CD4+ and CD8+ T-cell proliferation.20 Similarly, Shirota et al. 
found that IFNαR−/− and IRF3−/− mice displayed severely impaired 
antigen-speciﬁc CD4+ and CD8+ T cell responses, including the 
production of Th1, Th2, and Th17 cytokines.19 In contrast to the 
aforementioned studies, in this study we present evidence demon-
strating that, at least with DNA vaccines delivered by intradermal 
electroporation, IRF3- or MyD88-dependent type I IFN signaling 
is not required for the induction of fully functional antigen-speciﬁc 
T cell responses (Figs. 1 and 2). These opposing results can be 
explained by the different administration routes used in each par-
ticular case. Studies proposing a preponderant role for type I IFN 
signaling have been performed after intramuscular immunization 
Discussion
The promise that DNA vaccines would lead to a revolution in vac-
cine technology has not yet materialized. Many clinical trials have 
been falling short of their mark with little explanation as to pos-
sible reasons, while in contrast, mouse models have shown thera-
peutic and prophylactic efﬁcacy. In this work we attempt to shed 
some light on the mechanisms involved in establishing adaptive 
T cell responses elicited by DNA vaccination. We show here that 
naked plasmid DNA vaccines delivered via an intradermal route 
and assisted with electroporation produce antigen-speciﬁc CTL 
responses through a mechanism that relies on the activation of 
NF-κB. In contrast, the IRF3-type 1 IFN and TLR9-MyD88 
innate immune pathways, generally considered to contribute to the 
sensing of DNA and the initiation of adaptive immune responses, 
were not required for establishing antigen-speciﬁc CTLs.
Electroporated DNA vaccines lead to high expression levels of 
the plasmid-encoded antigen as well as the introduction of large 
amounts of plasmid DNA inside the cells that represent a strong 
signal for several DNA-sensing innate immune receptors. The 
sensing of DNA by PRRs has become a complex research ﬁeld, 
with a multitude of proteins binding to DNA and activating dis-
tinct signaling cascades, as recently reviewed in detail by Desmet 
et al.21 The net result of these pathways is the production of type I 
IFNs and proinﬂammatory cytokines, including IL-1β and IL-18 
that promote DC maturation and initiate robust cellular immune 
responses. In response to DNA, DAI, IFI16, DHX36, DDX41, 
Figure 2. Toll-like receptor 9 (TLR9) and myeloid differentiation primary response gene 88 (MyD88) are not essential for CTL induction. Wild-type 
(WT), TLR9−/− and MyD88−/− mice on C57BL/6 background were vaccinated twice. Levels of IFN-γ producing CD8 T cells induced by DNA vaccination 
against OVA and TRP2 were measured two weeks after the second DNA vaccination by flow cytometry. Bars indicate the mean ± SEM (A and C). In 
vivo cytotoxicity was measured by quantifying OVA pulsed CFSEHigh labeled target cells and compared with control pulsed CFSELow labeled cells in WT, 
TLR9−/− and MyD88−/− mice vaccinated with the OVA encoding plasmid pOVA. The mean percentage ± SEM of specific killing for each case is indicated 
(B). WT and IL-1β−/− IL-18−/− mice on C57BL/6 background were vaccinated with OVA or TRP2 encoded plasmid as described previously. The percent-
ages of IFN-γ-producing CD8 T cells were measured by flow cytometry after in vitro stimulation with TRP2 and control peptides (D). Functionality of 
OVA-specific CTLs was measured by in vivo cytotoxicity. Lymph nodes were harvested one day after mice were injected i.v. with OVA peptide pulsed 
CFSEHigh labeled splenocytes and control peptide pulsed CFSELow splenocytes. Bars indicate the mean percentage ± SEM of OVA-specific killing (E).
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described by Roos et al. that IL-1β mRNA expression is increased 
1000-fold after DNA electroporation in the skin.39 Although 
AIM2 can be expressed in skin-resident cells, IL-1β−/− IL-18−/− 
mice were able to generate CTL responses as efﬁciently as wild-
type mice further discarding that the inﬂammasome pathway is 
required for DNA vaccine-induced innate immune activation.
The maturation of DCs and the subsequent activation of 
adaptive immunity are regulated largely by NK-κB signaling 
pathways. The classical NF-κB signaling cascade triggered in 
response to dsDNA by DAI, IFI16, AIM2, DHX9, DDX41 DNA 
sensors,21 relies on formation and activation of the NEMO/IκB 
kinase complex. This complex phosphorylates IκBα, facilitating 
the ubiquitination and proteasomal degradation of this protein. 
Once IκBα is degraded, it is no longer able to sequester NF-κB in 
the cytosol, the p50-RelA dimer then translocates to the nucleus.40 
Our studies show the key role of transcription factor NF-κB in 
establishing effective anti-tumor CTL responses by intradermal 
electroporation of plasmid DNA vaccines. By co-electroporating 
a mutant IκBα construct into the dermis of the skin along with 
antigen-encoding plasmids, the mechanism for triggering adap-
tive immunity is abrogated, preventing the tumor protection oth-
erwise offered by DNA vaccines (Fig. 3). Electroporation of the 
IκBα-SR construct did not have an effect on tumor metastasis 
when administrated independently of the TRP2 encoding plas-
mid (data not shown). Among other targets, activation of NF-κB 
leads to the production of inﬂammatory cytokines, such as: IL-6, 
IL-1β, IL-12, and TNF-α. Among these molecules and similarly 
to type I IFNs, IL-12 is also able to provide the “third signal” to 
CD8+ T cells for promoting clonal proliferation and differentia-
tion into CTLs. Therefore, NF-κB can provide all the necessary 
signals for generating effective T cell immunity. Despite the abil-
ity of NF-κB to support malignant cell survival, proliferation, 
and metastatic potential when expressed in tumor cells;41 activa-
tion of NF-κB during antigen presentation has been extensively 
demonstrated to promote anti-tumor immune responses using 
TLR agonists27,28 and DNA vaccine adjuvants.24 In conclusion, 
in our study we demonstrate the essential nature of NF-κB in 
establishing CTL immunity after intradermal DNA vaccination. 
However, identifying which of the multiple DNA-sensing recep-
tors that is involved in sensing intradermally electroporated DNA 
will be the focus of future studies. A more complete understand-
ing of the DNA-sensing signaling networks initiated after DNA 
vaccination will allow us to design more effective vaccines.
Materials and Methods
Animals and cells. C57BL/6, TLR9−/−, MyD88−/−, IRF3 −/−, 
129sv, and IFN-αR−/− mice were kept in accordance with the 
local Animal Ethics Committee guidelines. Mice were bred 
and maintained at the Microbiology and Tumor Biology center 
at the Karolinska Institute. B16F10 were cultured in complete 
RPMI medium, supplemented with 100 IU/ml penicillin and 
100 μg/ml streptomycin, one percent non-essential amino acids, 
one percent sodium pyruvate and 10% heat-inactivated fetal 
bovine serum (Gibco 21875, 15140, 11140, 11360, and 10270 
respectively) in a humidiﬁed incubator at 37°C with 5% CO
2
.
(with or without electroporation), whereas our studies were con-
ducted using intradermal electroporation. It seems reasonable to 
expect that delivering DNA intramuscularly would target different 
sets of both DNA-sensing and antigen-presenting cells, than when 
injecting intradermally. Similar divergences have been found when 
immunizing with alphavirus replicon-based DNA vectors, which 
activate dsRNA-sensing innate immune receptors.28,29 Induction 
of antigen-speciﬁc T cell responses elicited by vaccination with rep-
licon-based DNA vectors delivered intramuscularly has shown to 
be dependent on type I IFNs27 while in a different study immuniz-
ing with the same kind of vector but delivered intradermally, type I 
IFN signaling was absolutely dispensable, and rather had a suppres-
sive effect.30 The contrasting results obtained by different groups 
seem to be related to the vaccination route, further encouraging 
the need of more comprehensive studies dissecting the signaling 
pathways activated in each particular tissue.30 Indeed, a different 
situation can be observed within the tumor microenvironment, 
where activation of type I IFN-producing PRRs has been shown to 
promote potent anti-tumor effects by acting on antigen-presenting 
cells and subsequently on tumor-speciﬁc T cells.31,32 Treatment of 
B16F10 melanoma tumors with poly(I:C) and CpG oligos, trig-
gering TLR3 and 9 respectively, protected mice from tumor chal-
lenge together with melanoma speciﬁc T-cell transfer. Poly(I:C) 
and CpG were shown to be responsible for upregulation of CD40 
and CD86 on pDCs enriched from tumor draining lymph nodes.31 
In the context of vaccination, it has been found that intratumoral 
injection of TLR3/9 ligands was responsible for reprograming 
the inﬁltrating immune cell population; signiﬁcantly increasing 
the CD8 to Treg cell ratio and anti-tumor effects of the vaccine 
strategy.32
In addition to type I IFNs, proinﬂammatory cytokines pro-
duced after DNA stimulation play a direct role in promoting DC 
maturation and T cell induction. Activation of TLR9-MyD88 
pathway is a major source of both type I IFNs and proinﬂam-
matory cytokines. However, the participation of TLR9 in the 
immunogenicity of DNA vaccines is controversial with differ-
ent studies showing TLR9-dependent and -independent mecha-
nisms. In this study, we found that TLR9 and the adaptor protein 
MyD88 did not play an important role in establishing the pDNA 
induced adaptive CTL responses, which were similar between 
the KO and WT mice. In vivo cytotoxicity showed a trend to less 
effective killing in the KO mice, though this was not statistically 
signiﬁcant (Fig. 2). Our ﬁndings are in agreement with previous 
investigations showing that TLR9 and MyD88 KO mice are able 
to mount antigen-speciﬁc CTL responses after i.m. DNA vac-
cination.33,34 Considering all these studies, it can be concluded 
that TLR9 contribute but is dispensable for T cell responses elic-
ited by DNA vaccines delivered, and targeting TLR9 represents 
an opportunity for improvement of adaptive immune responses. 
Indeed, strategies introducing more CpG motifs into the antigen-
encoding plasmid DNA vector have been shown to further boost 
antibody titers in i.m. DNA vaccines.35-37 A key proinﬂammatory 
pathway downstream of DNA recognition is the production of 
IL-1β and IL-18.36 The pro-forms of the IL-1 family members 
are cleaved into their functional state by caspase-1 through inter-
action with AIM2-containing inﬂammasome. It has also been 
2194 Human Vaccines & Immunotherapeutics Volume 9 Issue 10
TRP2 (kindly provided by Dr. T. Wölfel, Johannes Gutenberg 
University), pOVA encoding membrane-bound ovalbumin 
(kindly provided by Dr. A. Lew, Walter and Eliza Hall Institute 
of Medical Research), pIκBα-SR encoding the IκBα supper-
repressor (kindly provided by Dr R. Toftgård, Karolinska 
Institutet), and pNF-κB-Fluc encoding ﬁreﬂy luciferase under 
the control of a NF-κB promoter. Plasmids were puriﬁed using 
EndoFree Plasmid Giga Kit (Qiagen 12391).
Intracellular cytokine staining. Peripheral blood was taken 
13 d after the second DNA vaccination from the tail vein. 
Lymphocytes were cultured with 1 μg/ml of antigen-derived 
or control MHC class I-restricted peptide during eight hours. 
GolgiPlug was added during the last six hours. After surface 
staining, cells were stained intracellularly using the Cytoﬁx/
Cytoperm and ﬁxation/permeabilization kit (BD Biosciences 
554722 and 554723) following manufacturer’s instructions. 
Monoclonal anti-mouse CD-8α FITC conjugated, IFN-γ PE 
conjugated TNF-α APC antibodies were used (Biolegend clones 
5H10–1, XMG1.2 and MP6-XT22 respectively). Nonspeciﬁc 
binding was blocked by mouse Fc receptor blocking (Biolegend 
clone 93). Acquisition and analysis of cells was performed with 
FACSCalibur and FlowJo version 9.2, respectively.
In vivo cytotoxicity. Splenocytes harvested from naïve mice 
were pulsed with OVA or control peptide after being labeled with 
2 and 0.2 μmol/l of CFSE respectively. Then, 107 pulsed sple-
nocytes from each population were mixed and injected intrave-
nously into vaccinated mice. The next day, inguinal lymph nodes 
from recipient mice were analyzed by ﬂow cytometry. DNA vac-
cine mediated killing was determined as follows: 100 − (% of 
CFSEhigh OVA peptide-pulsed cells/% of CFSElow control pep-
tide-pulsed cells).
In vivo luminescence. Six hours after C57BL/6 mice were 
vaccinated with plasmid encoding ﬁreﬂy luciferase, under con-
trol of an NF-κB promoter, luminescence was measured. This 
was done by anesthetizing the mice with isoﬂurane prior to intra-
peritoneally injecting 100 μl of 30 mg/ml D-luciferin (Promega 
E1603) dissolved in phosphate buffered saline solution. Mice 
were scanned with the Xenogen IVIS 100 imaging system where 
bioluminescence was measured.
Lung metastasis model. DNA vaccinated C57BL/6 mice 
were challenged by intravenous injection of 105 B16F10 cells 14 
d after the second DNA vaccination. Three weeks after intrave-
nous challenge, mice were sacriﬁced and lungs were washed in 
phosphate buffered saline solution before bleaching in Feketes 
solution. Analysis of metastasis was performed by enumeration of 
the visible pigmented melanoma foci in the lung surface.
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DNA vaccination is an attractive approach to induce 
antigen-speciﬁc cytotoxic CD8+ T lymphocytes (CTLs), 
which can mediate protective antitumor immunity. The 
potency of DNA vaccines encoding weakly immunogenic 
tumor-associated antigens (TAAs) can be enhanced by 
codelivering gene-encoded adjuvants. Pattern recogni-
tion receptors (PRRs) that sense intracellular DNA could 
potentially be used to harness intrinsic immune-stimulat-
ing properties of plasmid DNA vaccines. Consequently, 
the cytosolic DNA sensor, DNA-dependent activator of 
interferon (IFN) regulatory factors (DAI), was used as a 
genetic adjuvant. In vivo electroporation (EP) of mice with 
a DAI-encoding plasmid (pDAI) promoted transcription 
of genes encoding type I IFNs, proinﬂammatory cytok-
ines, and costimulatory molecules. Coimmunization with 
pDAI and antigen-encoding plasmids enhanced in vivo 
antigen-speciﬁc proliferation, and induction of effector 
and memory CTLs. Moreover, codelivery of pDAI effec-
tively promoted CTL and CD4+ Th1 responses to the 
TAA survivin. The DAI-enhanced CTL induction required 
nuclear factor KB (NF-KB) activation and type I IFN signal-
ing, but did not involve the IFN regulatory factor 3 (IRF3). 
Codelivery of pDAI also increased CTL responses to the 
melanoma-associated antigen tyrosinase-related pro-
tein-2 (TRP2), enhanced tumor rejection and conferred 
long-term protection against B16 melanoma challenge. 
This study constitutes “proof-of-principle” validating the 
use of intracellular PRRs as genetic adjuvants to enhance 
DNA vaccine potency.
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INTRODUCTION
Cytotoxic CD8+ T lymphocytes (CTLs) are key effector cells 
of the immune system and critical components of protective 
immunity against infectious diseases and cancer. Activated CTLs 
have the potential to eradicate malignant cells with high specific-
ity. Indeed, intratumoral CTL infiltration is often associated with 
favorable clinical outcomes such as decreased disease recurrence 
and improved survival in diverse malignancies.1–3 Adoptive trans-
fer trials of tumor-specific CTLs that control disease progression 
in metastatic melanoma patients have provided direct evidence of 
the efficacy of CTLs.4 Accordingly, induction of effective and long-
lasting T cell immunity represents a major goal of cancer vaccines 
that have shown promising results in the clinic, especially when 
used as adjuvant therapy to standard cancer treatments in patients 
with minimal residual disease.5
DNA vaccination is an attractive and safe approach to gener-
ate protective CTL responses against cancer. This approach has 
been successful in animal models, but has shown limited effi-
cacy in clinical trials.6 One underlying reason is that most of the 
tumor-associated antigens (TAAs) recognized by T cells are nor-
mal nonmutated self-antigens and potentially self-reactive TAA-
specific T cells are either eliminated or become regulatory T cells 
by mechanisms involving central and peripheral immune toler-
ance. Therefore, efficient delivery systems and potent adjuvants 
are needed for cancer DNA vaccines to overcome tumor-associ-
ated T cell tolerance. In vivo electroporation (EP) has emerged as 
a simple, efficient, and clinically applicable method for deliver-
ing DNA vaccines that greatly enhances plasmid uptake, antigen 
expression, and immune responses.7 Moreover, DNA EP activates 
innate immunity resulting in infiltration of immune cells and the 
production of proinflammatory molecules that contribute to the 
induction of the immune responses.8,9 The versatility of DNA vac-
cines facilitates codelivery of genes encoding immunomodulatory 
molecules, typically cytokines and chemokines, as genetic adju-
vants. Moreover, the concerted action of several cytokines and 
costimulatory molecules clearly facilitates potent activation of the 
immune response.10 One means to this end is the use of adjuvants, 
which exploit the immune-stimulating effects of pathogens by 
activating pattern recognition receptors (PRRs). PRRs are a group 
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of evolutionary conserved innate immune receptors that sense 
pathogen-associated molecular patterns and activate downstream 
master transcription factors initiating the production of an array 
of cytokines, chemokines, and type I interferons (IFNs) to pro-
mote activation and maturation of adaptive immune responses.11,12 
A central feature of pattern recognition is the sensing of for-
eign nucleic acids. DNA-sensing PRRs include TLR9, located at 
endosomal compartments, and the recently described cytosolic 
sensors: DAI (also known as ZBP1 and DLM-1),13 absent in mela-
noma 2 (AIM2),14,15 and DNA-dependent RNA polymerase III.16,17 
In vitro studies revealed that DAI, the first cytoplasmic DNA sen-
sor described, recognizes double-stranded DNA and triggers the 
gene expression of type I IFNs, IFN-inducible chemokine Cxcl10, 
and proinflammatory cytokines, such as interleukin 6 (IL-6) and 
tumor necrosis factor-A (TNF-A) via two distinct signaling path-
ways. One involves DAI-mediated phosphorylation of the TANK-
binding kinase-1 and subsequent activation of the transcription 
factor IFN regulatory factor 3 (IRF3).13,18 The other pathway 
requires phosphorylation of the receptor interacting protein-1 
kinase, leading to phosphorylation of IKB-A, and subsequent acti-
vation of the transcription factor NF-KB.19
In the present study, we explored whether coexpressing a DNA-
sensing PRR could further potentiate intrinsic adjuvant proper-
ties of bacterial plasmids used for DNA vaccines. Although DAI is 
dispensable for DNA vaccine immunogenicity,20 we hypothesized 
that in vivo overexpression of DAI would boost DNA-induced 
innate immune activation and ultimately enhance adaptive T cell 
immunity.
RESULTS
DAI delivery promotes transcriptional  
upregulation of genes involved in innate  
and adaptive immunity in vivo
It has recently been established that intradermal (i.d.) DNA 
delivery followed by EP increases up to 200-fold the transcrip-
tion of genes encoding proteins involved in immune regulation, 
such as chemokines, activation markers, and proinflammatory 
molecules.21 To evaluate whether in vivo overexpression of DAI 
would further stimulate innate immunity, transcript levels of 
innate immune mediators were measured after DNA vaccination. 
Mice were inoculated i.d. with either control (pVAX) or DAI-
encoding (pDAI) plasmids, followed by EP. Total RNA isolated 
from skin biopsies taken 24 hours later was analyzed by reverse 
transcription real-time PCR. Gene expression was normalized to 
the L32 housekeeping gene. Although inoculation with pVAX or 
pDAI generated a similar local inflammatory response as deter-
mined by immunohistochemistry on electroporated skin sec-
tions (Supplementary Figure S1 and Supplementary Materials 
and Methods) and a similar upregulation of costimulatory mol-
ecules on dendritic cells isolated from the draining lymph node 
(Supplementary Figure S2), a significant increase (P < 0.05) was 
observed for genes encoding IFN-A, IL-6, TNF-A, and Cxcl10 in 
the pDAI-inoculated group relative to the control vector inocu-
lated group (Figure 1). A trend toward increased IFN-B expres-
sion was also observed (P = 0.055). Interestingly, pDAI inoculation 
also led to significant upregulation of the genes encoding the 
costimulatory molecules CD40 and CD80 required for T cell 
activation and differentiation into effector T cells. Moreover, we 
found that i.d. EP with pDAI also upregulated transcription of 
genes involved in antigen presentation, T cell proliferation and 
maturation, growth factors, and antiviral responses as compared 
to control DNA using two real-time PCR arrays investigating the 
transcriptional regulation of >400 genes involved in the IFN and 
inflammatory responses (Supplementary Table S1). For instance, 
multiple genes encoding cytokines such as IL-5, -9, -13, -20, -21, 
-23, and -31 were upregulated. Interestingly, the most upregulated 
gene was Ly75 (also DEC-205 or CD205), a C-type lectin recep-
tor expressed on skin-resident dendritic cells involved in direct-
ing captured antigens to antigen-processing compartments.22 
Vaccines targeting antigen to DEC-205-expressing dendritic cells 
has been used as a strategy to enhance crosspresentation and T 
cell responses.23 A list of the 20 most strongly upregulated genes, 
in addition to the genes assayed by the real-time PCR analysis, is 
provided in Supplementary Table S1.
Codelivery of DAI promotes in vivo proliferation  
and induction of CTLs
Given the observed upregulation of proinflammatory and costim-
ulatory transcripts in the skin, we studied whether pDAI coim-
munization enhanced adaptive immunity. To test this, mice were 
covaccinated with pDAI and an ovalbumin (OVA)-encoding 
plasmid (pOVA), and compared with mice vaccinated with pOVA 
alone. To correct for the immunostimulatory effects exerted by 
plasmid DNA, the total quantity of DNA was adjusted by addi-
tion of a non-coding pVAX plasmid, so that the amount of DNA 
was the same in every animal. CFSE-labeled splenocytes from 
OT-I mice, whose CD8+ T cells carry a transgenic TCR specific 
for the OVA(257–264) peptide, were adoptively transferred into the 
vaccinated mice. After 4 days, lymph nodes from recipient mice 
were isolated and the antigen-specific proliferation of OT-I CD8+ 
T cells was analyzed by flow cytometry. Both division (Figure 2a) 
and proliferation (Figure 2b) indexes were calculated. These anal-
yses show that in the pOVA+pDAI immunized mice, compared to 
the pOVA immunized mice, OVA-specific CD8+ T cells divided 
significantly more (division indexes: 0.42 versus 0.26, P = 0.02; 0.14 
is the basal level) and that dividing cells underwent more cycles of 
proliferation (proliferation indexes: 2.0 versus 1.6, P = 0.007; 1.23 
is the basal level), indicating that codelivery of pDAI promoted a 
more efficient antigen presentation in vivo.
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Figure 1 DAI EP promotes transcription of type I IFNs, proinﬂamma-
tory cytokines, chemokine, and costimulatory molecules. C57BL/6 
mice were electroporated with pVAX or pDAI (n = 6 per group) and skin 
biopsies were taken 24 hours later for gene expression analysis. Transcript 
levels of target genes were determined by quantitative real-time PCR. 
Relative pDAI/pVAX transcript levels represent the ratio between the lev-
els detected in pDAI- and pVAX-injected mice. Bars are the mean ± SEM. 
*P < 0.05. Data presented are pooled from two independent experi-
ments. EP, electroporation.
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The ability of DAI to induce functional OVA-specific CD8+ T 
cells in peripheral blood following two immunizations was deter-
mined 13 days postimmunization by intracellular cytokine stain-
ing and flow cytometry analysis. Codelivery of pDAI increased the 
frequency of IFN-G producing CD8+ T cells from 2.5% observed 
in pOVA immunized mice to 4.4% (P = 0.01) (Figure 3a). 
Functional OVA-specific IFN-G producing CD8+ T cells could also 
produce TNF-A (Figure 3b). Using a H-2Kb:OVA(257–264) pentamer 
(Supplementary Figure S3a), we found that the OVA-specific 
CD8+ T cells displayed a similar cytotoxic effector phenotype 
(CD25low, CD69low, CD44high, CD62Llow; Supplementary Figure 
S3b) regardless of pDAI administration. To evaluate the cytotoxic 
potential of the antigen-specific CD8+ T cells, spleen cells from 
naive mice were labeled with 0.2 or 2 μmol/l of CFSE and pulsed 
with control or OVA(257–264) peptides, respectively, and adoptively 
transferred to immunized mice. After 6 hours, lymph nodes from 
pDAI, pOVA, and pOVA+pDAI vaccinated mice were removed 
and the killing of the OVA(257–264)-pulsed population (CFSE
high) 
relative to the control population (CFSElow) was evaluated by flow 
cytometry. Vaccination with pOVA alone resulted in killing of 67% 
of the OVA(257–264)-pulsed target cells. Coadministration of pDAI 
significantly (P = 0.017) increased the killing of the target popula-
tion to 80% (Figure 3c), consistent with the observed increase in 
CTL frequency. No difference in antibody titers (Supplementary 
Figure S4 and Supplementary Materials and Methods) or 
immunoglobulin subclasses (data not shown) were observed 
between mice vaccinated with pOVA alone and pDAI+pOVA 
despite the induction of IFN-A (Figure 1) and cytokines such 
as IL-5 (Supplementary Table S1). In addition, the induction 
of different OVA(257–264)-specific CD8
+ memory T cell subsets 
was determined by CD44 and CD62L staining (Supplementary 
Figure S3c) 5 weeks after the last vaccination. Both effector mem-
ory (TEM; CD44
high CD62Llow) and central memory (TCM; CD44
high 
CD62Lhigh) CD8+ T cells were significantly increased (P = 0.024 
and P = 0.031, respectively) in the spleen of mice coimmunized 
with pOVA+pDAI, whereas a similar trend was observed for 
CD8+ memory stem cells (TSCM; CD44
low CD62Lhigh) (Figure 4a). 
This analysis also showed that TEM and TSCM subsets were signifi-
cantly increased in the blood (Figure 4b; P = 0.025 and P = 0.030, 
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Figure 2 Codelivery of pDAI enhances antigen-speciﬁc prolifera-
tion of CD8+ T cells. C57BL/6 mice were electroporated with pDAI, 
pOVA, or pOVA+pDAI (n = 6 per group). (a,b) In vivo antigen prolifera-
tion of adoptively transferred OT-I CD8+ T cells was evaluated 4 days 
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+ populations for each group are displayed includ-
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shown are from one representative of two independent experiments.
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Figure 3 Codelivery of pDAI promotes antigen-speciﬁc cytotoxic T 
cell responses. C57BL/6 mice were electroporated with pDAI, pOVA, or 
pOVA+pDAI twice at 2-week interval. (a, b) CD8+ T cell responses were 
analyzed in blood collected 13 days after the last vaccination (n = 6). 
(a) Frequency of IFN-G producing CD8+ T cells (over the gated CD8+ 
T cell population) after in vitro stimulation with trp2(180–188) (control) or 
OVA(257–264) (OVA) peptides (a). Bars are the mean ± SEM. *P = 0.01. 
(b) Representative histograms showing IFN-G and TNF-A expression on 
gated CD8+ population. The relative proportion of IFN-G+TNF-A– and 
IFN-G+TNF-A+ CD8+ T cells is indicated. (c) In vivo cytotoxic killing of 
OVA(257–264)-pulsed target cells (CFSE
high) relative to control trp2(180–188)-
pulsed cells (CFSElow). A representative histogram per group is shown 
(n = 8) with the percentage of speciﬁc killing (mean ± SEM).*P = 0.017. 
Data shown are from one representative of at least two independent 
experiments. IFN, interferon; OVA, ovalbumin; TNF-A, tumor necrosis 
factor-A.
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respectively). Altogether, this data shows that coadministration of 
pDAI effectively improves T cell immunity by enhancing in vivo 
antigen-specific proliferation of CD8+ T cells and the induction 
and persistence of effector and memory CTLs.
DAI efﬁciently induces CTL immunity to survivin TAA 
and promotes tumor protection
We next studied whether DAI coadministration would enhance 
the immunogenicity of a weakly immunogenic TAA. Survivin is 
an intracellular inhibitor of apoptosis that is strongly upregulated 
in many types of cancer cells and associated with enhanced tumor 
cell viability.24 While we were unable to detect responses to sur-
vivin in 129Sv mice vaccinated with a survivin-encoding plasmid 
(pSURV) alone, coadministration of pDAI overcame tolerance to 
the self-epitopes surv(20–28) and surv(56–64) and raised the frequency 
of IFN-G-producing CD8+ T cells in peripheral blood from non-
detectable (<0.2%) to 2.7% (P = 0.007) and 3.3% (P = 0.002) for 
surv(20–28) and surv(56–64), respectively (Figure 5a). Given that most 
of the transcripts upregulated by DAI overexpression observed 
in Figure 1 are potential targets for nuclear factor KB (NF-KB) 
(IFN-A, IL-6, TNF-A, Cxcl10, CD40, CD80),25 we asked whether 
activation of this pathway was responsible for the adjuvant effect 
in vivo. A plasmid encoding a nonphosphorylable, degradation-
resistant mutant of the NF-KB inhibitor, IKBA super-repressor 
(pIKBA-SR),26 which blocks NF-KB-dependent transcription, was 
codelivered. Interestingly, coadministration of pIKBA-SR com-
pletely ablated the survivin-specific response observed in pDAI-
vaccinated mice (Figure 5a), indicating that NF-KB activity is 
essential for the adjuvant effect of pDAI.
A hallmark of DAI signaling is the release of type I IFNs,13,18 
which are essential for optimal clonal expansion and enhanced 
effector function of CTLs.27,28 Therefore, we investigated whether 
type I IFN production would contribute to the adjuvant effect of 
DAI. The induction of survivin-specific IFN-G-producing CTLs 
observed in Sv129 mice vaccinated with pSURV+pDAI was dras-
tically reduced in IFN-A/B receptor-deficient mice (Figure 5b). 
Codelivered pDAI could only generate an insignificant increase 
in the frequency of IFN-G-producing CD8+ T cells. This indicates 
that type I IFN production was largely responsible for the adju-
vant effect of DAI, although other factors may also contribute.
DAI-induced type I IFN-secretion depends, at least partially, 
on IRF3-activation in vitro.13 Therefore, we studied the effect of 
pDAI coadministration on survivin-specific CTL responses in 
IRF3-deficient mice. Coimmunization with pDAI+pSURV in 
both C57BL/6 wild type and Irf3−/− mice increased the frequency 
of antigen-specific IFN-G-secreting CD8+ T cells more than five-
fold compared to pSURV alone, from 0.45 to 2.4% (P < 0.0001), or 
from 0.5 to 2.8–3.7% (P < 0.005), respectively (Figure 6a,b). These 
results indicate that IRF3 is not required for DAI-enhanced CTL 
induction. Interestingly, survivin-specific CTLs could simultane-
ously produce TNF-A and a small proportion also produced IL-2 
(Supplementary Figure S5). We further tested whether pDAI 
coimmunization would promote CD4+ Th1 responses to a major 
histocompatibility complex class II-restricted survivin epitope, 
surv(53–67). Indeed, pDAI increased the frequency of CD4
+ T cells 
producing simultaneously IFN-G and TNF-A after surv(53–67) pep-
tide stimulation from 0.049 to 0.19% (Figure 6c, P < 0.05). In 
order to assess its relative potency as a genetic adjuvant, pDAI 
was directly compared to the granulocyte-macrophage colony-
stimulating factor (GM-CSF)-encoding plasmid (pGM-CSF), a 
widely used genetic adjuvant.29 In contrast to pDAI, coimmu-
nization with pSURV+pGM-CSF did not boost either CD8+ 
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Figure 4 Codelivery of pDAI promotes memory CTL responses. 
C57BL/6 mice were electroporated with pDAI, pOVA, or pOVA+pDAI 
twice at 2-weeks interval (n = 6) and lymphocytes from (a) spleen and 
(b) blood were analyzed 5 weeks later by immunoﬂuorescence stain-
ing and ﬂow cytometry. Frequency of OVA(257–264)-speciﬁc CD8
+ T cells 
(over the gated CD8+ T cell population) showing one of the following 
memory subset phenotypes: effector memory (TEM; CD44
highCD62Llow); 
central memory (TCM; CD44
highCD62Lhigh); memory stem cells (TSCM; 
CD44lowCD62Lhigh). Bars are the mean ± SEM. *P < 0.05. CTL, cytotoxic 
CD8+ T lymphocytes.
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Figure 5 Codelivery of pDAI overcomes CTL tolerance to survivin 
TAA via a mechanism requiring NF-KB activation and type I IFN 
production. Mice were electroporated twice at 2-week intervals with 
pDAI, pSURV, or pSURV+pDAI (n = 6). Where indicated, pIkBA-SR was 
also administrated. (a, b) Peripheral lymphocytes were obtained from 
(a) 129Sv WT or (b) Ifnar−/− mice 13 days after the last vaccination. The 
frequency of IFN-G producing CD8+ T cells (over the gated CD8+ T cell 
population) after in vitro stimulation with trp2(180–188) (control), surv(20–28) 
(surv20), or surv(56–64) (surv56) peptides is shown. Bars are the mean ± 
SEM. **P = 0.002. Data shown are from one representative of at least 
two independent experiments. CTL, cytotoxic CD8+ T lymphocytes; 
IFN, interferon; NF-KB, nuclear factor KB; TAA, tumor-associated anti-
gens; WT, wild type.
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or CD4+ T cell responses to survivin (Supplementary Figure 
S6), indicating that DNA EP itself is a potent approach to elicit 
immune responses and probably masked the adjuvant effect of 
pGM-CSF observed by others including our group. Furthermore 
and considering the plethora of induced cytokines including 
IL-10, the potential induction of immunosuppressive cells such 
as CD25highFoxP3+ CD4+ regulatory T cells, and Gr1+CD11b+ 
myeloid-derived suppressor cells was investigated in the inguinal 
lymph nodes and spleens from vaccinated mice 13 days postim-
munization. Neither the vaccination with the TAA survivin nor 
the coimmunization with pDAI altered the frequency of regu-
latory T cells (Supplementary Figure S7). A small but signifi-
cant (P < 0.05) decrease in myeloid-derived suppressor cells was 
detected in the spleen of mice coimmunized with pDAI+pSURV 
as compared to pSURV alone. The enhanced CTL and CD4+ Th1 
responses observed suggested that pDAI coadministration might 
enhance protection against tumor formation elicited by pSURV 
DNA vaccination. Indeed, administration of pDAI+pSURV to 
C57BL/6 mice demonstrated a trend (P = 0.079) toward improved 
rejection of a subcutaneous tumor challenge of the syngeneic 
B16 melanoma when compared to mice immunized with pSURV 
alone (Figure 6d).
DAI enhances TRP2-speciﬁc CTL responses and 
confers long-term tumor protection
In order to confirm the ability of DAI to enhance antitumor CTL 
responses, we combined pDAI with a tyrosinase-related pro-
tein-2 (TRP2) encoding DNA vaccine (pTRP2). TRP2 is a highly 
expressed glycoprotein in human melanomas and a clinically rel-
evant model antigen used for CTL-mediated targeting of mouse 
B16 melanoma.30 An increased frequency of trp2(180–188)-specific 
IFN-G-producing CD8+ T cells was observed in mice covacci-
nated with pTRP2 and pDAI (pTRP2+pDAI) as compared to 
mice vaccinated with pTRP2 only (0.75 and 0.43% respectively, 
P = 0.043) (Figure 7a). We also tested whether pDAI covac-
cination would increase the rejection of B16 melanoma chal-
lenge and found that a higher proportion of the covaccinated 
mice rejected a B16 melanoma challenge compared to mice 
vaccinated with TRP2 alone (Figure 7b; P = 0.044). Given the 
enhancement of antigen-specific memory CD8+ T cell responses 
observed in Figure 4, mice that survived the B16 challenge from 
both pTRP2 and pTRP2+pDAI vaccinated groups were rechal-
lenged 3 months after the initial challenge with a higher dose 
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Figure 6 Codelivery of pDAI enhances CTL and CD4+ Th1 responses 
to survivin TAA and promotes tumor protection. Mice were elec-
troporated twice at 2-week intervals with pDAI, pSURV, or pSURV+pDAI. 
(a, b) Peripheral lymphocytes were obtained from (a) C57BL/6 WT or 
(b) Irf3−/− mice (n = 8) 13 days after the last vaccination. The frequency 
of IFN-G producing CD8+ T cells (over the gated CD8+ T cell population) 
after in vitro stimulation with trp2(180–188) (control), surv(20–28) (surv20), or 
surv(56–64) (surv56) peptides is shown. Bars are the mean ± SEM. ***P < 
0.0001, **P = 0.005. Data shown are from one representative of at least 
two independent experiments. (c) Peripheral lymphocytes were obtained 
13 days after the last vaccination (n = 7). The frequency of peripheral 
CD4+ T cells producing simultaneously IFN-G and TNF-A (over the gated 
CD4+ T cell population) after in vitro stimulation with ova(323–339) (control) 
or surv(53–67) (surv53) peptides is shown. Bars are the mean ± SEM. *P < 
0.05. (d) Survival of C57BL/6 WT mice challenged with B16 melanoma 
cells 2 weeks after the second vaccination (pDAI, n = 5; pSURV, n = 15; 
pSURV+pDAI, n = 11). P = 0.079 for the comparison between pSURV and 
pSURV+pDAI groups. Data presented were pooled from two indepen-
dent experiments. CTL, cytotoxic CD8+ T lymphocytes; IFN, interferon; 
TAA, tumor-associated antigens; WT, wild type.
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Figure 7 Codelivery of pDAI enhances TRP2-speciﬁc CTL responses and confers long-term protection to B16 melanoma challenge. C57BL/6 
mice were electroporated twice at 2-week intervals with pDAI, pTRP2, or pTRP2+pDAI. (a) Peripheral lymphocytes were obtained 13 days after the last 
vaccination. The frequency of IFN-G producing CD8+ T cells (over the gated CD8+ T cell population) after in vitro stimulation with surv(20–28) (control) 
or trp2(180–188) (trp2) peptides is shown (n = 6). Bars are the mean ± SEM. *P = 0.043. Data presented are from one representative of two independent 
experiments. (b) Survival of C57BL/6 WT mice challenged with B16 melanoma cells two weeks after the second vaccination (n = 14). *P = 0.044 for the 
comparison between pTRP2 and pTRP2+pDAI groups. Data presented were pooled from two independent experiments. (c) Long-term protection of 
C57BL/6 WT mice that had rejected the initial tumor challenge and were rechallenged with a higher dose of B16 melanoma cells in the opposite ﬂank 
3 months after initial challenge (pTRP2, n = 15; pTRP2+pDAI, n = 16). Data presented were pooled from two independent experiments. ***P < 0.0001. 
CTL, cytotoxic CD8+ T lymphocytes; IFN, interferon; TRP2, tyrosinase-related protein-2; TAA, tumor-associated antigens; WT, wild type.
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of B16 melanoma cells, without any additional immunization. 
Remarkably, almost 70% of the pTRP2+pDAI covaccinated mice 
rejected the melanoma cells whereas all mice vaccinated with 
pTRP2 alone succumbed to the second challenge (P < 0.0001) 
(Figure 7c). These results argue that DAI not only promotes the 
induction of functional effector cells, but also enhances immu-
nological memory.
DISCUSSION
In the present study, we describe for the first time the use of an 
intracellular PRR as a genetic adjuvant that enhances the immu-
nogenicity of DNA vaccines. DNA vaccines encode single (or 
few) antigens, which makes them highly specific but also inher-
ently less immunogenic than whole-cell or multicomponent 
vaccines developed in the past. Furthermore, DNA vaccines 
against cancer need to overcome the tumor-associated immune 
tolerance, which is generally characterized by low frequencies of 
TAA-specific T cell precursors or the presence of TAA-specific 
T cells with intermediate-low TCR affinity. Therefore, adjuvants 
that enhance the immunogenicity of the encoded antigen and 
efficiently induce TAA-specific effector T cells are essential com-
ponents of antitumor DNA vaccines. Genes encoding single 
cytokines and chemokines have been extensively used as genetic 
adjuvants. Notably genes encoding IL-2, IL-12, IL-15, and 
GM-CSF have successfully adjuvanted DNA vaccines in mice and 
nonhuman primates31–33 as well as in humans.34 However, some 
of these molecules, e.g., IL-235 and GM-CSF,36,37 are important 
in maintaining immune tolerance to self-antigens. Moreover, 
recent results from clinical studies have shown that IL-2 or 
GM-CSF as adjuvant for cancer vaccines or immunotherapies 
can promote the induction and recruitment of immunosuppres-
sive T regulatory cells38,39 and myeloid-derived suppressor cells.40 
The homeostatic roles of certain cytokines and sometimes the 
contradictory effects observed in clinical trials have raised some 
concerns about the use of single cytokines as adjuvants for can-
cer vaccines. Strategies involving the concerted action of several 
cytokines and costimulatory molecules can result in a potent 
activation of the immune responses, in particular against weakly 
immunogenic antigens.10 The production of several immunos-
timulatory molecules can be achieved by stimulation of innate 
immune PRRs, as occurs during natural infection. Consequently, 
strategies that boost innate immune PRR signaling by coexpress-
ing intracellular adaptor molecules or downstream transcription 
factors as genetic adjuvants, have been shown to enhance the 
potency of DNA vaccines.41,42 However, such strategies have 
not been combined with antitumor DNA vaccines. The strategy 
developed in this study consists of delivering both the DNA-
encoded intracellular PRR (DAI) and its activating ligand (plas-
mid DNA) to stimulate downstream transcription factors and 
initiate the production of several proinflammatory and costimu-
latory molecules, as well as type I IFNs, which ultimately pro-
mote adaptive T cell responses. The coadministration of pDAI 
was indeed comparatively more potent than the plasmid encod-
ing GM-CSF in enhancing survivin-specific T cell responses in 
the experimental setup described here (Supplementary Figure 
S6). Moreover, pDAI did not induce immunosuppressive cell 
populations, as it has been reported for other adjuvants,38–40 and 
rather showed decreased levels of myeloid-derived suppressor 
cells (Supplementary Figure S7).
In vitro studies have demonstrated that DAI signaling can 
activate both NF-KB and IRF3 to produce type I IFNs and other 
proinflammatory cytokines.13,18 Nevertheless, little is known 
about DAI signaling in vivo. Our data show that i.d. EP with 
pDAI induces transcriptional upregulation of molecules that are 
known downstream targets of NF-KB (Figure 1), indicating that 
this key mediator of the innate immunity was activated in mouse 
skin. NF-KB represents a master transcription factor for signal-
ing through TLRs43 and intracellular DNA-sensing PRRs.13,15,16,19 
Consistent with such a crucial role in DNA-induced innate 
immune activation, NF-KB was essential for DAI-promoted CTL 
induction (Figure 4a) and, quite unexpectedly, this effect was not 
dependent on IRF3 (Figure 5b). Based on these observations, 
the critical role of type I IFNs for DAI-enhanced CTL induction 
(Figure 4b) and that IRFs are the main transcription factors driv-
ing type I IFN expression, we speculate that NF-KB activation is 
required for the initial release of type I IFNs and the resulting 
signaling events then activate IRFs, other than IRF3, to ensure 
robust induction of innate immune responses. Type I IFN pro-
duction has been described to occur in two waves (reviewed in 
ref. 44). In the first wave, PRR signaling results in activation of 
NF-KB, IRF3, or both, and subsequent release of IFN-B. In the 
second wave, IFN-B transmits the danger signal to neighbor-
ing cells through binding to the type I IFN receptor. This turns 
on a signaling cascade that promotes gene expression of IFN-
inducible genes with antiviral activity as well as IRF7. Possibly, 
IRF7-signaling contributes to ensure type-I IFN responses in the 
absence of IRF3-signaling,13 thus sufficing the production of large 
amounts of type I IFNs.
The effects of type I IFNs include the release of cytokines and 
chemokines that modulate the function of dendritic cells resulting 
in, among other things, increased major histocompatibility com-
plex class I crosspresentation, as well as improved development 
of effector and memory CTLs.45,46 Our results support the notion 
that, in addition to antigen and coreceptor mediated stimulation, a 
third cytokine signal is important for effective CTL induction.27,28 
Among the cytokines that can provide the third signal, IFN-A but 
not IL-12 transcripts were upregulated after pDAI EP (Figure 1). 
Also, type I IFN signaling was essential for DAI-mediated CTL 
induction (Figure 4b). There is abundant evidence supporting 
the importance of type I IFNs in the generation of long-lasting 
antitumor immunity. Type I IFNs enhance tumor protection by 
increasing induction, proliferation, effector function, resistance to 
apoptosis, and long-term effector memory phenotype of CTLs.47 
On the other hand, defective type I IFN signaling and down-
stream activation of T cells is a common immune dysfunction 
in patients with different types of cancer.48 Here, we demonstrate 
that pDAI coimmunization promotes the induction and persis-
tence of memory CD8+ T cell of effector, central, and stem cell 
phenotypes (Figure 4). Accordingly, the combination of DAI- and 
TRP2-encoding plasmids elicited long-term protection against 
B16 melanoma (Figure 6c).
In summary, our studies show that in vivo overexpression of 
DAI boosts DNA-sensing innate immune activation and thereby 
generates a proinflammatory microenvironment essential for 
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effective CTL induction and long-lasting antitumor immunity. 
Thus, this study validates the use of intracellular innate PRRs 
as genetic adjuvants that harness intrinsic innate immune-
stimulating properties of plasmid DNA vaccines to enhance the 
immunogenicity of weakly immunogenic antigens. Hence, our 
findings are expected to improve the design of DNA vaccines for 
diseases where efficient cellular immunity is desired to confer 
protection.
MATERIALS AND METHODS
Mice and immunizations. C57BL/6, OT-I Rag-1−/−, Irf3−/−, and 129Sv and 
Ifnar−/− mice were kept according to the guidelines of the Regional Animal 
Ethics Committee. Mice anesthetized with isoflurane were injected i.d. with 
40 μl of phosphate-buffered saline containing 20 μg of each plasmid at two 
different sites (20 μl each). pVAX was used to equalize DNA quantity within 
the same experiment. A parallel needle array electrode (two rows of four 
2-mm pins, 1.5 × 4 mm gaps) was applied to deliver the electric pulses (two 
1,125 V/cm, 0.05 ms pulses followed by eight 275 V/cm, 10 ms pulses)49 
using the Derma Vax DNA Vaccine Skin Delivery System (Cyto Pulse 
Sciences, now Cellectics, Romainville, France). Mice were immunized two 
times with 2 weeks between immunizations. The following plasmids were 
used for immunizations: pOVA encoding membrane-bound OVA (kindly 
provided by Dr A. Lew, Walter and Eliza Hall Institute of Medical Research, 
Melbourne, Australia), pSURV encoding the human survivin gene has been 
described,50 pTRP2 encoding the human TRP2 (kindly provided by Dr T. 
Wölfel, Johannes Gutenberg University, Gutenberg, Germany), pIKBA-SR 
encoding the IKBA super-repressor (kindly provided by Dr R. Toftgård, 
Karolinska Institutet, Stockholm, Sweden) and pDAI. pDAI was produced 
by cloning the DAI coding sequence from mouse splenocytes into the 
pVAX vector (Invitrogen, Carlsbad, CA) using standard cloning proce-
dures. Primers used for DAI cloning are listed in Supplementary Table S1. 
Plasmids were purified using the GigaPrep Endofree Kit (Qiagen, Hilden, 
Germany). Tumor challenge and rechallenge was performed by injecting 
subcutaneously 1 × 105 and 2 × 105 B16 cells, respectively.
Quantitative real-time reverse transcription-PCR. Total RNA was iso-
lated from skin biopsies taken 24 hours after DNA EP and cDNA was pre-
pared (iScript cDNA synthesis kit; Bio-Rad, Hercules, CA). Transcript 
levels were determined by quantitative real-time PCR (iQ SYBR Green 
Supermix; Bio-Rad; ABI7500, Applied Biosystems, Foster City, CA) 
using a two-step cycling program (1 minute at 95 °C, followed by 40 
cycles of 15 seconds at 95 °C and 1 minute at 62–64 °C) and normalized 
to the L32 housekeeping gene. Primers are listed in Supplementary 
Table S2. Pooled cDNA from the pVAX and pDAI groups was added 
to the RT2 SYBR Green qPCR Master Mix (SABiosciences, Frederick, 
MD) and each sample was aliquoted on the Mouse IFN-A, B response, 
and the mouse inflammatory response and autoimmunity RT2Profiler 
PCR-arrays, respectively. All steps were done according to the manu-
facturer’s protocol for the ABI Prism 7500 and 7900 HT Sequence 
Detection System. To analyze the PCR-array data, excel macros were 
downloaded from the manufacturer’s website (http://www.sabiosci-
ences.com/pcrarraydataanalysis.php). Data normalization was based 
on correcting all Ct values for the average Ct  values of several constantly 
expressed housekeeping genes present on the array.
Antibodies and ﬂow cytometry. Monoclonal antibodies anti-mouse 
CD8A (clone 53-6.7), IFN-G (clone XMG1.29), TNF-A (clone MP6-XT22), 
VA2 TCR (clone B20.1), IL-2 (clone JES6-5H4), CD11b (clone M1/70), 
CD11c (clone N418), CD25 (clone PC61), CD40 (clone 1C10), CD44 
(clone IM7), CD62L (clone MEL-14), CD69 (clone H1.2F3), CD80 (clone 
16-10A1), FOXP3 (MF23), major histocompatibility complex class II 
(clone M5/114.15.2), Gr1 (RB6-85C) (BD Biosciences, San Jose, CA) and 
H-2Kb/OVA(257–264) pentamer (Proimmune, Oxford, UK) were used for 
immunoflorescence staining and flow cytometry analysis. Nonspecific 
binding was blocked by adding unconjugated rat anti-mouse CD16/CD32 
antibody (mouse BD Fc block, clone 2.4G2; BD Biosciences). Samples 
were analyzed on a FACSCalibur cytometer (BD Biosciences) and the data 
were processed using FlowJo version 6.4.7 (Tree Star, Ashland, OR).
Intracellular cytokine staining. Peripheral blood was collected 13 days 
after the last immunization and lymphocytes were stimulated with pep-
tides (1 Mg/ml) for 8 hours. GolgiPlug (BD Biosciences) was added after 
2 hours. Intracellular staining was performed using Cytofix/Cytoperm 
Fixation/Permeabilization Solution set (BD Biosciences) according to the 
manufacturer’s instructions.
In vivo antigen proliferation of OT-I CD8+ T cells. Spleen and lymph 
node cells from naive OT-I mice were isolated. Splenocytes were RBC 
depleted using PharmLyse buffer. Cells (108 cells/ml; phosphate-buffered 
saline 0.5% RPMI) were stained with 2 μmol/l CFSE (Sigma-Aldrich, St 
Louis, MO) for 5 minutes. A tenfold larger volume of 20% fetal bovine 
serum RPMI was added to stop CFSE staining. Cells were then washed 
twice, resuspended in phosphate-buffered saline at a final concentration of 
107 cells/ml and 2 × 106 cells were intravenously transferred into vaccinated 
recipients. Inguinal lymph nodes were sampled after 4 days and analyzed 
by flow cytometry.
In vivo cytotoxicity assay. Target spleen cells were labeled with 0.2 and 
2 μmol/l of CFSE, and pulsed with control or OVA peptide, respectively. 
Then, 107 cells from each population were mixed and injected intravenously 
into vaccinated mice. Lymph nodes were removed 6 hours later and ana-
lyzed by flow cytometry.50 CFSE+ donor target splenocytes were differenti-
ated from host cells and the percentage of specific killing was determined as 
follows: 100 – [(% of OVA peptide-pulsed targets/% of TRP2 peptide-pulsed 
targets in vaccinated recipients)/(% of OVA peptide-pulsed targets/% of 
TRP2 peptide-pulsed targets in control vaccinated recipients) × 100].
Statistical analysis. Statistical analysis was performed using the Graphpad 
Prism software (Graphpad Software, La Jolla, CA). Unpaired t tests were 
performed pair wise between relevant groups. No multiple comparisons 
were performed to control for type I errors. Statistical analyses of survival 
curves were performed using the one-tailed Mantel–Cox log-rank test.
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Abstract 
 
Cancer vaccines targeting antigens expressed by cancer stem cells (CSCs) 
have the potential to become potent cancer therapies. Cripto-1 (CR) is a 
glycoprotein that plays a critical role during embryogenesis and is over-
expressed in more than 50% of human carcinomas and melanomas but is 
expressed only at low levels on normal differentiated tissues. CR is involved 
in cellular processes, which are hallmarks of CSCs and aggressive metastatic 
disease, such as unrestrained cell-proliferation, epithelial-mesenchymal 
transition and tumor-related angiogenesis. We demonstrate that a DNA 
vaccine-encoding mouse (m) CR is able to induce a protective immune 
response in mouse melanoma and breast cancer models. Vaccination of 
C57Bl/6 mice elicited immunological protection against lung metastasis and 
subcutaneous challenges with B16F10 melanoma cells. This was mediated by 
mCR specific CTLs for which we identified a H2-Kb restricted epitope that was 
effective at stimulating CD8 T cells ex vivo and in vivo. In the 4T1 
metastasizing breast cancer model, vaccination against mCR reduced lung 
metastatic tumor burden and generated mCR specific antibodies. CR negative 
tumors grown in a spheroid culture system to enrich for CSCs demonstrated 
up-regulated CR expression and had acquired sensitivity for vaccination 
induced tumor rejection. In addition, vaccination with mCR in Her2 transgenic 
BALB-neuT mice in a therapeutic setting led to a significant reduction in 
metastatic spread. Our data indicate that DNA vaccination against mCR 
results in a protective immune response against CR expressing tumors, which 
could lead to the development of prophylactic and therapeutic tumor vaccines 
to be tested in the clinic. 
 
Introduction 
 
The largest hurdle in the treatment of cancer patients is not that of treating 
large tumors but to ensure that the disease does not disseminate in the 
patient, leading to metastasis and eventually death. Immunotherapy is coming 
to the forefront for treating metastatic disease (1) and success has been 
achieved with the treatment of metastatic melanoma and other tumor types 
using immune-checkpoint blockade (2). This releases the anti-tumor T cell 
immunity through removal of inhibitory signaling mediated by the PD1 or 
CTLA4 molecules (3). Similarly, adoptive transfer of ex vivo expanded and 
activated tumor infiltrating T cells has successfully cured a proportion of 
metastatic melanoma patients (4). These strategies, while potent, require the 
prerequisite that the patients have a pre-established anti-tumor immunity, 
which may frequently not be the case.  
 
This limitation can be overcome by educating the immune system through 
vaccination. Vaccination has a long history in the treatment of human 
diseases, and while very successful in preventing pathogenic infections, less 
success has been achieved when applying vaccines to treat cancer. Many of 
the antigen targets such as MAGE-A, GP100, NY-ESO-1, Tyrosinase and 
Her2, have been tested in vaccination trials with limited success (5). Vaccines 
have been shown to elicit both humoral and cellular responses in a substantial 
proportion of the patients, though these responses are typically not potent 
enough to have an impact on the disease burden. Removing large tumor 
burdens through vaccination-induced antigen-specific immune responses 
remains a challenge.  
 
Herein we describe that vaccination against the tumor-associated antigen 
Cripto-1 (CR) elicits specific immune responses and targets highly metastatic 
aggressive cancer models. CR is an embryonic tumor antigen and as such is 
related to most aspects essential for driving embryogenesis, including 
proliferation, angiogenesis as well as epithelial-mesenchymal transition (EMT) 
(6). These essential characteristics of embryogenesis resemble the 
aggressive traits of metastatic cancer cells and represent key hallmarks of 
cancer (7). Importantly, CR has been shown to be upregulated in cancer stem 
cell (CSC) populations in melanoma and breast cancer (8,9). Using a DNA 
vaccine based approach we are able to show in multiple in vivo models that 
CR can be targeted by the immune system, leading to decreased tumor 
burden and reduced metastatic spread. The vaccination was able to elicit CR-
specific CTL responses in C57BL/6 mice, and H2-Kb restricted-epitopes were 
identified. In addition to a cellular response, vaccination generated an 
antibody response in BALB/C mice. DNA vaccines encoding mouse (m) CR 
(pmCR) reduced lung metastasis in an orthotopic transplanted and 
metastasizing breast cancer model and was capable of inhibiting 
dissemination of spontaneously arising breast carcinoma to the lungs in 
BALB-neuT mice. 
 
 
 
Material and methods 
 
Mice and cell lines 
BALB/c, BALB-neuT and C57BL/6 mice were bred, maintained at either the 
Microbiology and Tumor Biology Center (Karolinska Institutet, Stockholm, 
Sweden) or the Molecular Biotechnology Center (University of Turin, Turin, 
Italy) and were handled by strict adherence to the European guidelines and 
University Ethical Committee. Animal studies performed in Sweden were 
reviewed and approved by the Regional Animal ethics committees; 
Stockholms Norra Djurförsoksetiska Nämnd Avdelning 2, Sweden with ethical 
permit number N426/11. RetV (generously donated by Prof. V. Umansky, 
DKFZ Heidelberg), MCA205, B16F10, B16F1, 4T1-luc, D2F2, TUBO, TSA 
and RMA-s were maintained with GlutaMAX-RPMI supplemented with 10% 
heat-inactivated FCS, 50 IU/mL penicillin, and 50 µg/mL streptomycin (Life 
Technologies). Cell lines were maintained at 37oC with 5% CO2 at 95% 
humidity and were split as was necessary using 0.05% Trypsine/EDTA (Life 
Technologies). To generate Cripto-1 overexpressing cell lines, mouse Cripto-
1 lentiviral particles were acquired (Amsbio, Abindon, U.K.) and were used to 
transduce D2F2 as well 4T1-luc cells with mouse Cripto-1. Followed by cell 
sorting for Cripto-1 positive cells using FACs. D2F2 cells were transfected 
using lipofectamine 2000 (Life Technologies) with human Cripto-1 expression 
vector and selected using Geneticin (G418 Sulfate, Life Technologies).  
 
Western blots 
Cell lysates were prepared with 1M RIPA buffer (50nM Tris-HCl, pH 7.4, 1% 
Triton-X, 0.5% Na-deoxycholate, 0.1% SDS, 150mM NaCl, 2mM EDTA, 50 
mM NaF) with 1x protease inhibitor (Roche, Cat. No. 04693159001) at 1x106 
cells/ml directly after collection from cell culture. Prior to loading on the gel 
protein concentrations were determined with BCA protein assay (Thermo 
Scientific, Rockford, IL) according to the manufacturers protocol. 20 µg 
protein per sample was loaded on 10% NuPAGE Bis-Tris acrylamide gels 
(Invitrogen) and run at 200 V for 45 minutes with MOPS SDS running buffer 
(Invitrogen) followed by transfer onto PVDF membrane (Immobilon-P; 
Millipore, Bedford, MA) for 3 hours at 40V. Blocking of the membrane was 
done using TBS-0.5% Tween 20 (Sigma-Aldrich), 2.5% milk powder or 2.5% 
BSA, followed by wash in TBS-0.5% Tween 20 and incubation with primary 
antibodies: rabbit α-human Cripto antibody, cross reactive to mouse 1:1,000 
(Rockland, cat.no. 600-401-997) and mouse α-beta-Actin antibody 1:25,000 
(Sigma-Aldrich) overnight at 4oC. Secondary staining was done using α-rabbit 
IgG, HRP-linked (Cell Signaling Technology) and α-mouse IgG, HRP-linked 
(Cell Signaling Technology) for 1 hour at room temperature. Development 
was done using Amersham ECl Prime Western Blotting Detection Reagent 
(GE Healthcare). Using a LAS-1000 CCD camera system (Fujifilm, Tokyo, 
Japan) luminescence was detected.  
 
Vaccination and Plasmids 
Mice were treated on week 8 and week 10 either by intradermal injection of 40 
µg of plasmid injected in PBS followed by electroporation protocol as 
described previously (10) using IGEA plate electrodes (C57BL/6, BALB/c) or 
by intramuscular injection of 50 µg of plasmid diluted in 20 μL of saline 
 
followed by electroporation with  IGEA array needle electrode (BALB/c, BALB-
neuT) to facilitate plasmid transfer BALB-neuT mice were i.m. injected on 
week 10 and 12 with 50 µg plasmid and electroporated after insertion of a 
needle electrode in the injected area. Cripto-1 encoding plasmids were 
generously provided by Bianco C et. al. and cloned into the pVAX vector 
(Invitrogen, Carlsbad, CA, USAP) (11). Plasmid based vaccines were 
produced by transformation of E. coli (TOP10, Invitrogen) with pVAX plasmid 
and grown in Luria-Bertani medium containing Kanamycin (50µg/ml). To 
generate endotoxin-free vaccine, plasmids were purified using GigaPrep 
Endofree Kit (Qiagen GMBH, Hilden, Germany).  
 
Tumor models 
B16F10 tumor cells were transplanted into the C57BL/6 mice to model 
melanoma. B16F10 was injected s.c (50,000) or i.v. (200,000) in 100µl PBS 
after being harvested when in vitro growth was logarithmic and at 80% 
confluence. Tumor size was monitored by palpation with calipers and mice 
were sacrificed when they became moribund or when the tumor reached a 
volume of 1,000 mm3. Mice that were injected i.v. were sacrificed at day 14 
and lungs were excised and B16F10 foci were enumerated. 200,000 4T1-
mCR cells were administered orthotopically by delivery into the mammary fat 
pad in 50 µl PBS. In vivo imaging was done with IVIS SpectrumCT 
(PerkinElmer) using D-Luciferin (Life Technologies), 5 µg per gram mouse 
was injected i.p. and allowed to disseminate in the mouse for two minutes 
followed by anesthesia with Isoflourane at 3% for three minutes prior to 
transfer onto the heated, 37oC, SpectrumCT platform for imaging. Lungs were 
harvested and transferred into 4oC PBS from the 4T1-mCR tumor bearing 
mice 23 days post challenge. Lungs were individually diced using scalpels in 
6-well plates and dissociated in 1mg/ml DNase in StemPro Accutase Cell 
dissociation reagent with TrypLE at a ratio of 1:1 (Life Technologies). Diced 
lungs were incubated for 30 minutes in dissociation reagent and further diced 
with scalpels before being mechanically dissociated using a 70 µm filter 
(Corning). Removal of red blood cells was done using RBC lysis buffer 
(BioLegend) and followed by suspension in supplemented RPMI-1640 media 
containing 6-Thioguanine (60µM) and seeded in 150 mm cell culture dishes 
(Corning). After 10 days cells cell were washed with PBS, followed by 
formaldehyde fixation and Hematoxylin Harris (VWR, 351945S) staining for 5 
minutes. Primary tumors were excised and weighed. To evaluate lung 
metastasis, colonies were enumerated and metastatic index was calculated. 
Vaccinated BALB/c mice were challenged with 105 TUBO cells per mouse. P3 
mammospheres were cultured as described below and 2x104 cells were 
injected s.c. into BALB/c mice. For BALB-neuT lung metastasis, lungs were 
harvested at approximately 28 weeks of age and fixed in paraffin followed by 
staining with hematoxylin and eosin. Using ImageJ metastatic index was 
calculated. 
 
Immunological assays 
Overlapping 15 amino acid Cripto-1 peptides were generated to cover the 
whole protein. RMA-s cells were washed with RPMI medium without FCS and 
kept at room temperature for 2 hours. 2x105 cells were seeded into 96-well 
plates containing complete medium as well as peptides at a concentration of 
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100 µg/ml for 6 hours. Cells were washed and stained with α-mouse-H2-Kb-
FITC (BioLegend, 116505) to detect cell surface MHC class I molecules by 
flow cytometry. Mouse derived peptides; mCR16-25 (SAFEFGPVA), mCR46-55 
(RSFQFVPSV), mCR1-9 (MGYFSSSVVL), Surv20-28 (ATFKNWPFL), TRP2180-
188 (SVYDFFVWL), OVA257-264 (SIINFEKL) were acquired from China Peptides 
(ChinaPeptides Co. Ltd. Shanghai, China) at >95% purity. Peptides were 
used to stimulate mouse lymphocytes in peripheral blood harvested from 
immunized mice. Cells were seeded into 96-well plates and stimulated with 
10µg/ml of MHC class I-restricted peptide. After 2 hours, GolgiPlug (Becton, 
Dickinson and Company) was added for the last 6 hours of stimulation. Cells 
were stained with α-mouse-CD8-FITC, α-mouse-IFN-γ, α-mouse-TNF-α using 
the Cytofix/Cytoperm Fixation/Permeabilization Solution (Becton, Dickinson 
and Company) according to manufacturer’s instruction prior to acquisition of 
cells on LSRII FACS (Becton, Dickson and Company).  Data were analyzed 
using FlowJo (Tree Star). CD8+ cells were isolated from immunized mice 
splenocytes using MACS Beads CD8+ positive selection (Miltenyi Biotec). 105 
lymphocytes were seeded into 96-well plates and either co-cultured with 
5x104 B16F10 cells or peptides (10µg/ml) or non-stimulated overnight and 
supernatants were harvested after 18 hours. IFN-γ was evaluated using 
Mouse IFN-γ ELISA development kit (MabTech, Nacka Strand, Sweden) 
following manufactures instruction. In vivo cytotoxicity was evaluated as 
previously described (12). Splenocytes were harvested from naïve C57BL/6 
mice and labeled with 0.2, lo, or 2 µM, hi, of CFSE in PBS for 5 minutes. 10% 
FCS containing PBS was used to halt labeling of the cells. Hi naïve target 
splenocytes were pulsed with target peptide (10µg/ml) and lo naïve 
splenocytes were pulsed with control peptide (10µg/ml). Labeled splenocytes 
were mixed and injected i.v. into naïve, antigen immunized (AI) or control 
immunized (CI) mice. After 20 hours spleens were harvested from the mice 
and acquired by flow cytometery. In vivo cytotoxicity was calculated as 
follows: 100 - ((percentage of hi mCR16-25 peptide-pulsed targets in AI or CI 
mice/percentage of lo control targets in AI or CI mice)/(percentage of hi 
mCR16-25 peptide-pulsed targets in naïve mice/ lo control targets in naïve 
mice) x 100). Antibodies from immunized mice were evaluated in serum by 
staining D2F2mCR cells with 1:20 dilution of serum in PBS for 20 minutes at 
4oC followed by 20 minutes of staining with α-mIgG-PE (Jackson Laboratory, 
115-116-071), α-mIgG1-FITC, α-mIgG2a-FITC and α-mIgG2b-FITC (RMG1-1, 
RMG2a-62, RMG2b-1, BioLegend). Samples were acquired on BD LSRII and 
analyzed on FlowJo. 
Cancer cell spheroid culture 
Both TUBO and B16F10 were used in the generation of spheroid cultured 
tumor cells. B16F10 cells were seeded into Ultra-Low Cluster Plate (Costar) 
with 50,000 cells in 3 ml of melanoma spheroid culture medium. B16F10 
melanoma spheroid culture medium consisted of MBM-4 (Lonza) containing 
the following: CaCl2, bovine pituitary extract (BPE), recombinant human 
Fibroblast Growth Factor (rhFGF), recombinant human Insulin, 
hydrocortisone, PMA, GA-1000 and 10% FBS (Lonza, CC-3249). TUBO 
breast cancer cells were cultured in DMEM with 20% FCS prior to being 
transferred to ultra-low-attachment flasks (Sigma-Aldrich) at 6x104 cells/ml in 
mammosphere medium consisting of DMEM-F12 medium (Invitrogen) with 
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basic fibroblast growth factor (bFGF, 20 ng/ml), recombinant human insulin (5 
µg/ml), epidermal growth factor (EGF, 20 ng/ml) and bovine serum albumin 
(BSA, 0.4%) (Sigma-Aldrich). Cells were monitored daily and split, using 
enzymatic and mechanical dissociation, every third day for melanoma 
spheres and seventh day for mammospheres or depending on sphere 
aggregate cluster size. Cells were collected prior to sphere culturing and at 
every consecutive passage, which were denoted as P1, P2 and P3 as their 
passage number indicated.  
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Results 
 
Vaccination with mouse Cripto-1 encoding DNA (pmCR) increases survival 
and reduces lung metastasis burden of B16F10 melanoma 
 
We first analyzed the presence of CR in different mouse tumor models. 
Mouse tumor cell lines from C57BL/6 (B6) background were screened for 
mCR expression by western blot. D2F2 cell line and mCR-transfectant 
D2F2mCR were used as negative and positive controls for mCR expression, 
respectively. Significant expression was detected in B16F10 and RetV 
melanoma cell lines, the latter derived from the metastatic melanoma ret 
transgenic mouse model (13). B16F1, a less aggressive B16 melanoma sub-
line (14,15), and the MCA205 sarcoma cell line had weaker expression of 
mCR (Fig. 1A, upper panel). Interestingly, when B16F10 were grown in a 
sphere culture system (Sup. Fig. 1A) to expand the proportion of CSCs 
(16,17), mCR expression was progressively increased after each round of 
sphere culture (Fig. 1A, lower panel). To evaluate mCR expression in healthy 
tissues we screened the healthy mouse tissue gene expression data set 
obtained by Su et. Al (GSE1133:GLP1073) (Sup. Fig. 2A) (18). As expected, 
within the data set we found that mCR is expressed during early 
embryogenesis, and expression is down regulated beyond day 8.5 into 
adulthood (Sup. Fig. 2B).  
 
We next analyzed if vaccination with mCR-encoding vaccines could elicit 
protective immunity in B6 mice challenged with B16F10 melanoma cells. Mice 
were vaccinated twice with plasmid DNA delivered i.d. followed by 
electroporation. Two weeks after last vaccination, mice received a s.c. 
B16F10 tumor challenge and tumor growth was monitored. A significant delay 
in tumor growth was observed in pmCR-vaccinated mice, as compared to the 
control empty vector pVAX immunized mice (Fig. 1B). The delayed tumor 
growth led to significantly extended survival in pmCR-vaccinated mice (Fig. 
1C). We then evaluated the ability of pmCR vaccination to protect against 
metastatic lung colonization of i.v. injected B16F10 cells. A significant 
decrease in the number of metastatic lung colonies (Fig. 1D) and total tumor 
foci (Fig. 1E) was observed in mice vaccinated with mCR. These results 
indicate that vaccines encoding CR induce immunity with the potential to 
target highly metastatic melanoma cells. 
 
Generation of tumor antigen-specific CD8+ responses in pmCR immunized 
mice 
 
To establish whether mCR-specific T cell immune responses were generated 
by the vaccination, we first defined the tumor epitopes recognized by the 
resulting CD8+ T cells. A library consisting of 33 long overlapping peptides 
(15-mers) derived from the mCR amino acid sequence was screened for the 
ability to bind MHC class I molecules H2-Kb using the RMA-s MHC class I 
stabilization assay. Three of the peptides tested were able to stabilize H2-Kb 
at the cell surface of RMA-S cells (mCR1-15, mCR16-30 and mCR46-60, Fig. 2A), 
and as expected, the positive control H2-Kb epitopes, Trp2180-188 (19) and 
OVA257-264, strongly stabilized H2-Kb. We then identified the presence of MHC 
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class I-restricted epitopes within these 15-mer peptides using an in silico 
prediction analysis (http://www.cbs.dtu.dk/services/NetMHCpan/) (Sup. Table 
1). The predicted 9-mer epitopes were then tested for their ability to be 
recognized by peripheral blood CD8+ T cells in vaccinated mice. Indeed, two 
of these predicted peptides, mCR16-25 (Fig. 2B) and mCR46-55, elicited an ex 
vivo IFN-γ and TNF-α response after peptide stimulation. No responses 
specific for mCR1-9 were detected (Sup. Fig 3). The serum from vaccinated B6 
mice contained no detectable antibodies specific for mCR (data not shown). 
We further confirmed the ability of CD8+ T cells isolated from spleens of 
vaccinated animals to secrete significant amounts of IFN-γ in response to 
mCR16-25 peptide and tumor cell stimulation but not after control stimulation 
with OVA peptide or left unstimulated (Fig. 2C). The ability of mCR16-25-
specific CD8+ T cells to mediate cytotoxic killing was further evaluated in vivo 
by transferring target spleen cells pulsed with either mCR16-25 or OVA control 
peptide and stained with high or low concentrations of CFSE, respectively. 
Specific killing of the mCR16-25 pulsed CFSEhi relative to the internal control of 
OVA pulsed CFSElo splenocytes was analyzed by flow cytometry one day 
after transfer to mice. Killing of mCR16-25 pulsed cells was observed to be 
significantly greater in mCR vaccinated mice than in control mice (45% ± 1% 
versus 2% ± 1%) (Fig. 2D, E). These results demonstrated that mCR16-25 
specific CTLs were able to elicit in vivo cytotoxic killing. 
 
Vaccination against mCR increases survival and reduces lung metastasis 
burden in mammary carcinoma models. 
 
To extend our study also to mammary carcinomas, four mouse mammary 
carcinoma cell lines on BALB/c background were screened by western blot for 
expression of mCR. In contrast to the melanoma cell lines none of the 
mammary carcinoma lines expressed high amounts of mCripto-1, though 
weak bands could be identified for 4T1 (20), TS/A and TUBO (21), while the 
D2F2 (22) line was negative for mCR expression. mCR transfectants were 
generated by transfecting the mCR negative D2F2 cell line with vectors 
encoding for mCR. These transfectants were used as positive controls for 
mCR expression. As a first approach to establish the protective potential of 
mCR vaccination-induced immune responses over the dissemination of 
mammary cancer cells in BALB/c models, we generated a stable mCR 4T1-
luc transfectant (4T1-mCR) (Fig. 3A), which was used as a model for 
spontaneous lung metastasis. BALB/c mice were vaccinated twice with pmCR 
or control pVAX plasmids prior to implantation of 4T1-mCR cells into the 
mammary fat pad. Primary tumor growth was evaluated by in vivo luciferase 
activity detection at day 14 (Fig. 3B) and by measuring tumor weight (Fig. 3C) 
at day 23 after tumor challenge. In mice vaccinated with pmCR tumor growth 
was significantly reduced as compared to pVAX mice. Furthermore, pmCR 
vaccination greatly reduced spontaneous metastasis to the lungs as 
evaluated by a colony formation assay (Fig. 3D). The humoral response was 
evaluated as the ability of serum antibodies to bind mCR on D2F2mCR 
transfectants; mCR negative D2F2 cell line were used as negative control. We 
were able to identify mCR specific IgG antibodies in pmCR-vaccinated mice 
while not in pVAX control mice (Fig. 4A). We further evaluated the subclasses 
of mCR specific antibodies that were generated as measured by flow 
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cytometry analysis using anti-IgG1, IgG2a and IgG2b – FITC conjugated 
antibodies (Fig. 4B). The predominant subclass detected in the serum was 
IgG2.  
 
To further validate pmCR vaccination strategy in a breast cancer setting 
relying on the endogenous expression of the antigen, TUBO cells, typically 
negative or low for mCR expression (Fig. 5A), were cultured in a sphere 
culture system using low attachment flasks to enrich for the small population 
of tumor cells with enhanced metastatic potential. These CSCs have been 
shown to be difficult to treat with classical therapies and (23) have been 
identified to express increased levels of CR (8,24,25). The mCR expression 
was found to progressively increase upon continuous passages under sphere 
forming conditions (Fig. 5A). The third passage (P3) of TUBO derived 
mammospheres exhibited higher mCR expression than either P1 or P2 (Fig. 
5A). We next tested the potential of pmCR vaccination against both TUBO 
cells grown in normal conditions and TUBO P3 spheres. As anticipated, 
vaccination with pmCR had no beneficial effect against mCR negative TUBO 
tumors. No increased survival (Sup. Fig. 4) or change in tumor growth was 
observed (data not shown). In contrast, pmCR vaccination induced decreased 
tumor growth (Fig. 5B) and prolonged survival (Fig. 5C) in mice challenged 
with TUBO derived P3 cells, as compared to the control vaccinated group. 
 
We finally tested the therapeutic potential of pmCR vaccination in a more 
clinically relevant mouse model. BALB-neuT female mice (26), which develop 
mammary carcinoma with a stepwise progression that mimics several 
features of human ErbB2 carcinogenesis (27) with the appearance of lung 
metastases from the 6th month onwards (28). Mice were vaccinated twice with 
pmCR or control plasmid at 10 and 12 weeks of age. In this setting, the 
immune response generated by the vaccine was not able to control the 
development of primary tumors, and consequently no differences in overall 
survival were observed between the groups (Fig. 6A). In addition to primary 
tumors, lungs were also harvested to evaluate the spontaneous metastatic 
spread of the developing tumors (Fig. 6B). Lungs were stained with 
hematoxylin and eosin to enumerate metastases and the metastatic index 
was calculated. Interestingly, pmCR vaccinated BALB-neuT mice displayed a 
significant suppression of the metastatic burden as compared to control 
vaccinated mice (Fig 6C). These results led us to conclude that pmCR 
vaccination efficiently induces antigen-specific immune responses able to 
target metastatic spreading in different preclinical models of melanoma and 
breast cancer. 
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Discussion 
 
Our current understanding of the complex nature of tumors has recently 
established that a small population of cancer cells within the heterogeneous 
tumor mass is particularly efficient in initiating the formation of disseminated 
cancerous lesions. These cells are referred to as cancer initiating cells or 
CSCs and have been shown to be difficult to eliminate with classical 
therapies(23). The development of therapies selectively targeting these CSCs 
to prevent metastatic disease therefore is of considerable importance. We 
demonstrate here that CR, which has been described to be upregulated in 
human breast CSC (24), can be used to target CSCs in the setting of a cancer 
vaccines.  
 
Prophylactic vaccination has been a success story in protecting us from a 
plethora of pathogens, but unfortunately the success seen in this context has 
not been translated well to therapeutic vaccination against cancer. Perhaps it 
should not be expected that vaccine-induced anti-tumor immune responses 
would be capable of removing bulky tumors, particularly when they consist of 
a heterogeneous cancer cell population that mediate a strong 
immunosuppression (29). Instead, vaccines should enable the immune 
system to reach distant sites of disease that evade the capability of traditional 
therapies. It is therefore essential that anti-cancer vaccines focus on the 
elimination of metastatic CSC populations. This study shows the potential of 
targeting the tumor-associated antigen CR with a plasmid DNA based 
vaccination approach capable of eliciting an immune response that in 
particular can inhibit aggressive tumor growth related to metastatic spread 
and cancer CSC initiated tumorigenesis.  
 
CR has been shown to be expressed on many different tumors (6), including 
uveal and cutaneous melanomas as well as breast cancer (30-32). 
Expression of CR indicates a poor prognosis for breast cancer patients (33) 
and CR positive tumor cells are endowed with an aggressive tumorigenic 
phenotype (34) which affects many of the pathways expected to be up-
regulated in metastatic malignant melanoma. Although CR has yet to be 
described for human metastatic melanoma, we identified several mouse B6 
metastatic melanoma cell lines positive for mCR. In mice that were vaccinated 
with i.d. delivered and electroporated DNA plasmids encoding mCR we found 
that growth of the highly aggressive B16F10 cell line was significantly 
inhibited. Of particular interest, prophylactic vaccination against mCR led to a 
marked reduction in the metastatic spread of B16F10 tumor cells to lungs. 
While immunization against CR leads to inhibition of both i.v. and s.c. injection 
of B16F10, these routes of delivery of tumor cells do not adequately model 
the different stages of EMT that tumors undergo (35). As an oncofetal antigen, 
CR through its interactions with TGF-beta ligands, nodal and glypican-1, 
initiates the transformation of cells to a state prepared for EMT (6). In MMTV-
CR transgenic mice, mammary lesions demonstrated loss of E-cadherin and 
gain of N-cadherin as well as vimentin leading to EMT (36). To model 
mammary carcinoma derived metastasis we employed the 4T1 orthotopic 
mouse model. After screening 4T1 as well as other mouse breast cancer cell 
lines, we found them all to be low- or none- expressers of mCR. This may be 
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explained by the down-regulated expression of CR found on long-term in vitro 
cultured breast cancer cell lines (24). This led us to produce stably 
transformed mCR expressing 4T1 cells, which we subsequently injected into 
the mammary fat pad post vaccination and monitored tumor development. 
While there was a moderately significant impact on luminescence, as 
measured two weeks after challenge, there was a very significant reduction of 
the metastatic index in the pmCR vaccinated mice compared to control 
vaccinated mice.  
 
CR is expressed on CSC populations from human metastatic melanoma cells 
(8), prostate cancer cells (25) and breast cancer cells (24). The promoter 
region of CR has been found to contain binding sites for the CSC markers 
Oct-4 and Nanog (37). Previously we (C. L., S.L., and F.C.) have cultured 
breast carcinoma cells, derived from the BALB-neuT mouse, in 
mammospheres and have found an up regulation of Oct-4, among many other 
CSC markers (9). Here we confirmed an increase in CR expression as a CSC 
marker upon passaging of the BALB-neuT mouse tumor TUBO on low 
adherent plates. A graded number of passage three TUBO mammospheres 
were transplanted s.c. into pmCR vaccinated and control vaccinated mice. 
pmCR vaccinated mice were able to control the growth of the tumors while 
control vaccinated were not, increasing their overall survival significantly.  
To confirm the therapeutic potential of CR-specific immunity elicited by DNA 
based vaccination, a more clinically relevant mouse model was used. We 
vaccinated BALB-neuT mice, which spontaneously develop tumors in the 
mammary tissue driven by rat Neu, a Her2 ortholog. At four weeks of age 
these mice display atypical hyperplasia in the mammary ducts that develop 
into in situ carcinomas by week eight (38). In this setting we therapeutically 
vaccinated the mice at 10 weeks of age. This led to significantly reduced 
metastatic burden in the lungs but not to increased overall survival (Fig. 6). 
Reducing metastatic burden represents the potential that vaccination against 
tumor-associated antigens has when unleashed on a small population of 
metastasizing cells.  
 
DNA vaccines have the potential to become a vaccine delivery method for a 
plethora of different diseases, but as yet much is to be desired from the 
clinical results generated by DNA based trials (39). The key to the potential of 
DNA vaccines lies in their ability to elicit both a cellular as well as a humor 
response to antigens encoded by the plasmids. Cytotoxic T lymphocytes are 
essential in an effective anti-tumor immune response (40). Herein, we are the 
first to describe a cytotoxic T cell response to mCR (Fig. 2). CR, as well as 
being a GPI anchored extracellular protein, interacts with Notch1 in the 
ER/golgi apparatus (41). This lends itself to MHC class 1 immunosome 
processing. By identifying strong stabilizing partners for H2-Kb with the help of 
the TAP-1 deficient RMA-s cell line (42) we were able to identify potential CTL 
epitopes and confirm them in silico. Splenocytes from vaccinated mice were 
able to generate IFN-γ and TNF-α responses to two out of the three predicted 
epitopes. We further validated that mCR16-25 is an epitope that CD8+ T cells 
could react to by isolating specific CD8+ T cells from the vaccinated mice, and 
further confirmed that also epitope specific killing in vivo is effective. In B6 
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mice we were able to raise T cells specific for mCR, but were unsuccessful in 
raising a humoral response (data not shown). In BALB/c mice the opposite 
was true, with a predominant humoral response with a dominant isotype of 
IgG2a and IgG2b. This suggests that antibody dependent cellular cytotoxicity 
(ADCC) may play a role in the protection generated by vaccination in mice of 
this background. Antibodies to CR have previously been shown to be effective 
in mouse models of cancer therapy. Adkins et. al were able to show that CR 
antibodies were able to block Nodal and Act-B interaction, leading to reduced 
tumor growth (43). Antibodies specific to CR were also able to induce cell 
death in doxorubicin resistant leukaemias (44). While we suspect that ADCC 
may play a role in the antibody response generated by our DNA vaccine, Kelly 
et. al could target CR expressing tumors with an antibody cytotoxic conjugate 
in a setting where no functional immune system is required (45). This antibody 
has undergone clinical trials (NCT00674947) but no results have been 
published yet (as of March 2015). 
In summary, our findings show that targeting CR using DNA vaccination elicits 
beneficial humoral and cellular immunity capable of significantly reducing 
aggressive metastatic as well as CSC based tumor growth. We identify, for 
the first time, CTL epitopes specific to mCR, and have in ongoing work also 
several human CTL epitopes defined. The possibility of targeting CR 
expressed on the small CSC population is attractive, particularly in an 
adjuvant setting to avoid metastatic spread.  
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 Figure 1. Vaccination against mCR increases survival and reduces 
metastatic lung burden in B6 mice challenged with mCR expressing B16F10. 
A, upper panel: tumor cell lysates from lines on B6 background, RetV, 
MCA205, B16F10 and B16F1 were checked by western blot for mCR 
expression and compared relatively to beta-actin. The D2F2 mCR transfectant 
(D2F2mCR) was included as positive control. A, lower panel, B16F10 tumor 
cells were grown on low attachment plates for one to three passages (P1, P2 
and P3) to enrich for tumor initiating cells and cell lysates were generated 
from each passage. B, survival of B6 mice (n=10 per group) prophylactically 
vaccinated with pmCR or control vector pVAX with two doses of 20 µg 
plasmid DNA delivered i.d. with electroporation prior to s.c. challenge with 
5x104 B16F10 cells, compared with Mantel-Cox test; **, P < 0.01.  The results 
shown here are representative of two experiments. C, tumor growth was 
compared in mice vaccinated with either pmCR or pVAX with 2-way ANOVA 
test; **, P < 0.01. D, representative photos of B16F10 metastatic lung burden 
in vaccinated mice harvested 14 days post i.v. challenge of 2x105 tumor cells. 
E, reduction in lung metastasis was evaluated by enumerating foci of tumors 
in lungs of B16F10 i.v. challenged mice and compared with non-parametric T 
test; *, P < 0.05. The results shown here are representative of three 
experiments.  
 
Figure 2. Vaccination with pmCR elicits an epitope specific functional CD8+ T 
cell response. A, RMA-s cells were used to measure surface stabilization of 
H2-Kb using an overlapping 15-mer peptides library. H2-Kb was analyzed by 
flow cytometery after loading with 100 µg/ml of peptide for 2 hours, with 
negative controls (un-stained, filled gray, and un-load, green), positive 
controls (OVA and TRP2, red) as well as the peptides mCR46-60, mCR16-30, 
mCR1-15 (solid black). C, peripheral blood lymphocytes from vaccinated mice 
(n=9) were stimulated with mCR16-25 specifically for 8 hours prior to ICS and 
significant increase in IFN-γ/TNF-α producing cells were found; ***, P < 0.001 
using Mann-Whitney T test. D, CD8+ T cells were isolated using MACs bead 
positive selection from B6 (n=5) mice vaccinated with either pmCR or pVAX 
and stimulated with CR expressing tumor cell line B16F10, mCR16-25 peptide, 
OVA peptide or with T cells alone; **, P < 0.01 using Mann-Whitney T test. E, 
splenocytes from naïve mice were harvested and labeled with lo and hi CFSE 
prior to loading with OVA and mCR16-25, respectively, and transferred into 
pmCR or pVAX vaccinated mice. Specific killing was analyzed by FACS after 
20 hours. F, mCR16-25 specific killing of splenocytes in vivo was found to be 
significantly greater in pmCR vaccinated mice; ***, P < 0.001 using Students 
T test. 
 
Figure 3. In the orthotropic 4T1-mCR breast cancer model   metastatic 
spread is inhibited by prophylactic pmCR vaccination. A, Tumor cell lines from 
BALB/c background were screened for mCR expression using western blot. 
Stable mCR transfectants expressing luciferase were generated from the 4T1 
and D2F2 breast carcinoma cell lines. B, 4T1-mCR was injected orthotopically 
in the mammary fat pad in BALB/c mice that had been vaccinated two weeks 
before with either pmCR or pVAX. In vivo luminescence was measured 14 
days post orthotopic 4T1-mCR challenge of vaccinated pmCR and pVAX 
(n=12) mice, a Mann-Whitney T test was used; **, P < 0.01 Mann-Whitney T 
 	
test. C, tumors were excised on day 23 after tumor challenge and weight was 
compared between pVAX and pmCR vaccinated mice; ***, P < 0.001 Mann-
Whitney T test D, spontaneous metastasis derived from orthotopically 
transplanted tumors were evaluated by colony formation assay and the weight 
of the primary tumor in vaccinated mice, a Mann-Whitney T test was used; ***, 
P < 0.001. The results shown here are representative of two experiments.  
 
Figure 4. Vaccination of BALB/c mice induces the production of mCR specific 
antibodies. A, BALB/c mice were vaccinated, as described in material and 
methods, and serum was harvested 14 day after the final vaccination. Serum 
from mice was then used to stain control CR negative cells (D2F2) and mCR 
positive D2F2mCR at a dilution of 1:20. Cells were then stained with 
secondary anti-mouse IgG-PE antibody followed by acquisition by flow 
cytometry. B, similarly, D2F2mCR were stained with pooled serum (1:20) 
derived from pmCR vaccinated mice and stained with either anti-mouse IgG1, 
anti-mouse IgG2a or anti-mouse IgG2b. Total MFI and the relative 
contribution of each antibody to this staining were calculated.  
 
Figure 5. pmCR vaccination protects against breast CSC challenge but not 
against parental cell line. A, TUBO cells were passaged on low attachment 
plates to generate P1, P2 and P3 mammospheres. Cell lysates were 
generated from these cultures and screened for mCR expression by western 
blot and relative mCR expression was compared by beta-actin control. B, 
2x104 P3 mammospheres derived from TUBO parental cells were injected s.c. 
into pmCR and pVAX vaccinated mice and tumor growth was compared. On 
day 69 evaluated tumor size was significantly different as calculated by Mann-
Whitney T test; *, P < 0.05. C, Survival was monitored in BALB/c mice 
challenged with P3 mammospheres post vaccination, compared with Mantel-
Cox test; *, P < 0.05. 
 
Figure 6. Vaccination of BALB-neuT mice against mCR shows protection 
against the spread of Her2/neu driven spontaneous metastasis to the lungs. 
A, BALB-neuT mice (n=6 per group) were vaccinated at 10 weeks of age, 
followed by a boost at 12 weeks; mice survival was monitored and compared 
between pmCR and pVAX vaccinated mice. B, representative sections of 
lungs harvested from BALB-neuT mice and stained for tumors with 
hematoxylin and eosin when ethical endpoint had been reached. C, 
metastatic index were enumerated and compared between pmCR vaccinated 
and pVAX mice, a Mann-Whitney T test was used; *, P < 0.05. 
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